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ABSTRACT 
 
 
 
In order of reducing the frequency of unwanted side effects of chemotherapy 
and recurrences in cancer, in the last ten years a major challenge has been the 
development of methods for the specific targeting to cancer cells. Aptamers are 
single-stranded RNAs able to form different three-dimensional structures, 
which allows them to specifically recognize their molecular targets. This 
makes aptamers attractive agents for targeted cancer therapy. Aptamers were 
first utilized for their ability to bind and inhibit the activity of their target 
protein, including extracellular ligands and cell surface proteins. More recently, 
aptamers were are also used as delivery agents. Thanks to their ability to be 
endocytosed, aptamers may specifically bring a therapeutic cargo inside the 
cells. 
In this thesis, I focused on different aspects regarding the aptamer-mediated 
targeting of cancer cells: 1) the selection of aptamers for a cancer stem cells-
targeted therapy. In fact, as widely recognized, cancer stem cells are 
responsible for tumor recurrence, repopulating the tumor after a 
chemotherapeutic treatment. 2) The formation of aptamer-microRNA chimera 
molecules in which the aptamer is the delivery vehicle for a microRNA. The 
use of microRNAs represent a challenging approach in cancer therapy because 
they are able to regulate the expression of cellular proteins modulating 
different pathways. However, to date the absence of reliable means that permit 
the specific delivery of microRNAs to the appropriate tissue represents an 
obstacle to the success of this approach. 
For the first purpose, I performed for the first time a SELEX (Systematic 
Evolution of Ligands by EXponential enrichment) method on human breast 
cancer stem cells, using in the counterselection step breast cancer differentiated 
cells. I selected putative aptamers specific for the stemness phenotype in breast 
cancer, useful to identify specific cell-surface targets, block molecular 
pathways and delivery therapeutics. For the second purpose, I selected an 
internalizing aptamer, GL21, that specifically binds to Axl receptor, 
overexpressed in many types of cancer cells. I linked this aptamer to miR-212. 
This microRNA is considered a tumour-suppressor miR because negatively 
regulates the anti-apoptotic protein PED found overexpressed in many tumors 
and involved in resistance to therapeutics. In A549 cells, TRAIL- resistant non-
small cell lung cancer cells overexpressing Axl, this chimera was able to enter 
within the cells and carry the microRNA to the processing machinery. MiR-
212, subsequently, targeted PED resulting in TRAIL sensitization.  
In conclusion, in this thesis I studied new possible applications for aptamers 
aimed at avoiding therapeutic recurrences and at delivering “therapeutic” 
RNAs, as microRNAs, to the appropriate cells. 
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1. BACKGROUND 
 
 
 
1.1 Cancer  
 
 
 
Cancer is thought to reflect a multi-step process, resulting from an 
accumulation of inherited and or acquired defects in genes involved in the 
regulation of cell proliferation. 
The development of a clinically recognizable human cancer may require the 
activation or inactivation of as many as four or five different genes. 
Changes in the expression of key proteins of the cellular signaling pathways 
are the major molecular abnormalities found in cancer. In fact, an increasing 
number of proteins involved in cell growth, including growth factors, 
receptors, intracellular mediators and transcription factors have been found to 
be altered through multiple mechanisms of oncogene activation, such as 
enhanced or ectopic expression, deletions, single point mutations and 
generation of chimeric proteins, formed by chromosomal translocations. 
Among these, many cell surface receptors with an intrinsic intracellular 
tyrosine kinase activity can act as oncogenes and cause cellular transformation 
(Kolibaba and Druker 1997). 
Therefore, as major molecular determinants of cancer cells, all these proteins 
represent primary targets in the rational approach of the cancer mechanisms. 
For this purpose, different types of molecules have been shown to be of 
potential utility for cancer diagnosis and therapy, including small chemical 
compounds, peptides, antibodies and nucleic acid ligands. 
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1.2 Aptamers 
 
 
 
For a long time nucleic acids were mainly considered as linear carriers of 
information, whereas most cell functions were ascribed to protein molecules 
possessing complex three-dimensional structure. 
It was found that single-stranded RNA molecules are able to form very 
different three-dimensional structures, which allows them to recognize 
specifically various molecular targets. They were called aptamers.  
The term aptamer is derived from the Latin word ‘‘aptus’’—which means 
fitting (Ellington and Szostak 1990) and the Greek word ‘‘meros’’ meaning 
particle. 
Aptamers are short single-stranded nucleic acid oligomers (ssDNA or RNA) 
with a specific and complex three-dimensional shape characterized by stems, 
loops, bulges, hairpins, pseudoknots, triplexes, or quadruplexes. Based on their 
three-dimensional structures, aptamers can well-fittingly bind to a wide variety 
of targets from single molecules to complex target mixtures or whole 
organisms. Binding of the aptamer to the target results from structure 
compatibility, stacking of aromatic rings, electrostatic and van derWaals 
interactions, and hydrogen bindings, or from a combination of these effects 
(Hermann and Patel 2000).  
The concept that nucleic acid ligands could modulate the activity of target 
proteins emerged from basic science studies of viruses. In the 1980s, research 
on HIV and adenovirus discovered that these viruses encode several small, 
structured RNAs that bind to viral or cellular proteins with high affinity and 
specificity. The observation that viruses utilize RNA ligands for their ends 
suggested to translational researchers in the late 1980s that RNA ligands might 
also be useful for therapeutic ends (Nimjee et al. 2005). 
Aptamers realizes their inhibiting function on a completely different 
mechanism with respect to miRNA and siRNA. Antisense, ribozymes, siRNAs, 
miRNAs recognize the target nucleic acid by complementary base pairing and, 
by activating an intracellular molecular machinery, impair the expression of the 
corresponding protein. Instead, aptamers act directly binding the target without 
interfering with its expression (Cerchia and de Franciscis 2006) (Fig.1). 
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Fig.1: Aptamer functionality. A) Schematic representation of aptamer three 
dimensional structure and functionality and B) its mechanism of action 
compared to that of other ncRNAs. 
 
 
 
Amongst drugs used for molecular targeting, monoclonal antibodies have made 
tremendous contributions in a wide range of applications. However, there are 
certain limitations associated with antibodies; monoclonal antibodies generally 
are incapable of membrane penetration due to larger size and hence are not 
ideal as carriers for targeted delivery of cytotoxic molecules inside the cells. 
Moreover, production of monoclonal antibodies is laborious, expensive, time 
consuming and suffers from batch-to-batch variations. They are also 
immunogenic, temperature sensitive, and their target binding kinetics cannot be 
easily modified. 
Aptamers, generally considered being oligonucleotides analogous to 
antibodies, rival antibodies in many ways. These short, single stranded 
DNA/RNA molecules fold to form unique tertiary structures, allowing them to 
bind to target proteins with high specificity and affinity, often leading to 
modulation of the target protein activity. Aptamers generally range in size from 
20 to 80 bases (6–26 kDa) which makes them larger than peptides but smaller 
than antibody fragments (scFv, Fab). Their small size enables them to access 
protein epitopes that might otherwise be inaccessible to bulky antibodies. It is 
also the small size, that provides aptamer a better chance of internalization than 
the antibodies, although this is possible only when it is bound to a target 
protein that undergoes internalization or the target is a cell surface receptor, to 
which it might act as a ligand. This feature allows aptamer to be used as 
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bifunctional ligands that, along with recognition, can also be employed as 
delivery vehicles. Once identified, aptamers can be chemically synthesized and 
stabilized to have a consistent structure-activity with little immunogenicity. 
These molecules are highly temperature-resistant and are stable over long term 
storage. Their targeted binding properties can be controlled and modified as 
desired, and the molecules can be derivatized easily for downstream 
applications (Fig.2). Due to these advantages, aptamers gained immediate 
attention for clinical development, and shortly after the advent of the 
technology, a substantial number of aptamers entered clinical trials for a wide 
range of applications (Dua et al 2011). 
 
 
 
 
 
Fig.2: Comparison between aptamer and antibody features. 
 
 
 
1.2.1 SELEX Method 
 
 
 
The identification of nucleic acid sequences with unique properties from a 
random pool of sequences is achieved through iterative cycles of in vitro 
selection called SELEX (Systematic Evolution of Ligands by EXponential 
enrichment). The process was independently developed in 1990 by Larry Gold 
and Jack Szostak (Ellington and Szostak 1990; Tuerk and Gold 1990). 
The starting material for the SELEX process is a DNA library obtained from 
combinatorial chemical synthesis. The library usually consists of random 
regions of 20–80 nucleotides (nt), flanked by defined constant 50 and 30 
regions, 18–20 nt long. The complexity of the library and its molecular 
diversity is characterized by the length of the random region, providing each 
individual oligonucleotide with a unique sequence. A starting complexity of 
1014–1015 is generally considered to be appropriate. A library containing 25 nt 
randomized nucleotides (425 = 1015) reaches the highest possible limit of 
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sequence diversity available for screening in a SELEX experiment. Further, all 
known single stranded oligonucleotide motifs can be built within this length. 
This suggests that libraries with short randomized regions are sufficient for a 
successful aptamer selection. Short libraries are better manageable, cost 
effective in chemical synthesis and involve lesser post-SELEX optimizations. 
However, longer randomized regions could provide greater structural 
complexity to the library and better opportunities for the identification of 
aptamers. The fixed region has a promoter region for T7/SP6 RNA polymerase 
and primers for reverse transcription (RT) and polymerase chain reaction 
(PCR). This DNA library is the basic starting material for selecting 
RNA/DNA/ ssDNA/chemically modified aptamers.  
High affinity aptamers have been successfully generated from both DNA-
SELEX and RNA-SELEX. The initial double-stranded oligonucleotide library 
is converted into single-stranded DNA (ssDNA) (in the case of DNA-SELEX) 
or transcribed to RNA via in vitro transcription (in the case of RNA-SELEX) 
(Fig.3). 
 
                 
 
Fig.3: Starting random DNA oligonucleotide library. The two fixed sequences, 
termed 1 and 2, act as primer binding sites in the PCR. Two special primers are 
needed for the PCR. The antisense primer, termed 2rc, is reverse 
complementary to the fixed sequence at 3’-end of the library. The sense primer, 
termed T7 promoter-1, is derived from the fixed sequence at the 5’-end and is 
modified by an extension containing the T7promoter sequence. 
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The pool of random single stranded molecules is allowed to adopt secondary 
structures and is then incubated with the target protein in a binding buffer at an 
appropriate temperature. In the initial binding step, only a very small fraction 
of the pool will bind to the target, which is separated from the unbound fraction 
through a suitable partitioning technique. 
The target-bound aptamers are isolated and amplified using PCR (or RT-PCR 
in the case of RNA-SELEX) to obtain an enriched pool, which is then used for 
the next round of SELEX. This repetitive selection/amplification cycle results 
in selective enrichment of sequences that physically interact with the target in 
high affinity. The enrichment efficiencies of the binders are governed by the 
stringency of selection, which can be obtained using suitable competitors 
during incubation, limiting target concentration, and by increasing the 
stringencies of the post-incubation washes. 
The progress of binder enrichment during SELEX can be monitored using 
binding assays. 
After reiterating these steps (the number of rounds of selection necessary is 
determined by both the type of library used as well as by the specific 
enrichment achieved per selection cycle), the resulting oligonucleotides are 
subjected to DNA sequencing. The sequences corresponding to the initially 
variable region of the library are screened for conserved sequences and 
structural elements indicative of potential binding sites and, subsequently, 
tested for their ability to bind specifically to the target molecule.   
Initially the SELEX method was focused on purified membrane proteins to 
identify cell surface targets, but the selection was done in not-physiological 
conditions. A modification of the traditional SELEX procedure is cell-SELEX, 
in which whole live cells are used as targets, aim at generating aptamers able to 
discriminate within the same tumor between two strictly related phenotype 
(Cerchia et al. 2009) and to discovery unknown targets that could be used as 
biomarkers. Compared with the traditional SELEX method using a single 
target protein, cell-SELEX usually requires more selection cycles (>20) and 
longer processing times for efficient enrichment of an aptamer population. 
Unlike SELEX with purified targets, cell-SELEX faces a major problem of the 
selection of ligands that recognize multiple surface proteins along with the 
target of interest. To avoid the parallel selection of aptamers for unintended 
targets, ‘Counter-SELEX’ or ‘negative selection’ is critical. It consists in a 
previous step on cells with different characteristics compared to the goal of the 
selection. Non-bound sequences from the negative step are added to the target, 
and the selection proceeds as usual. 
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1.2.2 Post-SELEX modifications 
 
 
 
Aptamers generated by the different SELEX schemes have many limitations 
for direct use in downstream applications. Natural, unmodified 
oligonucleotides, especially RNAs, are unstable in biological fluids. To protect 
RNA from digestion by nucleases, chemically modified nucleotides are 
incorporated into the oligonucleotide backbone. Various modifications at the 
20-carbon of the ribose sugar have been shown to render RNA resistant to 
nucleases. The endonucleases that target RNA in biological fluids are generally 
specific for pyrimidines; therefore, the introduction of modified pyrimidine 
residues is sufficient to stabilize it towards nucleases. The most commonly 
employed functional group modifications are 2’-F, OMe, or NH2 modifications 
of the pyrimidine nucleotides, all of which can be introduced at either the pre- 
or post-SELEX step. 
Even with extensive nucleotide modifications to hinder nuclease attack, 
aptamers can be cleared from the circulation within minutes (Hicke et al. 
2006). To increase the plasma half-lives of these molecules, it is important to 
increase aptamer size via conjugation with bulky groups. While several 
strategies have been attempted, including tagging with cholesterol (Rusconi et 
al. 2002) and attachment to liposomes (Willis et al. 1998), most efforts have 
concentrated on covalent conjugation with polyethylene glycol (PEG) 
(Farokhzad et al. 2004). PEGylation has been shown to significantly improve 
the serum half-lives of aptamers without substantially affecting their binding 
affinities. 
 
 
 
1.2.3 Internalizing Aptamers 
 
 
 
The negatively charged phosphate backbone of the nucleic acid molecule is the 
primary cause for its inadequate and inefficient cellular association, owing to 
electrostatic repulsion from the negatively charged cell surface. Moreover, 
oligonucleotides longer than 25 bases are difficult to import into cells because 
of their size and predispotition to self-hybridize (Patil et al. 2005). Though 
efforts have been made to incorporate aptamers into liposome vesicles (Mann 
and Dzau 2000) or other delivery vector systems (Chaloin et al. 2002; Good et 
al. 1997), it is highly desirable, augmenting the cell-specific aptamer selections 
described above, to select aptamers that not only recognize a cell, but also are 
endocytosed.  
In literature, are described few exceptions of internalizing aptamers, between 
these: DNA anti-PTK7 aptamer (Xiao et al. 2008) and RNA aptamers against 
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PSMA (Lupold et al. 2002), CD4 (Zhou Q et al. 2012) and HIV gp120 (Khati 
et al. 2003). 
Another published internalizing RNA aptamer is GL21. It emerged from a 
whole cell-SELEX on U87MG cells, a malignant human glioma cell line, using 
in the counter-selection step less malignant human T98G glioma cells. Cerchia 
et al. (2009) found that Gl21 aptamer is able to bind and inhibits the signaling 
of Axl receptor, belonging to the TAM family of tyrosine kinase receptors 
(RTKs) that also includes Sky (Tyro3, Dtk) and Mer. They are characterized by 
an extracellular domain consisting of two immunoglobulin-like domains 
followed by two fibronectin type 3-like domains. Axl-family members are 
activated by Growth-arrest-specific gene 6 (Gas6), a member of the vitamin K-
dependent protein family that resembles blood coagulation factors rather than 
typical growth factors (Fig.4).  
 
                         
 
Fig.4: Axl receptor and Gas6 structures. 
 
 
 
Axl overexpression has been reported in many human cancers and is associated 
with invasiveness and/or metastasis in lung (Shieh et al. 2005), prostate 
(Sainaghi et al. 2005), breast (Zhang et al. 2008), gastric (Wu  et al. 2002) and 
pancreatic cancers (Koorstra et al. 2009), renal cell carcinoma (Chung  et al. 
2003) as well as glioblastoma (Hutterer et al. 2008). Furthermore, by a 
phosphoproteomic approach based on the profiling of phosphotyrosine 
signaling, activated Axl protein was detected in ~5% primary tumors of non-
small-cell lung cancer (Rikova et al. 2007). Using a rational approach based on 
its predicted secondary structure they designed a 34-mer truncated version of 
the 92-mer original molecule, named GL21.T, which contains the active site of 
GL21 and preserves high binding affinity to the U87MG cells. Determining the 
cell type specificity, GL21.T didn’t bind other human cancer cell types 
including neuroblastoma, lung and breast without Axl receptor, while bound 
A549 cells, a non-small cell lung cancer (NSCLC) cell line, that, instead, 
presents the receptor on the cellular surface. It is also able to be endocytosed 
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into target cells, getting ~30% of cell internalization following 15-minute 
incubation and reached ~60% following 2 hours of aptamer treatment (Cerchia 
et al. 2012). 
 
 
 
1.2.4 Molecular Chimeras 
 
 
 
Instead of directly interrupting a disease process, as would do a function-
blocking aptamer, endocytosed aptamers could work as delivery agents into 
cells. They were called by Hicke et al. “escort aptamers” (Hicke and Stephens 
2000). Escort aptamers have been successfully adapted for the targeted 
delivery of active drug substances both in vitro and in vivo, including anti-
cancer drugs, toxins, enzymes, radionuclides, virus, and siRNAs. The cargoes 
are attached to the aptamers either through their assembly with functionalized 
groups linked to the aptamer and cargos, or through direct conjugation to the 
aptamer, creating a molecular chimera, as in the case of oligonucleotides (Zhou 
and Rossi 2010.).  
Aptamer-mediated targeted delivery can enhance the therapeutic efficacy and 
reduce the toxic effects of drugs.  
The three RNA aptamers above-named have been exploited for the creation of 
a molecular chimera for siRNA delivery (Fig.5). 
1) Anti-PSMA RNA aptamer-mediated RNAi 
Three independent groups have successfully employed the anti-PSMA RNA 
aptamers to specifically deliver siRNAs to target cells.  
- In Chu et al. work (2006) two biotinylated siRNAs and two aptamers 
were non-covalently assembled via a streptavidin platform. 
- Giangrande and collegues conjugated the RNA aptamer to the sense 
strand of the siRNA followed by annealing of the complementary 
siRNA sense strand to complete the chimeric molecule (McNamara et 
al. 2006). In a subsequently work they inverted sense and antisense 
strands. A 2 nucleotide (UU)-overhang and a polyethylene glycol tail 
were added to the 3’-end of the guide strand and to the 5’-end of 
passenger strand, respectively (Dassie et al. 2009).  
- Wullner et al. (2008) generated bivalent anti-PSMA aptamer-siRNA 
chimera using the siRNA itself as a linker to join the two aptamers. 
2) Anti-CD4 RNA aptamer-mediated RNAi 
In which the anti-CD4 aptamer or siRNAs were non-covalently joined via 
phi29 RNAs (ncRNA molecules of the bacteriophage phi29) containing 
complementary loop domains. Two pRNA molecules were respectively fused 
with siRNAs and the anti-CD4 aptamer. Through the interaction of right and 
left interlocking loops, the two chimeric pRNAs could precisely dimerized into 
a stable nanovector of approximately 25 nm in diameter (Guo et al. 2005). 
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3) Anti-gp120 RNA aptamer-mediated RNAi 
27-mer Dicer substrate RNA duplex and the aptamer were attached with 
complementary ‘sticky’ sequence. After a simple annealing, they formed stable 
base pairs (Zhou et al 2009). 
In this design format, one pair of complementary GC-rich sticky bridge 
sequences was chemically attached to the 3’ end of the aptamer. The 
complement to this sequence was attached to one of the two siRNA strands and 
the aptamer and siRNA were joined by Watson-Crick base pairing. A flexible 
three-carbon atom hinge (C3) was added as a spacer between the adhesive 
(sticky) sequence and the aptamer to allow spatial and structural flexibility. 
Importantly, this sticky bridge-based strategy can be used to facilitate the 
effective interchange of different siRNAs with a single aptamer, which is 
required to avoid viral resistance to the siRNA component. 
 
 
 
 
 
Fig.5: Representations of molecular chimeras: A) Anti-PSMA RNA aptamer-
mediated RNAi (Chu et al.); B) Anti-PSMA RNA aptamer-mediated RNAi 
(Dassie et al.); C) Anti-CD4 RNA aptamer-mediated RNAi; D) Anti-gp120 
RNA aptamer-mediated RNAi. 
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1.3 MicroRNAs 
 
 
 
Short non coding RNAs, as small interfering RNAs and microRNAs, for their 
ability to inhibit the expression of complementary RNA transcripts are being 
exploited as a new class of therapeutics for a variety of diseases. 
Since their discovery nearly two decades ago, microRNAs (miRNAs, miRs) 
have been one of the most investigated families of molecules. In fact, a recent 
PubMed search found nearly 18,000 miRNA-related articles in the literature 
(Nana-Sinkam and Croce 2013). 
MicroRNAs (miRNAs) are small non-protein-coding molecules that regulate 
gene expression by a post-translational repression mechanism. MiRNAs are 
members of a family of small RNAs, tipically 19-30 nucleotides, which 
includes small nuclear RNA (snRNA) involved in mRNA splicing, small 
nucleolar RNA (snoRNA) which direct modification of ribosomal RNA and 
short interfering RNA (siRNA) produced from long double-stranded RNA 
precursors. Similar to miRNA, siRNA also functions to regulate gene 
expression. 
miRNAs are endogenous RNAs highly conserved in the genomes of animals, 
plants, fungi and viruses.  In humans, miRNAs are transcribed as long primary 
transcripts (pri-miRNA) over 1 kb in size, which have a stem-loop structure, 
are capped at the 5’-end and have a 3’-poly (A) tail. Pri-miRNA transcripts 
undergo to a two steps maturation process to produce functional miRNA. The 
first step occurs in the nucleus and is facilitated by Drosha, an endonuclease 
RNAse III, and the double-stranded RNA-binding domain (dsRBD) protein 
DGCR8. Drosha cleaves both strands of the pri-miRNA transcript in a 
staggered manner, producing a stem-loop precursor molecule (pre-miRNA), 
approximately 70 nucleotides in length. 
These pre-miRNA molecules are, then, transported from the nucleus to the 
cytoplasm, a process mediated by Exportin-5, a nuclear transport receptor, and 
the nuclear protein Ran-GTP. 
The final processing step is facilitated by the RNA III enzyme Dicer and a 
dsRBD protein TRBP, which cuts both strands of the pre-miRNA at the base of 
the stem-loop. This produces a duplex molecule approximately 22 nucleotides 
long. The duplex molecule contains the single-stranded mature miRNA and a 
fragment termed miRNA*, which is derived from the opposite complementary 
arm of the pre-miRNA. The miRNA: miRNA* molecule is then incorporated 
into a large protein effector complex called the RNA-induced silencing 
complex (RISC). The RISC is activated upon unwinding of the miRNA: 
miRNA* duplex. The miRNA* strand is subsequently degraded, whilst the 
miRNA molecule guides the RISC complex to the target mRNA. It is the 
interaction of the miRNA/RISC and its target mRNA that results in gene 
regulation. 
17 
 
The interaction between a miRNA and its target is restricted to the 5’-end of 
the miRNA. Sequence complementarity between nucleotides 2-8 is vital for 
target sequence recognition. The degree of complementarity between the 3’-
UTR region of the target mRNA and this so called “seed region” in the 5’-end 
of the miRNA determines the mechanism by which the miRNA regulates the 
target. If the miRNA bears sufficient sequence complementarity (near perfect) 
to the target mRNA, then regulation is carried out by a process called RNA 
interference, in which the RISC complex is directed to cleave the target 
mRNA. 
If there is insufficient complementarity, which is generally the case in 
mammals, regulation is achieved by repression of translation, the exact 
mechanism of which is still under debate (Lynam-Lennon et al. 2009) (Fig.6). 
To date, at least six models of translational repression have been proposed: (i) 
RISC induces deadenylation which causes decrease of translational efficiency 
by blocking target mRNA circularization; (ii) RISC blocks cap function by 
interacting with either the cap or eIF4E; (iii) RISC blocks a late step in 
initiation of translation such as recruitment of 60S ribosomal subunit; (iv) 
RISC blocks a post-initiation step such as elongation and⁄or ribosome drop-off; 
(v) RISC induces proteolysis of nascent peptides during translation; or (vi) 
RISC recruits target mRNAs to processing bodies, in which mRNA is degraded 
and⁄or stored in a translationally inactive state. These models do not necessarily 
exclude each other (Kwak et al 2010). 
  
 
        
 
Fig.6: MiRNA biogenesis and mechanisms of gene expression regulation. 
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MiRNA regulation appears to be an extremely dynamic process. Since the 
perfect complementarity to the target is not required for regulation, a single 
miRNA can regulate a number of target genes and, inversely, a single gene can 
be targeted by different miRNAs. This ultimately makes the identification of 
target genes much more difficult, the result of which is that the functions of 
many miRNAs are still unknown. 
 
 
 
1.3.1 Role of microRNAs 
 
 
 
As master gene regulators, miRNAs are able to impact a variety of cellular 
pathways and functions. Since their discovery in C.elegans more than a decade 
ago (Lee et al. 1993), thousands of miRNAs have been identified to date in a 
variety of organisms. For example, over 1000 human miRNAs are reported in 
miRBase version 18 (http://mirbase.org) (Mo 2012).  
Early studies have shown that miRNAs are critical to developmental timing, 
cell death, cell proliferation, immunity and patterning of the nervous system. 
Deregulation of miRNAs can lead to a variety of human disease. Thus, it is 
critical to understand how miRNAs are regulated in normal cellular processes 
as well as during disease processes.  
The first evidence for miRNA involvement in human cancer came from a study  
by Calin et al. (2002) examining a recurring deletion (65% of patients) at 
chromosome 13q14 in the search for a tumor suppressor gene involved in 
chronic lymphocytic leukemia (CLL). In this study was found that the region 
of deletion encodes two miRNA: miR-15a and miR-16-1. Subsequent 
investigations have confirmed the involvement of these two miRNAs in the 
pathogenesis of CLL (Calin et al. 2005; Cimmino et al. 2005). 
To date, a lot of miRNAs have been characterized for their function in cancer. 
Several experiments and clinic analysis suggest that miRNAs may function as 
a novel class of oncogenes or tumor suppressor genes. Oncogenic miRNAs, 
called “oncomirs”, may promote tumor development by negatively inhibiting 
tumor suppressor genes and/or genes that control cell differentiation or 
apoptosis. On the other hand, some tumor suppressor miRNAs may prevent 
tumor development by negatively inhibiting oncogenes and/or genes that 
control cell differentiation or apoptosis. Their expression is decreased in 
cancerous cells (Zhang et al. 2007). 
The identified mechanisms for this observed alteration include impaired 
miRNA processing, chromosomal alterations, effects of environmental factors 
(e.g., cigarette smoke and infection), transcriptional enhancers or repressors, 
epigenetic regulation, and polymorphisms. 
A tumor-suppressor miRNA is miR-212.  
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It belongs to miR-132/212 family. They are two miRNAs sharing close 
sequences highly conserved among vertebrates. miR-132 and miR-212 were 
first reported to be transcribed in rats and in mice from regions in the non-
coding transcripts. Similarly to their rodent orthologues, hsa-miR-132 and hsa-
miR-212 share the same primary transcript. In addition, in human, they are 
found in an intergenic region located on chromosome 17p13.3. MiR-132 and 
miR-212 exhibit similar mature sequences and share the same seed region. 
They may therefore target the same mRNAs (Wanet et al. 2012).  
Regarding its transcriptional regulation, the miR-212/132 locus was first 
identified in neuronal cells as a target of the cAMP-response element binding 
(CREB) protein transcription factor. In non-neuronal cells the miR-212/132 
locus is under the control of the transcriptional repressor Repressor Element 1 
silencing transcription factor/neuron-restrictive silencer factor (REST/NRSF) 
(Wu and Xie  2006). 
Given their involvement in neuronal development and functions, it is not 
surprising that deregulated expression patterns of miR-132 and miR-212 have 
been associated with developmental defects as well as brain-related disorders. 
For example, a down-regulation of miR-212 has been identified in foetuses 
with anencephaly (Zhang et al. 2010)). Moreover, miR-132 and miR-212 are 
both deregulated in the prefrontal cortex of individuals affected by 
schizophrenia and bipolar disorders (Perkins et al. 2007; Kim et al. 2010). 
MiR-212 was also found to be down-regulated in Alzheimer’s disease patients, 
and its expression modulation correlates with the density of neurofibrillary 
tangles, a characteristic lesion of Alzheimer’s disease (Wang et al. 2011). In 
the last 5 years, several groups, performing miRNA expression profiling in 
diverse immune-related contexts, came to highlight the induction of miR-132 
(and miR-212) in several cell types including monocytes, macrophages, mast 
cells and lymphatic endothelial cells. So, besides their numerous roles in 
neuronal development, functions and related diseases, increasing evidences 
point towards an important involvement of miR-132 and miR-212 in mediating 
inflammatory processes. Indeed, miR-132 was recently designated as a 
‘NeurimmiR’, a class of miRNAs regulating both neuronal and immune 
functions and was suggested to function as a cross-talk between both systems 
(Soreq and Wolf  2011). 
Despite their neurimmiR functions, miR-212/132 are shown to be deregulated 
in different cancer types. For example, miR-212 down-regulation has been 
associated with the resistance/bad response to several anti-cancer treatments 
(Hatakeyama et al. 2010). Other reports suggest that miR-212 would negatively 
affect gastric cancer cells proliferation (Wada et al. 2009).  
In non-small cell lung carcinoma, miR-212 negatively regulates the anti-
apoptotic protein PED/PEA15 (Fig.7). PED (Phosphoprotein Enriched in 
Diabetes) is a death-effector-domain (DED) family member of 15 kDa found 
overexpressed in a number of different tumors including gliomas, squamous 
carcinoma, thyroid, breast, lung cancer, and B-cell chronic lymphocytic 
leukemia. It inhibits the assembly of a functional death-inducing signaling 
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complex (DISC) of death receptors following stimulation and activation of 
caspase 8. Zanca et al. (2008) found that PED is overexpressed and mediates 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance in 
non-small cell lung cancer. TRAIL is a relatively new member of the tumor 
necrosis factor (TNF) ligand family, which induces apoptosis in a variety of 
cancers. Successively, Incoronato et al. (2010) found that PED/PEA15 is 
targeted by miR-212 increasing TRAIL sensitivity. In fact, analyzing human 
tissues specimens of normal and lung cancer they found that the up-regulation 
of PED protein in lung cancer tissues was correlated with miR-212 silencing 
and in vitro with apoptosis resistance. The explanation of silencing is 
demonstrated to reside in histone modifications (Incoronato et al. 2011). 
 
                     
Fig.7: Representation of miR132/212 family structure and miR-212 targeting 
to PED. A) Predicted stem loop structures of human pre-miR-132 and pre-miR-
212. The mature miRNA sequences are indicated in red, the miRNA* 
sequences are indicated in grey and predicted hydrogen bounds are blue. B) 
Mature sequence of miR-212 and its pairing with PED/PEA15 3’UTR. 
 
 
 
1.3.2 MicroRNAs en route to the clinic 
 
 
 
In light of recent advances in the field, it is likely that we will see the transition 
of therapeutics that are based on miRNAs into the clinic in the not-so-distant 
future. 
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They are similar to protein-coding genes in that they regulate many survival-
signaling pathways, are themselves subject to mutagenesis and often have 
conflicting roles in various disease states. They differ, however, in their 
therapeutic potential. In essence, miRNA replacement therapies may do what 
protein-coding gene replacement therapies have tried to do, but with fewer 
obstacles to overcome. MiRNA are much smaller and less antigenic than their 
protein-coding counterparts and, as such, cellular delivery is possible without 
the use of potentially harmful viral-based delivery mechanisms that are needed 
for the cellular uptake of larger protein-coding genes. 
Likewise, effective tools for systemically silencing miRNAs have been 
developed, that specifically and safely target miRNAs. These antagomirs act as 
small sponges that soak-up miRNAs, resulting in subsequent miRNA 
degradation and, thus, the upregulation of predicted targets with an in vivo 
effect that can be sustained for over 3 weeks. This is in contrast to standard 
antisense miRNA targeting, which has a limited ability to suppress miRNA 
functions and often leads to toxicity. Thus far, antagomirs have proven to 
efficiently silence miRNA function with limited side effects. 
Although the initial proof-of-principle studies using miRNAs as therapeutics 
took advantage of adenoviral-based and lentiviral-based delivery methods, 
translation into clinical practice requires the development of safer delivery 
vehicles. These include packaging mature miRNAs into lipid-based 
nanoparticles (neutral or charged) that can be delivered locally to the tumor 
tissue or systemically, in which case they have been found to accumulate and 
to therapeutically regulate their targets in the lung, pancreas and prostate. 
Expanding on this, physical and chemical moieties of the particles that 
facilitate the targeted distribution and the controlled and sustained release of 
miRNA – including liposomes, polymers and dendrimer conjugates – are under 
clinical investigation. 
Certainly, we must be cautious of the possible side effects of these molecules 
in human trials, independently of the side effects that could be associated with 
the delivery agents. Even in situations in which the miRNA is delivered 
directly to the tumour, miRNA could escape from the tumor cells and become 
systemic, either through microvesicle exocytosis or secretion of miRNA-
Argonaute2 complexes. It is plausible that miRNA overexpression could lead 
to the saturation of the miRNA machinery and non-specific effects. 
Furthermore, increasing the cellular concentration of miRNAs may suppress 
lower-affinity targets that might not be targeted at endogenous miRNA levels.  
Similarly to current chemotherapies, concentration and dose schedules need to 
be evaluated for efficacy and toxicity, and the long-term effects following 
treatment must be assessed (Nana-Sinkam and Croce 2012). 
Given all these problems, fewer studies using directed miRNA targeting have 
reached clinical trial. MiR-122 is the one miRNA that has successfully reached 
clinical trials as a targeted therapy (Elmén et al. 2008). The hepatic-specific 
miR-122 has been shown to drive HCV viral load through directed targeting of 
HCV. Investigators eventually translated these largely in vitro findings to large 
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animal models, demonstrating that systemic delivery of antimiR-122 could 
reduce HCV viral load in a chimpanzee model of chronic HCV infection with 
minimal toxicity (Lanford et al. 2010). Santaris Pharma subsequently 
conducted a human phase IIa trial demonstrating safety and antiviral function 
using miravirsen (a locked nucleic acid-modified miR-122 antagonist).  
 
 
 
1.4 Breast Cancer 
 
 
 
Breast cancer is a leading cause of cancer mortality among women, second 
only to lung carcinoma, and fifth most common cause of cancer death (after 
lung cancer, stomach cancer, liver cancer, and colon cancer). 
The mammary gland is not like most vertebrate organs that are formed during 
embryogenesis and maintain their basic structure throughout adult life. In 
males, it is present in a rudimentary and generally non-functional form. In 
females, it is a highly dynamic organ that undergoes dramatic morphogenetic 
changes during puberty, pregnancy, lactation and regression. 
The adult human mammary gland consists of a branching system of ducts 
surrounded by a collagenous and fatty stroma. An inner layer of luminal 
epithelial cells lines the system of ducts and lobules and an outer layer of 
contractile myoepithelial cells surrounds the luminal cells (Clayton et al. 2004) 
(Fig.8).  
Ducts form before birth, by branching and invading the mammary fat pad. 
During puberty, ductal outgrowth rapidly increases under hormonal 
stimulation, resulting in side branching (Rudland et al. 1997; Hennighausen 
and Robinson 2001). The final differentiation stage is achieved in the 
mammary gland during pregnancy and lactation, when numerous lobulo-acinar 
structures containing the milk-secreting alveolar cells are formed through 
extensive proliferation, followed by terminal differentiation. 
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Fig.8: Mammary gland structure. 
 
 
 
Although the adult breast is often called ‘resting’ (outside pregnancy and 
lactation), proliferation and apoptosis occur during each menstrual cycle. 
Thymidine labeling has shown that proliferation occurs mainly in the luminal 
cells, is maximal during the second half of the cycle and declines with age 
(Potten et al. 1988). In addition, most breast cancers arise from luminal 
epithelial cells (Gusterson et al. 1982) 
Therefore, a compartment of cells with high proliferative potential and 
differentiation ability is needed in order to sustain numerous pregnancies, a 
description that fits the definition of stem cells or early progenitor cells (Dontu 
et al. 2003). 
In the 19th century, the developments in surgical procedures led to the 
establishment of the radical mastectomy that was used for almost a century, 
until the 1970s, when conservative procedures started being explored together 
with the use of radiotherapy. There is now no doubt that estrogenic hormones 
of ovarian origin promote the growth of human breast cancer. This 
confirmation prompted the search for hormones that would antagonize the 
effects of estrogen, which led to the discovery of tamoxifen in 1966. 
Tamoxifen was quickly validated, and it was also shown that the mechanism of 
action of tamoxifen is to block the activity of the estrogen receptor (ER) in 
tumor cells, therefore blocking their growth (Vivanco 2010). 
 
 
 
 
 
24 
 
1.4.1 Stem Cells and Cancer Stem Cells 
 
 
 
Stem cells, as classically defined, are cells with the ability to self-renew and to 
generate daughter cells that can differentiate down different cell lineages to 
form all the cell types that are found in the mature tissue. 
In order to maintain this ability indefinitely, they must be able to perform 
asymmetric cell divisions. Each cell, therefore, generates one that is identical to 
it as well as another which is different, in that it is more committed towards a 
certain differentiation pattern. The identical cell maintains the stem cell 
compartment through time; the distinct cell undergoes a series of divisions and 
differentiation steps that result in the generation of terminally differentiated 
cell populations. The cells in intermediate states between the stem cell and the 
terminally differentiated cell are usually referred to as progenitors, transit cells 
or transit amplifying cells. Although both stem cells and transit amplifying 
cells divide and produce similar end products (a range of differentiated 
progeny), they differ in their ability to proliferate and maintain an 
undifferentiated state for an extended period of time (Cariati and Purushotham 
2008). 
In contrast to the ‘stochastic’ model of oncogenesis, where transformation 
results from random mutations and subsequent clonal selection, experimental 
and clinical data have accumulated to support the hypothesis that cancer may 
arise from mutations in stem cell populations (Cancer Stem Cell Hypothesis) 
(Reya et al. 2001) (Fig.9). As a matter of fact, about 10 years ago, John Dick’s 
team provided evidence that leukemia growth and propagation are driven by a 
small population of leukemia cells that have the ability to perpetually self-
renew. They called this cell population as cancer stem cells (CSC) (Bonnet and 
Dick 1997). Since then, putative CSC have been isolated from many other 
tumors including breast, brain, colon, pancreas, prostate, lung and head and 
neck tumors. 
       
 
Fig.9: Schematic representation of normal differentiation and “cancer stem cell 
hypothesis”. 
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The basic arguments supporting the idea that tissue stem cells may be primary 
targets for transformation can be summarized as follows: (i) stem cells are 
long-lived, slowly dividing cells that persist in tissues long enough to 
accumulate multiple genetic alterations required for neoplastic transformation, 
while somatic cells are constantly replaced through periodic cell turnover; 
moreover, long-lived cells are exposed to genotoxic insults much longer than 
are short-lived ones; (ii) molecular pathways, which play a critical role in 
governing stem cell self-renewal (i.e. Wnt, Notch, Sonic Hedgehog, PTEN) are 
often deregulated in a number of tumors; (iii) normal stem cells and tumor cells 
share a number of phenotypic features, such as: a relatively undifferentiated 
state, the ability to self-renew, the activation of cytoprotective mechanisms (i.e. 
telomerase activity, overexpression of anti-apoptotic proteins, increased trans-
membrane molecule efflux capability) as well as a remarkable competence for 
migration (Ponti et al. 2006).  
Mutations, probably regarding dysregulation of self-renewal pathways, can hit 
normal stem cells, but also strike more developmentally advanced, although 
still immature, early progenitor cells. So cancer may derive from different 
“cells of origin” (Visvader 2011). 
This leads to expansion of this cell population that may undergo additional 
genetic and epigenetic changes. The nature of these genetic and epigenetic 
changes, the microenvironment and the type of progenitor they target, probably 
contribute to the cellular heterogeneity found in tumors (Charafe-Jauffret 
2008). 
 
 
 
1.4.2 Characterization of mammary stem cells 
 
 
 
Given the paucity of normal stem cells in adult tissues and the lack of universal 
morphologic traits, their isolation represents a major hurdle for their study. 
The purification and characterization of normal adult stem cells specific for the 
mammary gland could therefore be extremely helpful for understanding normal 
mammary development, as well as carcinogenesis. 
The existence of self-renewing, multipotent mammary stem cells was first 
suggested decades ago by the work of Daniel et al. Their studies in mice and 
rats (Daniel et al. 1971; Kim et al. 2000) demonstrated that an entire mammary 
gland can be generated from serially transplanted random fragments of 
epithelium. Generally, senescence occurred after the fourth transplant, but in 
about 25% of cases, seven and eight serial transplantations were achieved. This 
indicates that mammary stem cells are dispersed throughout the entire gland 
and have a potent, although limited, self-renewal capacity. More recently, 
Kordon and Smith (1998), using mammary epithelium marked with mouse 
mammary tumour virus (MMTV) showed that clonal dominant populations 
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were responsible for the generation of a new gland in recipient animals. Serial 
transplantation of the clonally derived outgrowth recapitulated the entire 
functional repertoire of the gland, demonstrating the existence of self-renewing 
and multipotent mammary stem cells. 
Propagation of mammary gland cells in an undifferentiated state in vitro could 
help to escape difficulties. In fact, a major advance in neural stem cell research 
was achieved when it was found that an undifferentiated multipotent 
population of neural cells can be grown in suspension as neurospheres 
(Reynolds and Weiss 1996; Weiss et al. 1996). Neurospheres were shown to 
consist of 4%–20% stem cells, the rest of the population representing 
progenitor cells in various stages of differentiation. 
Analogous to primary neural cells, Dontu et al. (2003) found that also human 
mammary epithelial cells form spherical colonies, termed “nonadherent 
mammospheres,” when cultured on nonadherent surfaces in the presence of 
growth factors and in absence of serum. They demonstrate that nonadherent 
mammospheres are enriched in cells with functional characteristics of 
stem/progenitor cells: self-renewal and multi-lineage differentiation. In fact, 
mammosphere-derived cells are able to form new spheres, containing 
multipotent cells. They have also shown that mammospheres contain cells 
capable of clonally generating functional ductal alveolar structures in 
reconstituted three-dimensional culture systems in Matrigel. When combined 
with human mammary fibroblasts they are able to reconstitute the mammary 
tree in the cleared mammary fat pad of NOD/SCID mice (Liu et al. 2005) 
(Fig.10). Successively, Ponti et al. demonstrated that also cancer stem cells are 
able to form mammospheres in vitro (Ponti et al. 2005). 
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Fig.10: Experimental design for assessing the differentiation and self-renewal 
potential of cells grown as mammospheres. A) Self-renewal is tested by 
evaluating the ability of mammosphere-derived cells to form new spheres, 
containing multipotent cells; B) Differentiation into ductal and myoepithelial 
cells is assessed on cells cultivated on collagen in the presence of serum; C) 
Differentiation into ductal, myoepithelial, and alveolar cells is tested in the 
same conditions as in b with the addition of matrigel as an overlayer; D) 
Differentiation and self-renewal is assessed combining cells with human 
mammary fibroblasts. They are able to reconstitute the mammary tree in the 
cleared mammary fat pad of NOD/SCID mice. 
 
 
 
1.4.3 Clinical implications for “Cancer Stem Cell Hypothesis” 
 
 
 
The cancer stem cell model has fundamental implications in clinic. 
Tumor response is usually defined in the clinic as the shrinkage of a tumor by 
at least 50%. However, if cancer stem cells exist, then shrinkage of tumors may 
reflect the effects of these agents on the differentiated cells in a tumor rather 
than the cancer stem cell component. This may explain why in clinical trials for 
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advanced cancers, tumor regression often does not translate into clinically 
significant increases in patient survival.  
By virtue of their fundamental importance in organogenesis, normal stem cells 
have evolved mechanisms that promote their survival and resistance to 
apoptosis, maintained by cancer stem cells. There are several molecular 
mechanisms that may account for the resistance to apoptosis. These include: (a) 
cell cycle kinetics. Many cancer stem cells are not cycling and are in G0 and 
thus resistant to cell cycle–specific chemotherapy agents. (b) DNA replication 
and repair mechanisms. Stem cells may be resistant to DNA-damaging agents 
by virtue of being able to undergo asynchronous DNA synthesis in addition to 
displaying enhanced DNA repair. (c) During asynchronous DNA synthesis, the 
parental ‘‘immortal’’ DNA strand always segregates with the stem cell and not 
the differentiating progeny. This process may be regulated by P53. This 
prevents the stem cell compartment from accumulating mutations associated 
with replication or from being affected by DNA damaging agents. (d) 
Antiapoptotic proteins. Stem cells express higher levels of antiapoptotic 
proteins, such as members of the Bcl-2 family and inhibitors of apoptosis, 
compared to differentiated cells. (e) Transporter proteins. Stem cells express 
high levels of transporter proteins, such as ABCG2 (BCRP1), as well as P-
glycoprotein (Wicha et al. 2006). 
Therefore, eradication of cancers may require the targeting and elimination of 
cancer stem cells. Thus, one must devise strategies that can selectively kill 
these cancer stem cells while sparing normal stem cells.  
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2. AIM OF THE STUDY 
 
 
 
The present work aims at investigate new possible applications for aptamers in 
targeted anti-cancer therapies. 
- AIM-1: Selection of aptamers for a cancer stem cell-targeted therapy. 
In fact, one of the limits of the conventional treatment in cancer therapy is the 
lack of efficacy to eradicate tumor cells. So, the existence of cancer stem cells 
has significant implications in cancer treatment.  
We wanted to select aptamers able to bind with high affinity and specificity 
breast cancer stem cells. 
- AIM-2: Aptamers as delivery vehicles for “therapeutic” RNAs. 
Knowing the specific surface molecule targeted, aptamers could be used to 
block specific molecular pathways or, if internalized, as delivery vehicles, 
conjugating them to “therapeutic” RNA. In particular, “therapeutic” RNAs 
could be considered microRNAs for their capability to regulate expression of 
many cellular proteins. So, we created a molecular chimera linking GL21 
aptamer, which specifically binds Axl receptor and is endocytosed within the 
cell, and miR-212. This miR negatively regulates the anti-apoptotic protein 
PED and modulates response to therapy. 
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3. MATERIALS AND METHODS 
 
 
 
3.1 Cell culture and transfection 
 
 
 
Breast cancer stem cells (BCSCs) and breast cancer differentiated cells (BCCs) 
used for SELEX method were provided by Matilde Todaro and Giorgio 
Stassi’s lab (Department of Surgical and Oncological Sciences, Cellular and 
Molecular Pathophysiology Laboratory, University of Palermo, Palermo, 
Italy). BCCs were trypsinized and counted and the same amount of BCSCs was 
dissociated to obtain single cells using trypsin 0.05% - EDTA for the SELEX 
cycle performed the day after. 
A549 cells were grown in RPMI 1640, while U87MG and MCF7 cells were 
grown in DMEM. All the cells came from American Type Culture Collection. 
Their media were supplemented with 10% heat-inactivated fetal bovine serum 
(FBS) 10%, 2mM Glutamine and 100 U/mL penicillin/streptomycin. For miRs 
transient transfection, cells were transfected using Oligofectamine (Invitrogen) 
with 100nM (final concentration) of pre-miR-212 or scrambled (Applied 
Biosystem). For siRNA-PED transient transfection, A549 were transfected 
using Lipofectamine 2000 (Invitrogen) with 100nM of si-RNA PED or an 
empty vector (Ribok, Euroclone).  
 
 
 
3.2 Whole-Cell SELEX 
 
 
 
The SELEX cycle was performed essentially as described (Fitzwater and 
Polisky 1996). Transcription was performed in the presence of 1 mM 2’-F 
pyrimidines and a mutant form of T7 RNA polymerase (2.5 u/ml T7 R&DNA 
polymerase, Epicentre Biotechnologies) was used to improve yields. 2’F-Py 
RNAs were used because of their increased resistance to degradation by seric 
nucleases. 2’F-Py RNAs (1100-500 pmol) were heated at 85°C for 5 min in 1.5 
ml of DMEM-F12 serum free, snap-cooled on ice for 2 min, and allowed to 
warm up to 37°C. Before incubation in the cells, 13.5 ml of medium were 
added to RNA to reach a final volume of 15 ml. 
Counterselection step against BCCs. To avoid selection for aptamers non-
specifically recognizing BCSCs surface, the pool was first incubated for 30 
min (up to round 8) or for 15 min (for the following rounds) at 37°C with 
1.5x106 BCCs (100-mm cell plate), and unbound sequences were recovered for 
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the selection phase. This step was meant to select sequences recognizing 
specifically the BCSCs. 
Selection step against BCSCs. The recovered sequences were incubated with 
3x106 for the first three cycles or 1.5x106 BCSCs (for the following rounds) at 
37°C in a 50 ml tube with gentle shaking. Sequences were recovered after 
several washings with 4 ml of DMEM-F12 serum free by total RNA extraction 
(Ambion). 
During the selection process, we progressively enhanced the selective pressure 
by increasing washings number (from one for the first cycle up to three for the 
last cycles) and by decreasing the incubation time (from 30 to 15 min from 
round 9). It was also increased the number of counterselection steps from one 
to two from cycle 10 and was introduced the use of 100 µg/ml polyinosine, as a 
nonspecific competitor (Sigma). 
To follow the evolution of the pool we performed a binding assay for the 
starting and final cycles. 
At the end of SELEX method, sequences of the pools were subjected to 
Illumina sequencing. The sequences have been analyzed for multiple alignment 
(ClustalW) (Thompson et al. 1997) and structural elements (MFOLD) (Zuker 
2003) indicative of potential binding sites. 
For cycles of internalization, 1.5x106 U87MG were incubated with 1000pmol 
(for the first round) and 500pmol (for the second round) and treated with 0.5 
µg/ml proteinase K (Roche). Following 30- and 15-minute treatment for the 
first and second round, respectively, the amount of RNA internalized was 
recovered. Sequences were either cloned with TOPO-TA cloning  kit 
(Invitrogen) and subjected to Illumina sequencing and analyzed. 
 
 
 
3.3 RT-PCR, mutagenic and non-mutagenic PCR for cell-SELEX method 
 
 
 
RNA extracted from each SELEX cycle was retro-transcribed using MuLV 
(Murine Leucemia Virus) reverse Transcriptase (Roche) according to the 
manufacturer’s protocol. The retro-transcription reaction was as follow: 90°C 
for 3min, 42°C for 15min and 50°C for 30min. The product was used for 
mutagenic PCR, characterized by higher concentration of MgCl2 and dNTP, 
using 0.5 U/µl of Taq DNA-polymerase (Roche) and 2µM primers: 
P10: 5’ TAATACGACTCACTATAGGGAGACAAGAATAAACGCTCAA 
P20: 5’ GCCTGTTGTGAGCCTCCTGTCGAA 
The mix was prepared by adding MgCl2 and dNTP to a final concentration of 
7.5 mM and 1mM, respectively. The reaction was as follow: 93°C for 3min, 10 
cycles of 93°C for 1 min, 53°C for 1min and 72°C for 1 min, and a final 
extension of 72°C for 5min. 
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The PCR product was, then, amplified through a non-mutagenic PCR using 0.1 
U/µl of Taq DNA-polymerase (Roche) and 200µM dNTP, not adding MgCl2 to 
that contained in the Taq Buffer. The reaction was as follow: 95°C for 3min, 8 
cycles of 95°C for 30 sec, 60°C for 1min and 72°C for 30 sec, and a final 
extension of 72°C for 5min. 
Amplified DNA was purified using Amicon Ultra Centrifugal Filters 
(Millipore). 
 
 
 
3.4 Illumina sequencing 
 
3.4.1 Illumina sequencing sample preparation 
 
 
 
The DNA pools for selection rounds 0, 3, 5, 7, 10, 12, 13, 15 were amplified 
using High Fidelity PLUS Taq (Roche) in presence of p10 and p20 primers. 
The protocol is as follows. The DNA pool was heated at 95°C for 3 min, 
followed by 10 cycles of heating at 95°C for 30 sec, annealing at 60°C for 1 
min and extending at 72°C for 30 sec and a final extension step at 72°C for 
5min. The PCR product was run on an 8% acrylamide gel and the appropriate 
band (~100bp) was excised, gel purified and DNA quantitated using a 
Nanodrop spectrophotometer (Thermo Scientific). Samples were submitted for 
ILLUMINA® NEXT GENERATION SEQUENCING (NGS) (San Raffaele 
Hospital, Milan, Italy – Unità Funzione del Genoma) where samples were 
processed by TruSeq DNA Sample Prep v2 kit (Illumina®), controlled on an 
Agilent Technologies 2100 Bioanalyzer and sequenced by Illumina MiSeq 
System. 
 
 
 
3.4.2 Illumina sequencing data processing 
 
 
 
Illumina sequencing data were pre-processed and filtered by a multiple 
sequence alignment algorithm to identify the variable region sequences. Total 
sequences of a given round were compared to total rounds to extract those 
more representative and to examine their enrichment evolution. 
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3.5 Chimeras treatment 
 
 
 
GL21-miR212 (2g) long strand, miR-212 (2g) short strand, miR-212 (1g) short 
strand were purchased from Chemgenes as 2’-fluoropyrimidine RNAs: 
- GL21-miR212 (2g) long strand: 
5’0GGAUGAUCAAUCGCCUCAAUUCGACAGGAGGCUCACGGUACCU
UGGCUCUAGACUGCUUACUUU    
- miR-212 (2g) short strand:  
5’ AGUAACAGUCUCCAGUCACGGCCACC 
- miR-212 (1g) short strand:  
5’ UAACAGUCUCCAGUCACGGCC 
while  GL21scr-miR212 long strand and GL21-miR212 (1g) long strand were 
previously amplified and, then, transcribed in presence of 2’-
fluoropyrimidines. 
- GL21scr-miR212 long strand: 
5’0GGGTTCGTACCGGGTAGGTTGGCTTGCACATAGAACGTGTCAGG
CCGTGACTGGAGACTGTTA 
- GL21-miR212 (1g) long strand:  
5’0GGGATGATCAATCGCCTCAATTCGACAGGAGGCTCACGGCCGTG
ACTGGAGACTGTTA 
The amplification was done using: 
- GL21scr-miR212 forward primer: 
 5’ TAATACGACTCACTATAGGGTTCGTACCGGGT 
- GL21-miR 212 (1g) forward primer: 
5’ TAATACGACTCACTATAGGGATGATCAATCGC 
- GL21-miR212 (1g)/GL21scr-miR212 reverse primer: 
 5’ AATAACAGTCTCCAGTCACG 
The reaction was as follow: 94°C for 4 min, 20 cycles of 94°C for 30 sec, 55°C 
for 30 sec and 72°C for 30 sec, and a final extension of 72°C for 3 min. 
Before each treatment, the RNA long strand was denatured at 98°C for 20 
minutes, the RNA short strand at 55°C for 10 minutes and annealed each other 
using Binding Buffer 10X (200 mM Hepes, pH 7.4, 1.5 M NaCl, 20 mM 
CaCl2).  
 
 
 
3.6 Binding and internalization assays 
 
 
 
Binding to BCSCs of the starting and final pools was performed in 2ml tubes in 
triplicate with 5’-[32P]-labeled RNA. 3.5x104 cells per tube were incubated 
with the pools (200 nM as final concentration) in 200 µl of DMEM-F12 serum 
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free for 15 minutes at 37°C with gentle shaking and in the presence of 100 
µg/ml polyinosine, as a nonspecific competitor (Sigma). After two washings 
with 500 µl of medium, bound sequences were recovered in 100 µl of SDS 1% 
and the amount of radioactivity recovered was counted. The background value 
obtained with the starting pool was subtracted from the value obtained with the 
final pool. 
For chimeras binding assay, A549 and MCF7 cells were plated in 24 multi-
well in triplicate. RNAs were 5’-[32P]-labeled and incubated on cells at a final 
concentration of 200nM at 37°C for 15 minutes and the amount of radioactivity 
recovered was counted. To check the endocytosis rate, after the incubation with 
radiolabeled chimeras, cells were incubated with High Salt PBS (0.5M NaCl). 
Following 5 minutes-treatment at 4°C, the amount of RNA internalized was 
recovered and counted. In both assays, results were normalized for cells 
number. 
 
 
 
3.7 Protein isolation and Western blotting 
 
 
 
Cells were washed twice in ice-cold PBS and lysed in JS buffer (50 mM 
HEPES pH 7.5 containing 150 mM NaCl, 1% Glycerol, 1% Triton 100X, 1.5 
mM MgCl2, 5 mM EGTA, 1 mM Na3VO4 and 1X protease inhibitor cocktail). 
Protein concentration was determined by the Bradford assay (BioRad) using 
bovine serum albumin as the standard and equal amounts of protein were 
analyzed by SDS-PAGE (15% acrylamide). Gels were electroblotted onto 
nitrocellulose membranes (Millipore). For immunoblot experiments, 
membranes were blocked for 1 hr with 5% non-fat dry milk in Tris Buffered 
Saline (TBS) containing 0.1% Tween-20 and incubated at 4°C over night with 
primary antibody. Detection was performed by peroxidase-conjugated 
secondary antibodies using the enhanced chemiluminescence system 
(Amersham-Pharmacia Biosciences). Primary antibodies used were: anti-PED 
(Condorelli et al. 1998), anti-Axl (R&D Systems), anti-Caspase-8 Cell 
Signalling) and anti-βactin (Sigma). 
 
 
 
3.8 RNA extraction and RealTime-PCR 
 
 
 
Total RNAs (miRNA and mRNA) were extracted using Trizol (Invitrogen) 
according to the manufacturer’s protocol. Reverse transcription of total miRNA 
was performed starting from equal amounts of total RNA/sample (1µg) using 
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miScript reverse Transcription Kit (Qiagen). Quantitative analysis of miR-212 
and RNU6B (as an internal reference) were performed by RealTime-PCR using 
specific primers (Qiagen) and miScript SYBR Green PCR Kit (Qiagen). The 
reaction for detection of miRNAs was performed as follow: 95°C for 15min, 
40 cycles of 94°C for 15sec, 55°C for 30sec and 70°C for 30sec. All reactions 
were run in triplicate. The threshold cycle (CT) is defined as the fractional 
cycle number at which the fluorescence passes the fixed threshold. For 
quantization the 2(-∆∆CT) method was used as previously described (Livak and 
Schimmgen 2001). Experiments were carried out in triplicate for each data 
point and data analysis was performed by using software (Bio-Rad). 
 
 
 
3.9 Proliferation assay and cell death quantification 
 
 
 
A549 and MCF7 cells were treated with GL21-miR212 (2g) and GL21scr-
miR212 for 3 hours and then plated in 96 multi-well plates in triplicate for 24, 
48, 72 and 96 hours. Alternatively, A549 cells were transfected with siPED 
RNA and an empty vector and plated in 96 multi-well plates in triplicate for 
24, 48 and 72 hours. Cell viability was assessed with CellTiter 96 Aqueous 
One Solution Cell Proliferation Assay (Promega). Metabolically active cells 
were detected by adding 20 µl of MTS to each well and plates analyzed in a 
Multilabel Counter (BioTek).  
For cell death quantification, cells treated were incubated with TRAIL at a 
final concentration of 50 ng/ml for 24h.  
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4. RESULTS 
 
 
 
4.1 AIM-1 
 
 
 
4.1.1 Characterization of breast cancer stem cells (BCSCs ) and breast 
cancer cells (BCCs) 
 
 
 
Stemness phenotype includes the capability to propagate in an undifferentiated 
state in non-adherent conditions as spheres, to differentiate and to express some 
stemness markers. Both BCSCs and BCCs were obtained disgregating a breast 
cancer sample from a patient undergone to surgery. A part of cells was plated 
in suspension in a medium containing growth factors, as EGF and bFGF, and 
in absence of serum observing mammospheres formation, typical of BCSCs. 
The rest of cells were, instead, plated in adherence in presence of serum 
forming a culture of primary adherent BCCs. Both types of cells were assessed 
for markers of stemness and differentiation. BCCs were analyzed by 
immunofluorescence for the expression of CK14 (differentiation marker). On 
the other hand, BCSCs were evaluated by  fluorescence-activated cell sorting 
(FACS) resulting CD24(-/low)/CD44+ (Al-Hajj et al. 2003), CK14- and 
expressing ALDH1 by immunofluorescence (Ginestier et al. 2007). Moreover, 
to evaluate differentiation property, mammospheres were disgregated and 
plated in adherence with serum obtaining a culture assessed for differentiation 
markers. Indeed, the obtained BCCs were analyzed by immonufluorescence 
showing an increase in the expression of CK8/18 and CK14 (differentiation 
markers) and a reduction of CK5 (stemness marker) (Fig.11). 
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Fig.11: In vitro propagation and characterization of BCSCs and BCCs from a 
human sample. A) BCSCs and BCCs were obtained plating cells from a breast 
tumor in suspension (with EGF and bFGF and in absence of serum) and in 
adherence (in presence of serum), respectively. BCCs resulted CK14+ 
(fluorescent red) by immuofluorescence; B) characterization of BCSCs for 
stemness markers resulting CD24(-/low)/CD44+ by FACS (right panel), 
CK14- and ALDH1+ by immunofluorescence (fluorescent green) (left panel); 
C) analysis of BSCSs capability to differentiate in BCCs. BCSCs were plated 
in adherence with serum and differentiation markers were evaluated after 2 and 
7 days. Cells showed an increase of CK8/18 (fluorescent green) and CK14 
(fluorescent red), while a reduction of CK5- (fluorescent green) by 
immunofluorescence. 
EGF=epidermal growth factor, bFGF=basic fibroblast growth factor, 
CK=cytokeratin, ALDH1= aldehyde dehydrogenase 1. 
 
 
 
4.1.2 Enrichment of selection for a complex target 
 
 
 
In order to isolate cell specific ligands for a given tumor condition, I used as 
target in the selection steps BCSCs and in the counterselection steps BCCs 
from the same patient. For the SELEX cycle it was used a library of RNAs 
formed by a central degenerated sequence of 45 nucleotides flanked by two 
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fixed regions recognized by T7-RNA Polymerase. The library is modified with 
2’Fluoro-Pyrimidines (2-F-Py) to resist to nuclease degradation. At each round, 
the selection step on BCSCs was preceded by one or two counterselection steps 
against BCCs. All the unbound sequences were, then, recovered and incubated 
on BCSCs (Fig.12).  
During the selection process, I progressively increased the selective pressure 
by changing both incubation and washing conditions (Table 1). After several 
washings of the cells with DMEM serum free, the bound RNAs was recovered 
by total RNA extraction. Sequences enriched by the selection step were 
amplified by RT-PCR followed by mutagenic PCR (in presence of high 
concentration of nucleotides and magnesium) to increase library variability and 
by in vitro transcription, before a new cycle of selection. In total I performed 
15 cycles. 
 
 
      
Fig.12: SELEX method scheme. A library of ssDNAs, formed by a 
degenerated central region of 45 nt flaked by two fixed region, was amplified 
and transcribed in presence of 2’-fluoropyrimidines (2-F-Py). The 2-F-Py RNA 
library was incubated on BCCs (counterselection step). Unbound sequences 
were, then, incubated on BCSCs. Bound sequences were recovered by RNA 
extraction and RT-PCR, amplified by mutagenic PCR to increase library 
variability and used for the next SELEX cycle. 
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Table 1: Conditions used for each of 15 SELEX cycles. 
 
 
 
At the end of SELEX cycles, to evaluate the enrichment of the library for the 
desired target we compared the binding capacity of the final pool (cycle 15), 
named B15, to the naive starting one (B0). For the binding assay both pools 
were 5’-[32P]-labeled and, then, incubated on BCSCs for 15 minutes at 37°C 
with gentle shaking. Finally, bound sequences were recovered and the amount 
of radioactivity counted. B15 showed a higher capacity to bind BCSCs respect 
to B0, 1.6 times more (Fig.13). So, the final pool was enriched for aptamers 
that preferentially bind to BCSCs. 
 
     
 
Fig.13: Binding assay for B15 pool on BCSCs. B0 and B15 were radiolabeled 
and incubated on BCSCs. The binding affinity of the final pool was compared 
to B0, the starting one. 
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4.1.3 Selection of the most enriched sequences 
 
 
 
In order to isolate individual aptamers that may distinguish BCSCs from BCCs, 
I performed Illumina sequencing on DNA pools for selection rounds 0, 3, 5, 7, 
10, 12, 13, 15. A total of 8 Gigabyte sequences reads were obtained from the 
sequencing experiments. To count and align sequences, we designed a multiple 
sequence alignment algorithm. The first step of the algorithm was to extract the 
raw Illumina data. The sequences were, then, size selected with a distribution 
of lengths up to 45 nucleotides, which corresponds to the random region of 
aptamers. By this algorithm, I noted that there was a tendency through the 
cycles. Indeed, the maximum enrichment was observed in the 7th cycle with a 
reduction in the following ones. 386 sequences were extracted from the 
sequencing analysis of each SELEX cycle. Among these sequences, 43 showed 
a higher enrichment index and were, therefore, analyzed for alignment and 
structure prediction. Sequences corresponding to variable regions were aligned 
using ClustalW and aptamers grouped in families based on their primary 
sequence similarity. I found a big family of 39 sequences that were divided in 2 
groups on the base of their structure prediction. Two representative aptamers of 
each group with the most elevated enrichment index were selected. They will 
be used for further analysis (Fig.14). 
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Fig.14: Analysis of enriched sequences. A) Dendrogram (obtained by using 
ClustalW program) for visual classification of similarity among 43 individual 
sequences with a higher enrichment index obtained by Illumina sequencing. 
Red squares indicate the most enriched sequences, DSB389 and DSB241; B) 
their predicted structure (by using RNA structure 5.3 program).  
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4.2 AIM-2 
 
 
 
4.2.1 Selection of internalizing aptamers 
 
 
 
GL13 pool, an enriched pool of aptamers after 13 rounds of SELEX against 
U87MG, a malignant glioblastoma cell line, was used to find internalizing 
sequences. Two rounds of internalization were done. Cells were incubated with 
GL13 and, then, treated with proteinase K, able to destroy surface proteins, for 
30 min (first round) or 15 min (second round) at 37°C. The bound aptamers 
were discarded and the internalized aptamers were recovered by RNA 
extraction (Fig.15).  
 
         
Fig.15: Schematic representation of both rounds of internalization. 
 
 
 
The resulting GL13i2 pool enriched for internalizing aptamers was analyzed to 
obtain individual sequences. 50 sequences were cloned, aligned using 
ClustalW and grouped in families based on their primary sequence similarity 
(Fig16-A). I identified 5 principle families and, in one of these, I found a 
sequence, M13, identical to GL21 analyzed in a previous work (Cerchia et al. 
2009). It was used for further analysis and was found that M13/GL21 is able to 
bind Axl receptor expressed on the surface of U87MG, but also of other cell 
lines expressing Axl, as A549 of NSCLC (Cerchia et al. 2012). 
Each round of the two cycles of internalization was also subjected to Illumina 
sequencing. Most 100 enriched individual sequences were extracted through 
the same algorithm used for Illumina sequencing in AIM-1 and the enrichment 
reported in graphic (Fig16-B). Comparing Cloning and Illumina sequencing 
results, I found a little correspondence. In fact Gi-98, -71 and -13, that showed 
the highest enrichment index, presented identical sequence of M23, M28, M50 
family; M5, M45, M48, M38 family and M7 sequence, respectively (Table 2).  
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Fig.16: Representation of internalizing aptamers: two cycles of internalization 
were performed on U87MG cells and individual sequences were obtained 
through Cloning and Illumina sequencing. A) Dendrogram for visual 
classification of sequences obtained by cloning. Families were indicated with 
red squares; B) visual representation for enrichment of sequences obtained by 
Illumina sequencing.  
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Table 2: Corrispondance between most enriched sequences coming from 
Cloning and Illumina sequencing. 
 
 
 
4.2.2 Binding and internalization capability of GL21-miR212 chimeras  
 
 
 
Based on the demonstration that A549 cells express Axl receptor and PED 
protein targeted by miR-212, we designed two different chimeras (1g and 2g), 
in which we joined GL21 aptamer to miR-212. A scrambled chimera, 
GL21scr-miR212, was also designed, in which the portion regarding GL21 had 
a no-related sequence. In the first generation chimera, GL21-miR212 (1g), the 
aptamer is covalently linked to antisense strand of mature miR-212 hybridized 
to 21-mer sense strand. Instead, in the second generation chimera, GL21-
miR212 (2g), both antisense and sense strands are longer and not completely 
complementary. In fact, antisense strand is modified in the way to present an 
imperfect pairing with the sense strand, making structure more similar to that 
of a pre-miR. In both types of chimera the antisense strand presents two 
overhanging bases (UU) at 3’ end necessary for Dicer processing (Fig.17). 
 
                
                                          
 
                
                            
46 
 
                
                            
                 
                            
Fig.17: Chimeras structure prediction: A) GL21; B) GL21-miR212 (1g); C) 
GL21-miR212 (2g); D) GL21scr-miR212. They were designed with RNA 
structure 5.3 program. 
 
 
 
Even if by structure prediction GL21 seems to maintain its three-dimensional 
conformation within chimera, it was necessary to assure that GL21-miR212 
chimeras were able to bind and internalize into A549 cells. So, I performed a 
binding and an internalization assay in A549, using MCF7 cells as control. In 
fact, the latter do not express Axl receptor while expresses PED protein. 
Chimeras were 5’-[32P]-labeled and incubated on cells at 37°C for 15 minutes 
and the amount of radioactivity recovered was counted. Instead, for the 
internalization assay after incubation with radiolabeled chimeras, cells were 
treated with High Salt PBS C for 5 minutes at 4°. 
I found that GL21-miR212 (1g) and GL21-miR212 (2g) were both able to bind 
and internalize into A549. This was not obtained in MCF7 cells that do not 
express Axl. Comparing results for both assays, GL21-miR212 (2g) showed a 
lower binding affinity to A549 cells, but a higher internalization rate than 
GL21-miR212 (1g) (Fig.18). 
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Fig.18: Binding and internalization analysis of the two generations of 
chimeras. A) Binding assay and B) internalization assay for chimeras on A549 
(left panels) and MCF7 cells (right panels). Results were normalized over cells 
number; C) percentage of internalization rate respect to the bound amounts. 
 
 
 
4.2.3 GL21-miR212 (2g) targets PED protein 
 
 
 
First of all, we wanted to test the best chimera secondary structure that was 
processed by miRNA machinery and that was, therefore, functional. So, I 
treated A549 cells with both chimeras using GL21scr-miR212 and GL21 
aptamer as negative control. The treatment was at a final concentration of 400 
nM for 48h. Although both chimeras were able to internalize into A549 cells, 
as previously demonstrated, only GL21-miR212 (2g) targeted PED, 
downregulating its protein level. This means that only the second generation 
chimera is correctly processed by Dicer on the base of its structure. On the 
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other hand, either GL21scr-miR212 or the aptamer alone are unable to target 
PED (Fig.19). 
                                   
Fig.19: Comparison of functionality between two generations of chimeras. 
PED protein levels in A549 cells, treated at a final concentration of 400nM, 
were evaluated by western blot. Cell lysates were immunoblotted with anti-
PED antibody. To confirm equal loading, the membrane was immunoblotted 
with anti-β-actin antibody. 
 
 
 
Relying on literature (McNamara et al. 2006), I started the experiments using a 
final concentration of 400 nM for chimera treatment, but I performed a dose-
response assay to evaluate if chimera worked at lower doses. So, A549 cells 
were treated with different final concentrations (50, 100, 200, 300 and 400 nM) 
of GL21-miR212 (2g) and its control, GL21scr-miR212. By western blot, we 
observed that PED disappearance was already appreciable at 200 nM (Fig.20). 
              
 
 
Fig.20: Dose-response effect of GL21-miR212 (2g) chimera treatment. A549 
cells were treated with different final concentrations (50, 100, 200, 300, 400 
nM) of chimera and scrambled chimera for 48h. 
 
 
 
In order to assess if the effects of GL21-miR212 (2g) were specific for cell 
type, we treated both A549 and MCF7 cells. Chimeras treatment was realized 
at a final concentration of 300nM, an intermediate condition on the base of the 
dose-response assay. MiR-212 and GL21 were used as positive and negative 
controls, respectively. GL21-miR212 (2g) chimera downregulated PED as 
miR-212 in A549 cells, while no effects were observed in MCF-7 cells (Fig.21-
A). To confirm that the results on PED protein levels were correlated with 
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miR-212 RNA levels, the same samples were monitored by RT-PCR (Fig.21-
B). It showed that GL21 efficiently delivered miR212 inside the target cells, 
resulting in PED downregulation. 
 
 
         
 
               
 
Fig.21: PED and miR-212 expression levels. A549 and MCF7 cells were 
treated with GL21-miR212 (2g) for 48h. GL21scr-miR212 and GL21 were 
used as negative controls, while transfection with pre-miR-212 as positive 
control. Control scrambled was used to assure transfection efficiency. The 
same samples were subjected to western blot (A) for PED protein levels and to 
RT-PCR (B) for miR-212 expression levels. 
 
 
 
4.2.4 GL21-miR212 (2g) inhibits cell viability 
 
 
 
In order to verify if PED targeting had effects on cell viability, A549 and 
MCF7 cells were plated in triplicate and treated with GL21scr-miR212 and 
GL21-miR212 (2g) for 24, 48, 72 and 96 hours at 300 nM as final 
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concentration. Cell viability was evaluated using an MTT assay. A decrease in 
A549 cell vitality was observed already at 24 hours of treatment and viability 
decreased during time, compared to scambled chimera (Fig.22-A). Instead no 
effects were observed on MCF7 cells. To confirm that the effect was directly 
due to PED downregulation, I transfected A549 cells with a siRNA for PED 
and a control vector, and an MTT assay was performed after 24, 48 and 72 
hours. PED silencing confirmed a miR-212-mediated decrease in cell viability 
after chimera treatment (Fig.22-B).  
 
                                                         
         
 
 
 
Fig.22: GL21-miR212 (2g) effects on cell viability. A) A549 (left panel) and 
MCF7 cells (right panel) were treated with GL21-miR212 (2g) and scrambled 
chimera for 24, 48, 72 and 96 hours. Cell viability was evaluated with an MTT 
assay. B) A549 cells were transfected with a siRNA for PED and an empty 
vector. MTT assay was performed at 24, 48 and 72 hours. 
 
 
 
4.2.5 GL21-miR212 (2g) regulates TRAIL-induced cell death 
 
 
 
To verify that chimera sensitizes to TRAIL-induced apoptosis owing to PED 
targeting by miR-212 (Incoronato et al. 2010), A549 and MCF7 cells were 
treated with GL21scr-miR212 and GL21-miR212 (2g) for 48 hours and were 
exposed to TRAIL for 24 hours at 50 ng/mL as final concentration. After this 
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time, cell viability was assessed using an MTT assay. A549 cells underwent to 
TRAIL-induced cell death when treated with the chimera, while MCF7 cells 
remained insensitive, as expected (Fig.23-A). To confirm this data, I analyzed 
caspase-8 activation. I treated A549 cells with GL21-miR212 (2g) using 
GL21scr-miR212 and transfection with pre-miR-212 as negative and positive 
controls, respectively. Caspase-8 activation was then evaluated following 
treatment with TRAIL for 3 hours (Fig.23-B). As shown, cleavage of caspase-8 
was evident in cells treated with GL21-miR212 (2g) or, alternatively, 
transfected with pre-miR-212. So, the presence of exogenous miR-212 
internalized by the chimera led to caspase-8 activation, resulting in induced-
cell death only in target cells. 
 
 
 
 
 
 
                      
 
Fig.23: TRAIL sensitization. A) A549 (left panel) and MCF7 cells (right 
panel) treatment with TRAIL 50 ng/mL for 24h. Cell viability was evaluated 
with MTT assay. B) A459 cells were transfected with pre-miR-212 or 
alternatively treated with GL21-miR212 (2g). Control scrambled and 
scrambled chimera were used as negative controls. Cells were treated for 3h 
with TRAIL 50 ng/mL and cell lysates were immunoblotted with anti-caspase-
8 antibody. 
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5. DISCUSSION 
 
 
 
Since their discovery more than a decade ago, aptamers are emerging as new 
tools in the scenario of targeted anti-cancer therapy. In fact, considerable 
interest has been shown in developing novel treatments that target only cancer 
cells, thus avoiding the toxicity of conventional therapies, as chemotherapy and 
radiotherapy, against normal tissues adjacent to the tumor. Moreover, 
conventional therapies are initially effective in controlling tumor growth, but 
still many patients relapse over time. 
Here we show new applications for aptamers in anti-cancer targeted therapies, 
as tools for cancer stem cell-targeted therapy and as possible molecular 
vehicles for microRNAs.  
For recurrences, at least two major explanations exist. The first is that all 
cancer cells acquire resistance, resulting in decreased sensitivity to therapy 
over time. In this case, the relative proportion of cells in residual tumors with 
tumorigenic properties would be expected to be similar before and after 
treatment. The second explanation is that a rare subpopulation of cells with 
tumorigenic potential is intrinsically resistant to therapy. In this case, the 
relative proportion of cells in residual tumors with tumorigenic properties 
would be expected to increase after treatment. Consistent with this hypothesis, 
it has been previously shown that the gene expression pattern of residual tumor 
cells is different from that of cells of the initial tumor, in particular with 
differential expression of genes involved in cell cycle arrest and survival 
pathways (Chang et al. 2005). So, although the majority of cells in the original 
tumor may be killed by chemotherapy, the most important target, a small 
population of therapy-resistant cancer cells that possess tumorigenic capacity, 
is spared, thereby allowing tumor regrowth. It is well established that this 
tumorigenic subpopulation of cancer cells is represented by cancer stem cells 
(Li X et al. 2008). This hypothesis provided a unified explanation for the 
successes and failures of cytotoxic chemotherapy. 
The starting point for a targeted therapy is the identification of cancer-specific 
biomarkers, which may be used to assess changes in expression states of 
certain proteins or genes within a primary tumor.  
In breast cancer some markers for stemness phenotype were identified, as the 
expression of CD44 (CD44+) but low or no of CD24 (CD24-/low ) and a panel 
of nonepithelial lineage markers (Lin-). This subpopulation can form 
mammospheres in vitro and was shown to be enriched for tumorigenic cells by 
its ability to form xenograft tumors in immunocompromised mice (Al-Hajj et 
al. 2003). The tumorigenicity of CD44+/CD24-/low cells has been confirmed in 
subsequent studies (Ponti et al. 2005; Patrawala et al. 2006). This 
subpopulation is found enriched in residual breast cancer after conventional 
therapy, so it is responsible for recurrence (Phillips et al. 2006; Creighton et al. 
2009).  
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During time, other markers were identified for breast stem cells, as expression 
of epithelial specific antigen or ALDH1, but no of sialomucin (MUC-/ESA+) 
(Gudjonsson et al. 2002, Ginestier et al 2007). However, mammary gland is 
very heterogeneous and stem cells need to be better characterized. Therefore, 
finding molecular probes capable of identifying CSCs with specificity is an 
important challenge for making the elimination of CSCs a long-term success 
treatment. Aptamers respond to many necessities because they can distinguish 
among thousand proteins and do so in a short period. They can detect small 
differences between proteins that are otherwise quite similar in structure, an 
essential property if proteins are differentiated on the cell surface.  
Here, for the first time it has been set up a differential SELEX protocol to 
target whole living human cancer stem cells. In particular, I performed 15 
cycles using breast cancers stem and differentiated cells coming from the same 
patient. Firstly, the aptamers library was incubated on the BCCs and unbound 
sequences were recovered for the selection phase, on breast cancer stem cells 
The use of living cells as targets for SELEX has been already described. 
Indeed, it has been demonstrated that it is possible to obtain aptamers for a 
given transmembrane tyrosine kinase receptor (RET), if an appropriate 
protocol is adopted. This provided the first evidence for the possibility to use 
SELEX to distinguish between cells that differ for a single (or few) membrane 
epitope (Cerchia et al. 2005). Then, a similar approach was adopted to 
distinguish between closely related tumor cell lines by targeting unknown 
epitopes on the cell surface (Cerchia et al. 2009). Here I adopted a similar 
approach to distinguish among two different cancer cell states: stem and 
differentiated. Three works already exist on the selection of aptamers for stem 
surface epitopes. The first one identified aptamers for the epithelial cell 
adhesion molecule EpCAM (also known as CD326 or ESA) and the second 
one for the cancer stem cell marker CD133 (Shigdar et al. 2011; Shigdar et al. 
2013). In both cases, SELEX was done on purified protein and, then, aptamers 
were tested on cells. However, this strategy presents some limitations. In fact, 
aptamers have the potential of being used in living systems, especially within 
human biological conditions, so it becomes important select aptamers in their 
native conformation and condition. Cell-SELEX, performed here, uses whole 
living cells to avoid the disadvantage of selecting physiologically 
nonfunctional aptamers. A third work exist to discovery aptamers for cancer 
stem cells. In this one, the authors identified DNA aptamers for prostate cancer 
stem cells. However, although DNA aptamers have some advantages over 
RNA aptamers, as simpler chemical modifications in order to grant nuclease 
resistance, secondary structures formed by ssDNA are less stable than those of 
RNA molecules (Harada and Frankel 1995). 
In this study, after 15 cycles of cell-SELEX on BCSCs I performed Illumina 
sequencing on DNA pools for many selection rounds. Analyzing results with 
an algorithm, the maximum enrichment was reached in the 7th cycle with a 
reduction in the following cycles. This result reflects the enrichment found in 
the binding assay. In fact, 5’-[32P]-labeled B15 and B0 cycles were compared 
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for their binding affinity to BCSCs, showing a fold change of ≤ 1.6. This not so 
high rate probably is due to the fact that, after the maximum enrichment, the 
method has begun to select also less specific sequences for the stemness 
phenotype. So, it is important to set up the appropriate SELEX protocol for the 
selection goal. 
A panel of 386 sequences was obtained. Among these, 43 sequences were 
extracted on the base of the enrichment index and grouped for their primary 
sequence similarity. I identified a big family of 39 sequences showing a high 
grade of similarity. This family was, then, regrouped on the base of structure 
prediction and the two most representatives sequences were extracted for future 
analysis. This two sequences will be assessed for their binding capability and 
specificity to discover the specific surface epitope, identifying new possible 
biomarkers for stemness phenotype in breast cancer. Then, these aptamers will 
be analyzed for their ability to block signal transduction of cancer stem cells. In 
fact, aptamers act in the same way as antibodies by folding into a three-
dimensional structure to bind to their target, but in a advantageous way. First of 
all, both DNA and RNA ligands bind their targets with dissociation constants 
(Kd) in the low picomolar (1×10−12 M) to low nanomolar (1×10−9 M) range. 
This makes binding of an aptamer a highly specific interaction, with the ability 
to discriminate between related proteins that share common sets of structural 
domains. Aptamers also display low to no immunogenicity when administered 
in preclinical doses 1000-fold greater than doses used in animal and human 
therapeutic applications. Bioavailability and pharmacokinetics can also be 
modified in order to render aptamers resistant to nuclease degradation or to 
reduce renal clearance (Nimjee et al. 2005). 
It is possible also to select aptamers that not only recognize a cell, but are also 
endocytosed. It is a competitive application for developing targeted delivery 
vehicles. Here I have set up a SELEX protocol for a rapid internalization of 
aptamers within cells identifying many individual sequences, as GL21 aptamer. 
Since their discovery, escort aptamers have been successfully adapted for the 
targeted delivery of active drug substances forming a molecular chimera.  
This approach aims at combining an aptamer with another non-aptamer moiety 
(biomacromolecules, drug, or dyes), where one molecule engages with the 
target and the other one has a functional effect on the target molecule. It is 
difficult to know beforehand whether the joining may diminish the activity of 
one or both of the recombining partners (Burke and Willis 1998). However, 
with the progress of research in this field, as discussed here, it is very clear that 
chimeras are highly stable and efficient in activity. 
I have developed and characterized an aptamer-miRNA chimera that target 
specific cells and act as substrate for Dicer, thereby triggering cell type-specific 
gene silencing. In this study, I have targeted an anti-apoptotic gene, PED, with 
a tumor suppressor microRNA specifically in cancer cells expressing the cell-
surface receptor Axl. To date, all published RNA chimeras are made with 
siRNAs, so the conjugation of an aptamer with a microRNA is a new concept.  
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Due to their relatively small molecular weight (~6,000) and the endogenous 
power of targeting broad-range regulators, miRNAs have emerged as 
promising therapeutics. However, although synthetic miRNAs might be locally 
or systemically (intravenously) administered, negatively charged miRNAs have 
difficulty in penetrating hydrophobic cellular membranes, therefore requiring 
assisted cellular delivery. Moreover, miRNAs target a broad range of target 
genes in a context-dependent manner leading to unexpected effects in certain 
cells or tissues. So, it is very challenging to deliver tumor cell-specific miRNA 
therapeutics via an affordable and convenient approach. 
One approach was the use of lentiviral or adenoviral vectors expressing 
miRNA precursors or inhibitors (antagomirs) (Kumar et al. 2008). However, 
the safety issue of viral vectors is a concept to consider in clinical applications. 
Other delivery approaches include nanoparticles or liposomes (Babar et al. 
2012; Wu et al. 2011). In comparison with these approaches, an aptamer-
microRNA chimera responds to many necessities, first of all that regarding the 
specific delivery, thus avoiding side effects. Moreover, an aptamer-miRNA 
chimera is a molecule totally composed by RNA sequences. This may have 
important advantages in terms of cost and production, flexibility regarding 
chemical modification and safety. Notably, the approach developed here is 
compatible with chemical synthesis of RNAs. Short RNA aptamers (25–35 
bases) that bind various targets with high affinities have been described 
(Pestourie et al. 2005). Chimeras designed with such short aptamers would 
have a long strand of 45–55 bases, a length that can currently be produced with 
chemical synthesis. In contrast, protein reagent production in cell culture is 
considerably more complex and difficult to control. Moreover, chemically 
synthesized RNA is amenable to various modifications such as pegylation that 
can be used to modify its in vivo half-life and bioavailability. Of course, in the 
case of aptamer-miRNA chimeras, such modifications would need to be tested 
to determine whether they interfere with mechanisms such as uptake and 
processing by Dicer. An additional, notable advantage of the chimera over 
alternative approaches is its simplicity. As above mentioned, the chimera 
consists only of RNA, and any nonspecific side effects may, therefore, be 
limited to those already produced by the miRNAs themselves. Finally, as RNA 
is believed to be less immunogenic than protein, the chimeric RNAs would 
also be expected to produce less nonspecific activation of the immune system 
than protein-mediated delivery approaches. This fact may be important 
especially in case of following repeated administrations. In light of these 
reasons, microRNAs bioconjugated with aptamers are more advantageous 
compared to other approaches already existing. 
Here I have generated two chimeras with distinct secondary structures, but they 
were not equally functional. In fact, the production of mature miRNAs is 
dependent on endogenous miRNA processing machinery. In first generation 
chimera, GL21-miR212 (1g), the aptamer is covalently linked to antisense 
strand of mature miR-212 hybridized to 21-mer sense strand. Instead, in second 
generation chimera, GL21-miR212 (2g), 26-mer antisense and sense strand are 
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not completely complementary, but they present an imperfect pairing making 
structure more similar to a pre-miR. Despite in both generations the antisense 
strand presents two overhanging bases (UU) at 3’ end necessary for Dicer 
processing, between them only the second generation chimera is able to 
downregulate the miRNA target. The reason resides in the fact that Dicer-
mediated processing of RNAs may result in more efficient incorporation of 
resulting miRNAs as well as siRNAs into RISC (Kim et al. 2005)). This 
suggestion is based on the observation that longer double-stranded RNAs (~29 
bps), which are processed by Dicer, deplete their cognate mRNAs at lower 
concentrations than 19- to 21-bp miRNAs, which are not processed by Dicer. 
Thus, it is tempting to speculate that, because second generation chimera is 
correctly processed by Dicer, may be more potent in terms of gene-silencing 
ability than dsRNAs of 19–21 bps that are not processed. 
GL21-miR212 (2g) was designed on the experience of Dassie et al. (2009) for 
A10-Plk1 chimera, in which A10 truncated aptamer recognizes PSMA receptor 
on the surface of prostate cancer cells and vehicles siPlk1 to RISC complex. 
So, I used the truncated version of GL21 aptamer consisting of 34 nucleotides 
of the 92mer original molecule. It maintains the active site of GL21 and 
preserves high binding affinity to cells expressing Axl, a receptor 
overexpressed in many human cancers. Chimera designed with the short 
aptamer has a long strand of 62 bases, a length that can be efficiently produced 
with chemical synthesis. Moreover, the aptamer is covalently linked to 
antisense strand to enhance loading of the guide strand into RISC. Optimal 
loading of the guide strand into RISC is thought to reduce off-target effects that 
result from inappropriate incorporation of both miRNA strands into the 
silencing complex (Sledz et al. 2003). Although we cannot rule out potential 
off-target effects mediated by the guide strand itself, these effects would likely 
be restricted to the tumor, as the miRNAs are targeted to Axl expressing cancer 
cells. 
GL21-miR212 (2g) is able to bind and internalize into A459 cells, non-small 
cell lung cancer cell line, in a specific way. In fact, a scrambled chimera, 
GL21scr-miR212, which has a not-related structure in the aptamer portion, is 
unable to bind and internalize. In the same way, chimeras does not bind and 
internalize if assays are performed on MCF7, breast cancer cells not expressing 
Axl receptor. 
Because chimera is totally made of RNA that is prone to degradation by 
nucleases into the blood, it was already synthesized with 2’-fluoropyrimidines 
to increase in vivo stability. So I performed experiments to mimic 
physiological conditions. This modification is well characterized in humans 
and is reported to be well tolerated with little toxicity (Behlke 2008). RNA 
oligonucleotides with this modification have already been approved for use in 
humans (Macugen), with many more quickly moving through the clinical 
pipeline (Katz and Goldbaum 2006). Although we cannot completely rule out 
potential intracellular toxicity of 2’fluoropyrimidines-modified RNAs leading 
to nonspecific immunostimulation, experiments in vivo demonstrated that 
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problematic toxicity in humans is not expected (Dassie et al. 2006). To reduce 
this possibility, however, I tested different concentrations of chimera from 50 
up to 400 nM to determine the minimum concentration that had effect on miR 
target. 
In the chimera the aptamer is linked to miR-212. It is a tumor suppressor 
miRNA because negatively modulates PED/PEA-15 expression, a protein with 
a broad antiapoptotic action. As known, apoptosis is the predominant 
mechanism by which cancer cells die in response to cytotoxic drugs, but 
deregulation of apoptosis-related proteins can led to resistance to drug 
treatments. 
The anti-apoptotic action of PED is accomplished, at least in part, through its 
DED domain, which acts as a competitive inhibitor for pro-apoptotic molecules 
during the assembly of a functional death-inducing signaling complex (DISC) 
and inhibiting the activation of caspase 8, which take place following treatment 
with different apoptotic cytokines (CD95/FasL, TNF-alfa and TRAIL).  
PED is found overexpressed in a number of different human tumors, including 
non-small cell lung cancer, which represents about 80% of all lung cancer and 
is mostly diagnosed at an advanced stage (either locally advanced or metastatic 
disease). 
Because of resistance to therapeutic drugs, standard treatment of this tumor has 
only a 20% to 30% positive clinical response. In the last years, the discovery of 
the pivotal role in tumorigenesis of the Epidermal Growth Factor Receptor 
(EGFR) has provided a new class of targeted therapeutic agents: the EGFR 
tyrosine kinase inhibitors (EGFR-TKIs). Since their introduction in therapy, in 
advanced NSCLC patients harboring EGFR mutations, the use of EGFR TKIs 
in first-line treatment has provided an unusually large progression-free survival 
(PFS) benefit with a negligible toxicity when compared with cytotoxic 
chemotherapy. Nevertheless, resistance invariably occurs (Sgambato et al. 
2012). TRAIL (ApoL/TNF-related apoptosis-inducing ligand) is a relatively 
new member of the tumor necrosis factor (TNF) ligand family, which induces 
apoptosis in a variety of cancers, both in vitro and in vivo, without producing 
significant effects in normal cells. This unique property makes TRAIL an 
attractive candidate for cancer therapy. However, a significant proportion of 
cancer cell lines is resistant to TRAIL-induced apoptosis. As already published 
by Incoronato et al. (2010), miR-212 targeting PED is able to increase TRAIL 
sensitivity. Here, I demonstrated that GL21-miR212 (2g) chimera is not only 
correctly processed by miRNA machinery, but is also functional. In fact, 
exogenous miR-212 delivered by GL21 aptamer led to TRAIL sensitization 
through caspase-8 activation in TRAIL-resistant cells, as A549.  
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6. CONCLUSIONS 
 
 
 
In conclusion, in this study I have explored new possible applications for 
aptamers in targeted anti-cancer therapies. Through an appropriate SELEX 
protocol, I demonstrated that it is possible to select specific aptamers for the 
stemness phenotype in human breast cancer. Knowing that stem cells are 
responsible for tumor recurrences, aptamers could have important clinical 
benefits to overcome therapy resistance. At the same time, I also set up a 
SELEX protocol to identify aptamers able to be rapidly internalized within 
cells. I demonstrated that internalized aptamers can be used to create 
bioconjugates with “therapeutic” RNAs, as miRNAs. This strategy is 
advantageous over others already existing for miRNAs delivering, because 
summarizes many positive aspects: the specific delivery of miRNAs aptamer-
mediated to avoid side effects, the clinical potential of miRNAs themselves and 
advantages in terms of cost, production, flexibility regarding chemical 
modification and safety of all made-RNA molecules. 
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DoPED/PEA-15 (PED) is a death effector domain family member of 15 kDa with a broad antiapoptotic function
found overexpressed in a number of different human tumors, including lung cancer. To date, the mechanisms
that regulate PED expression are unknown. Therefore, we address this point by the identification of micro-
RNAs that in non–small cell lung cancer (NSCLC) modulate PED levels. In this work, we identify miR-212 as a
negative regulator of PED expression. We also show that ectopic expression of this miR increases tumor
necrosis factor–related apoptosis-inducing ligand (TRAIL)–induced cell death in NSCLC cells. In contrast,
inhibition of endogenous miR-212 by use of antago-miR results in increase of PED protein expression and
resistance to TRAIL treatment. Besides, in NSCLC, we show both in vitro and in vivo that PED and miR-212
expressions are inversely correlated, that is, PED is upregulated and miR-212 is rarely expressed. In conclusion,
these findings suggest that miR-212 should be considered as a tumor suppressor because it negatively regu-
lates the antiapoptotic protein PED and regulates TRAIL sensitivity. Cancer Res; 70(9); 3638–46. ©2010 AACR.Introduction
Lung cancer is one of the most common causes of cancer-
related deaths worldwide. About 80% of all lung cancers
are of the non–small cell lung carcinoma (NSCLC) type,
which is divided in to three subtypes: squamous cell carcino-
ma (25–30%), adenocarcinoma (40%), and large-cell carcino-
ma (10–15%; ref. 1). Because of their resistance to therapeutic
drugs, standard treatment of these tumors has only a 20% to
30% positive clinical response. Therefore, to develop new
therapeutic strategies to improve therapy for NSCLC is
important in understanding the molecular mechanisms
involved in cell death resistance.
Apoptosis is the predominant mechanism by which cancer
cells die in response to cytotoxic drugs. Resistance to drug
treatment is due to deregulation of apoptosis-related proteins.
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on March 2cancerres.aacrjournals.org wnloaded from (DED) family member of 15 kDa having a variety of effects on
cell growth and metabolism (2–4). PED/PEA-15 was found
overexpressed in a number of different human tumors, includ-
ing gliomas, squamous carcinoma, thyroid, breast, lung can-
cer, and B-cell chronic lymphocytic leukemia (5–9). PED/
PEA-15 has a broad antiapoptotic action, being able to inhibit
both the intrinsic and the extrinsic apoptotic pathways. Inhi-
bition of the extrinsic pathway is accomplished through its
DED, which likely acts as a competitive inhibitor for proapop-
totic molecules during the assembly of the death-inducing sig-
naling complex (3, 6). Recently, regulation of PED/PEA-15
phosphorylation by PTEN was shown to play a key role in de-
termining whether a cell dies by type I or type II Fas-induced
apoptosis (10). We recently showed that in NSCLC, PED/
PEA-15 overexpression is responsible for a tumor necrosis
factor–related apoptosis-inducing ligand (TRAIL)–resistant
phenotype (9). Furthermore, PED is upregulated in breast
cancer where it induces resistance to chemotherapeutic treat-
ment (8, 9). To date, although PED/PEA-15 is overexpressed
in a number of different cancer types, the mechanisms that
regulate its expression are unknown.
An important mechanism of protein expression regulation
involves microRNAs (miRNA). These molecules are evolution-
arily conserved, endogenous noncoding RNAs of about 22 nu-
cleotides (nt) in length that function at the posttranscriptional
level (11). In animals, single-stranded miRNAs bind with spe-
cific mRNAs through sequences that are partially complemen-
tary to the 3′ untranslated region (UTR) of the target mRNA
(12). miRNAs are involved in numerous cellular processes in-
cluding development, differentiation, proliferation, apoptosis,
and response to stress (13, 14). To date, more than 600 human
miRNAs have been experimentally identified and estimated toh. 
9, 2013. © 2010 American Association for Cancer
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Published OnlineFirst April 13, 2010; DOI: 10.1158/0008-5472.CAN-09-3341 regulate more than one third of cellular mRNAs. Interestingly,
numerous oncogenes and tumor suppressor genes are regulat-
ed bymiRNAs. With the advent of miRNA expression profiling,
significant effort is being made to correlate miRNA expression
with tumor prognosis (15, 16). To date, a number of downre-
gulated miRNAs found in lung cancer correlate with patient
survival (17, 18) and with therapeutic response (19).
In this article, we identify amiRNA that regulates PED/PEA-
15 expression. Our data indicate that miR-212 negatively mod-
ulates PED/PEA-15 expression and sensitizes non–small cell
lung cancer (NSCLC) cells to TRAIL-induced apoptosis. More-
over, we report that NSCLC-affected lung tissue overexpres-
sing PED/PEA-15 protein has a concordant downregulation
of miR-212.
Materials and Methods
Cell culture and transfection. Calu-1 (NSCLC) cells were
grown in DMEM; H460 cells were grown in RPMI. Media
were supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 2 mmol/L L-glutamine, and 100 units/mL pen-
icillin/streptomycin. For transient transfection, cells at 50%
confluency were transfected using Lipofectamine 2000 (Invi-
trogen) with 100 nmol/L (final) of pre-miR-212, pre-miR-34a,
pre-miR-124a, scrambled, or antisense miR-212 (Applied Bio-
systems). Transfections were done with Lipofectamine 2000
according to the manufacturer's instructions (Invitrogen).
Meg01 cells (human, chronic myelogenous leukemia cells)
were grown in RPMI 1640 + 2 mmol/L glutamine + 10% FBS.
Lung cancer samples. A total of 18 snap-frozen normal
and malignant lung tissues (12 men and 6 women; median
age, 70.0 y; range, 55–82 y) were collected at the Ohio State
University Medical Center (Columbus, OH).
Protein isolation and Western blotting. Cells were
washed twice in ice-cold PBS and lysed in JS buffer [50
mmol/L HEPES (pH 7.5) containing 150 mmol/L NaCl, 1%
glycerol, 1% Triton X100, 1.5 mmol/L MgCl2, 5 mmol/L
EGTA, 1 mmol/L Na3VO4, and 1× protease inhibitor cocktail].
Protein concentration was determined by the Bradford assay
(Bio-Rad) using bovine serum albumin as the standard, and
equal amounts of proteins were analyzed by SDS-PAGE
(12.5% acrylamide). Gels were electroblotted onto polyvinyli-
dene difluoride membranes (Millipore). For immunoblot ex-
periments, membranes were blocked for 1 h with 5% nonfat
dry milk in TBS containing 0.1% Tween 20 and incubated at
4°C overnight with primary antibody. Detection was done with
peroxidase-conjugated secondary antibodies using the
enhanced chemiluminescence system (Amersham-Pharmacia
Biosciences). Primary antibodies used were anti-PED (3),
anti–caspase-8 (Cell Signaling), and anti–β-actin (Sigma).
Cell death quantification. Calu-1 cells were transfected
with pre-miR-212 or control for 48 h. Cells were then trypsi-
nized, plated in 96-well plates in triplicate, and further incu-
bated with 10 or 25 ng/mL superkiller TRAIL (Alexisis
Biochemicals) for 24 h. Cell viability was evaluated with the
CellTiter 96 AQueous One Solution Cell Proliferation Assay
(Promega) according to the manufacturer's protocol. Meta-
bolically active cells were detected by adding 20 μL of MTSwww.aacrjournals.org
Researc
on March 2cancerres.aacrjournals.org Downloaded from to each well. After 2 h of incubation, the plates were analyzed
in a Multilabel Counter (BioTek).
Cell death assessment by Annexin V staining. Calu1 cells
were transfected with 100 nmol/L miR scrambled and with
100 nmol/L miR-212. After 48 h, cells were treated with 10 or
25 ng/mL of TRAIL for 24 h, harvested, washed twice with
cold PBS, and stained with Annexin V-FITC Apoptosis Detec-
tion Kit 1 (BD Pharmingen). Briefly, cells were resuspended
in 100 μL of 1× binding buffer and 5 μL of Annexin V and
then incubated for 15 min at room temperature. Apoptotic
cells were analyzed by flow cytometry.
RNA extraction and real-time PCR. Total RNAs (miRNA
and mRNA) were extracted using miRNeasy Mini Kit
(Qiagen) according to the manufacturer's protocol. Reverse
transcription of total miRNA and mRNA was done starting
from equal amounts of total RNA/sample (1 μg) using miS-
cript Reverse Transcription Kit (Qiagen). For cultured cells,
quantitative analyses of PED, glyceraldehyde-3-phosphate
dehydrogenase (as an internal reference), miR-212, and
RNU5A (as an internal reference) were done by real-time
PCR using specific primers (Qiagen), miScript SYBR Green
PCR Kit (Qiagen), and QuantiTect SYBR Green PCR Kit
(Qiagen), respectively. The reaction for detection of mRNAs
was done as follows: 95°C for 15 min, 40 cycles of 94°C for
15 s, 55°C for 30 s, and 72°C for 30 s. The reaction for de-
tection of miRNAs was done as follows: 95°C for 15 min, 40
cycles of 94°C for 15 s, 55°C for 30 s, and 70°C for 30 s. To
analyze PED and miR-212 expression in lung tissue speci-
mens (neoplastic and normal tissue), real-time PCR was
done using a standard TaqMan PCR Kit protocol on an
Applied Biosystems7900HT Sequence Detection System
(Applied Biosystems). The reactions were incubated at
95°C for 10 min, followed by 40 cycles of 95°C for 15 s
and 60°C for 1 min.
All reactions were run in triplicate. The threshold cycle (CT)
is defined as the fractional cycle number at which the fluores-
cence passes the fixed threshold. For relative quantitation,
the 2(−ΔCT) method was used as previously described (20). Ex-
periments were carried out in triplicate for each data point,
and data analysis was done by using Bio-Rad IQ software.
Luciferase assay. The 3′UTR of the human PED gene was
PCR amplified using the PED primers 5′-tctagaaaggcaaaga-
gaccactcaaccccca-3′ (forward) and 5′-tctagaatgttcttcaccaag-
gagagagggaaggtt-3′ (reverse) and cloned downstream of the
Renilla luciferase stop codon in pGL3 control vector (Prome-
ga), giving rise to pcDNA/PED-clone1 (3). This construct was
used to generate, by inverse PCR, the p3′-UTRmut-PED plas-
mid (primers: PED-mut1, FW 5′-tgtttgtactcctgtgctgtcctgag-
taccagc-3′, RW 5′-gctggtactcaggacagcacaggagtacaaaca-3′;
PED-mut2, FW 5′-agttgttcctactcagcactctaaacctagggagg-3′,
RW 5′-cctccctaggtttagagtgctgagtaggaacaact-3′). MeG01 cells
were cotransfected with 1 μg of p3′UTR-PED and with p3′
UTRmut-PED plasmid and 1 μg of the Renilla luciferase ex-
pression construct pRL-TK (Promega) with Lipofectamine
2000 (Invitrogen). Cells were harvested 24 h posttransfection
and assayed with Dual Luciferase Assay (Promega) according
to the manufacturer's instructions. Three independent
experiments were done in triplicate.Cancer Res; 70(9) May 1, 2010 3639
h. 
9, 2013. © 2010 American Association for Cancer
Incoronato et al.
3640
Published OnlineFirst April 13, 2010; DOI: 10.1158/0008-5472.CAN-09-3341 miRNA locked nucleic acid in situ hybridization of
formalin-fixed, paraffin-embedded tissue section. In situ
hybridization was carried out on deparaffinized human lung
and liver tissues using previously published protocol (21),
which includes a digestion in pepsin (1.3 mg/mL) for 30
min. The sequence of the probes containing the six dispersed
locked nucleic acid (LNA) modified bases with digoxigenin
conjugated to the 5′ end was miR-212-(5′) UAACAGUCUCCA-
GUCACGGCC. The probe cocktail and tissue miRNA were co-
denatured at 60°C for 5 min, followed by hybridization at 37°C
overnight and a low stringency wash in 0.2× SSC and 2%
bovine serum albumin at 4°C for 10 min. The probe-target
complex was seen due to the action of alkaline phosphataseCancer Res; 70(9) May 1, 2010
Researc
on March 2cancerres.aacrjournals.org Downloaded from on the chromogen nitroblue tetrazolium and bromochloroin-
dolyl phosphate. Negative controls included the use of a probe,
which should yield a negative result in such tissues. No coun-
terstain was used to facilitate colabeling for PED protein. After
in situ hybridization for the miRNAs, as previously described
(21), the slides were analyzed for immunohistochemistry using
the optimal conditions for PED (1:800, cell conditioning for 30
min). For the immunohistochemistry, we used the Ultrasensi-
tive Universal Fast Red system fromVentanaMedical Systems.
We used normal lung tissues as controls for these proteins.
The percentage of tumor cells expressing PED and miR-212
was then analyzed with emphasis on colocalization of the
respective targets (miR-212 and either PED).Figure 1. PED expression is regulated by miR-212. A, top, complementary sites on PED 3′UTR for miR-34a, miR-124a, and miR-212. The capital
letters identify perfect base matches according to the Pictar, TargetScan, miRanda, and miRBase softwares (bottom). Western blot analysis of cellular
extracts of Calu-1 cells transfected for 72 h with pre-miR-34a, pre-miR-124a, pre-miR-212, or a scrambled oligonucleotide (scrb). Cell lysates were
immunobloted with anti-PED antibody. To confirm equal loading, the membrane was probed with anti–β-actin antibody as indicated. B, Meg01 cells were
transiently cotransfected with the luciferase reporter containing PED 3′UTR and pre-miR-212 or scrambled oligonucleotide. C, left, complementary sites
for miR-212 on PED 3′UTR. The bold letters identify the deletion regions of mutants (mut) 1 and 2, respectively. Right, Meg01 cells were transiently
transfected with the luciferase reporter containing full-length PED 3′UTR, mut1, or mut2 in the presence of pre-miR-212 or scrb. C and D, luciferase activity
was evaluated 24 h after transfection as described in Materials and Methods. Representative of at least three independent experiments.Cancer Research
h. 
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Published OnlineFirst April 13, 2010; DOI: 10.1158/0008-5472.CAN-09-3341 Statistical analysis. Continuous variables are expressed
as mean values ± SD. One-tailed Student's t test was used
to compare values of test and control samples. P < 0.05
was considered significant.Results
Identification of miRNA involved in PED regulation. To
identify miRNAs that specifically target PED (PED/PEA-15),
we used bioinformatic analyses available on the web, includ-
ing Pictar, TargetScan, miRanda, and miRBase. Comparing
the results obtained from the different searches, we found
that miR-34a, miR-124a, and miR-212 consistently showed
the highest score of probability for targeting PED 3′UTR.
PED 3′UTR contains two potential binding sites for miR-
212 at nt 507 and nt 741, one for miR-34a at nt 1142, and
two for miR-124a at nt 1491 and nt 1527 (Fig. 1A, top).
To asses whether exogenous expression of the selected
miRNAs induced PED downregulation, we used Calu-1 cells,www.aacrjournals.org
Researc
on March 2cancerres.aacrjournals.org Downloaded from which express high PED levels (9). To this end, Calu-1 cells
were transiently transfected with 100 nmol/L of the indicated
pre-miRNAs for 72 hours, and PED expression levels then
identified by Western blot analysis (Fig. 1A, bottom).
As shown, miR-212 induced the greatest decrease in PED
protein.
The most widely used approach for experimentally validat-
ing miRNA targets is to clone the predicted miRNA-binding
sequence downstream of a luciferase reporter construct and
to cotransfect it with the miRNA of interest. To this end, we
cloned the 3′UTR sequence of human PED into the luciferase
expressing vector pGL3-control downstream of the luciferase
stop codon; Meg01 cell lines were transiently transfected
with this construct in the presence of pre-miR-212 or a
scrambled oligonucleotide acting as a negative control. As
reported in Fig. 1B, miR-212 significantly reduced luciferase
activity compared with the scrambled oligonucleotide. This
indicates that miR-212 binds to the 3′UTR of Ped and impairs
PED mRNA translation.
As reported above, miR-212 targets two regions of the 3′
UTR of PED mRNA (Fig. 1A). To determine which of the
two regions is implicated in the binding with miR-212, we
generated two deletion mutants (Fig. 1C, left): mut1, lacking
the first binding site, GACTGTT (top); and mut2, lacking the
second binding site, AGACTGTT (bottom). The two mutants
were cloned into the 3′UTR of the luciferase gene and co-
transfected with pre-miR-212 into the Meg01 cell line. As
shown in Fig. 1C (right), miR-212 did not significantly reduce
luciferase activity in the presence of the mut2 sequence. This
result indicates that miR-212 targets PED mRNA at the
AGACUGUU sequence.
miR-212 modulates PED mRNA levels. To asses whether
PED upregulation in lung cancer cells was due to decreasing
expression of miR-212, we analyzed in Calu-1 and H460 cells,
expressing different amounts of PED protein (Fig. 2A), the
levels of miR-212 and PED mRNA by real-time PCR. As
shown in Fig. 2B and C, an inverse correlation between
PED mRNA and miR-212 levels was found.
It is known that miRNAs regulate gene expression either
by direct cleavage of the targeted mRNAs or by inhibiting
translation (22). To determine whether the binding of miR-
212 to PED 3′UTR results in mRNA degradation, Calu-1 cells
were transfected for 48 or 72 hours with pre-miR-212, and
PED expression was then evaluated by real-time PCR and
Western blot. As shown in Fig. 3A, exogenous expression of
miR-212 induced a marked reduction of PED mRNA (top) as
well as PED protein (middle) levels. The efficiency of miR-212
transfection was evaluated by reverse transcription-PCR (RT-
PCR; bottom). Next, to assess whether miR-212 plays a phys-
iologic role in controlling PED expression, we treated H460
cells, which express high levels of miR-212, with a specific
antago-miR-212. As shown in Fig. 3B, increased expression
of PED mRNA (top) and PED protein (middle) was evident
already at 48 hours of antago-miRNA transfection. The effi-
ciency of antago-miR-212 transfection was evaluated by RT-
PCR of the endogenous miRNA (bottom). Taken together, the
results show that in lung cancer cells, PED and miR-212 ex-
pressions are inversely correlated and that miR-212 regulates
PED expression.Figure 2. PED and miR-212 expression levels are inversely correlated in
NSCLC. A, cell lysates from Calu-1 and H460 cells were immunoblotted
with anti-PED antibody. To confirm equal loading, the membrane was
immunoblotted with anti–β-actin antibody. Blots are representative of at
least four independent experiments. B and C, total RNA (mRNAs and
miRNAs) was extracted from Calu-1 and H460 cells and 1 μg was
reverse transcribed and amplified as described in Materials and Methods.
Relative expressions of PED mRNA (B) and miR-212 (C) were calculated
using the comparative CT methods. Columns, mean of four different
experiments; bars, SD. *, P < 0.05, Student's t test. There is an inverse
correlation between PED and miR-212 expressions in NSCLC.Cancer Res; 70(9) May 1, 2010 3641
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uate whether PED upregulation in lung cancer is related to
decreased miR-212 levels also in vivo, we analyzed PED and
miR-212 expression levels in tissue specimens collected from
18 patients (14 NSCLC-affected individuals and 4 with nor-
mal lung tissue). As shown in Fig. 4, in normal lung samples,
the levels of miR-212 were high whereas PED was expressed
at low levels. On the contrary, in the majority of lung cancer
samples, miR-212 was expressed at low levels and PED was
overexpressed.
To corroborate these findings, in situ hybridization analy-
sis was done, using 5′-dig-labeled LNA probes, on NSCLC and
normal lung tissues, followed by immunohistochemistry for
PED (Fig. 5). MiR-212 and PED expressions were inversely re-
lated in NSCLC and the adjacent normal lung tissues. Lung
cancer cells showed high expression of PED and rarely ex-
pressed miR-212 (Fig. 5A–C), whereas the adjacent nonmalig-
nant lung expressed miR-212 abundantly and rarely showed
detectable PED signal (Fig. 5A–C). Costaining of PED and
miR-212 showed that the two labelings did not overlapCancer Res; 70(9) May 1, 2010
Researc
on March 2cancerres.aacrjournals.org Downloaded from (Fig. 5C-c), showing that PED andmiR-212 were not expressed
in the same cell. In situ hybridization was done for 110 sam-
ples. The majority of cancer cells were positive for PED (84%).
Seventy-three percent of the samples were negative for miR-
212. When we analyzed for double staining, we found that
60% (65 of 110 patients) of the cells were PED positive/miR-
212 negative (PED+/miR−), 24% (26 of 110 patients) were
PED+/miR+, 3.6% (4 of 110 patients) were PED−/miR+, and
13% (15 of 110 patients) were PED−/miR−. These results further
support our above finding that the upregulation of PED in
lung cancer is dependent on decreased miR-212 levels.
MiR-212 increases TRAIL-induced cell death in NSCLC
cells. We have previously shown that a TRAIL-resistant pheno-
type in NSCLC is related to overexpression of PED (9). The ob-
servation that miR-212 targets PED suggests that ectopic
expression of this miRNA should increase sensitivity to TRAIL.
To this aim, we transfected Calu-1 cells with pre-miR-212, and
caspase-8 activation was then evaluated following treatment
with TRAIL (Fig. 6A). As shown, PED expression decreased in
the presence of exogenous miR-212, and caspase-8 activationFigure 3.miR-212 regulates PED expression levels. A, top, Calu-1 cells were transfected for 48 and 72 hwith pre-miR-212 or scrb. After transfection, total RNA
was extracted and 1 μg was reverse transcribed and amplified as described in Materials and Methods. As shown, PED mRNA was downregulated by
miR-212 transfection. Middle, cell lysates from Calu-1 cells were collected after 48 and 72 h from pre-miR-212 or scrb transfections and immunoblotted with
anti-PED antibody. To confirm equal loading, the membrane was immunoblotted with anti–β-actin antibody. As shown, decreasing amount of PED protein
was evident in the presence of exogenous pre-miR-212 (bottom). Relative expression of ectopic miR-212 after the transfection was evaluated. B, top,
H460 cells were transfected for 48 and 72 h with antago-miR-212 (anti-212) or scrb. After transfection, total RNA was extracted and 1 μg was reverse
transcribed and amplified as described in Materials and Methods. As shown, an increasing amount of PED mRNA was evident in the presence of exogenous
anti-212 (middle). Cell lysates from H460 cells were collected after 48 and 72 h from anti-212 or scrb transfections and immunoblotted with anti-PED
antibody. To confirm equal loading, themembranewas immunoblottedwith anti–β-actin antibody. As shown, an increasing amount of PEDproteinwas evident
in the presence of exogenous anti-212 (bottom). Relative expression of endogenous miR-212 after the antago-miR-212 transfection was evaluated.
Blots are representative of at least four independent experiments. Columns, mean of four different experiments; bars, SD. *, P < 0.05, Student's t test.Cancer Research
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with lane 6 and lane 7 with lane 8). To further confirm this re-
sult, we analyzed TRAIL-induced cell death in the presence of
exogenous pre-miR-212 with a cell viability assay (Supplemen-
tary Fig. S1A) and Annexin V apoptosis assay (Fig. 6B and
Supplementary Fig. S1B for representative dot blot). By time
course and dose/response analysis (data not shown), we found
that to better appreciate a difference in cell viability, low con-
centrations of TRAIL were needed. To this end, Calu-1 cells
were transfected for 48 hours with pre-miR-212, then stimulat-
ed with 10 and 25 ng/mL of TRAIL for 24 hours, and cell death
was evaluated. As shown in Fig. 6B, transfection of miR-212 in-
creased TRAIL-induced cell death up to 3-fold that of Calu-1
cells. Thus, PED downregulation induced by miR-212 increases
sensitivity to TRAIL in lung cancer cells.
To further evaluate the role of miR-212 in apoptosis sensi-
tivity, TRAIL-sensitive H460 cells were transfected with an-
tagomiR-212 to decrease endogenous miR-212 and then
analyzed for their susceptibility to TRAIL-induced cell death.
As shown in Fig. 6C, antago-miR treatment increased PED
protein and rendered H460 cells more resistant to TRAIL.
To confirm that PED is an important target of miR-212 for
regulation of apoptosis, Calu-1 cells were transfected with
pre-miR-212 in the presence or in the absence of PED-mycwww.aacrjournals.org
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on March 2cancerres.aacrjournals.org Downloaded from cDNA that lacks 3′UTR. As shown in Fig. 6D, ectopic expres-
sion of miR-212 and PED-myc cDNA restores the apoptotic
resistance, assessed as caspase-8 activation. To confirm this
result, we analyzed TRAIL-induced cell death in the presence
of exogenous pre-miR-212 and PED-myc with a cell viability
assay, obtaining the same results (Supplementary Fig. S1C).
Taken together, these results indicate that miR-212 increases
TRAIL sensitivity by targeting the antiapoptotic protein PED.
Discussion
The resistance of tumors to current chemotherapeutic
protocols remains a major problem in cancer therapy. De-
fects in the apoptotic program may contribute to treatment
resistance and tumor progression and may be caused by de-
regulated expression of antiapoptotic molecules. Better
knowledge of tumor biology is providing the opportunity to
treat lung cancer with a new class of anticancer drugs. PED is
overexpressed in lung cancer, as well as in other human tu-
mors including gliomas, squamous carcinoma, breast cancer,
and thyroid cancer, and its overexpression is related to resis-
tance to chemotherapy and TRAIL-induced cell death (4–9).
Furthermore, we recently showed that PED is upregulated
and induces resistance to TRAIL in NSCLC (9). Even so, theFigure 4. Correlation of endogenous miR-212 and PED mRNA expression levels in human lung cancer. Left, total RNA extracted from tissue specimens
collected from 14 NSCLC-affected individuals and 4 control individuals was used to analyze miR-212 and PED mRNA expression by real-time PCR
(right). Average of control versus tumor samples. Columns, mean PED or miR-212 expression of all the tumor samples (T) and normal tissue (N); bars, SD.
*, P < 0.05, t test. As shown, there is an inverse correlation between miR-212 and PED mRNA expression levels. The normal lung RNA expressed high
miR-212 and low PED mRNA levels; all the tumors analyzed expressed high PED mRNA and very low miR-212 levels.Cancer Res; 70(9) May 1, 2010 3643
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cancer cells are still unknown. We therefore have set out to
identify possible miRNAs able to regulate PED expression in
human lung cancer.
Here, we found that in lung cancer cells, miR-212 was able
to target PED 3′UTR and decrease its levels, thus suggesting
that by maintaining PED levels low, miR-212 action may con-
tribute to tumor suppression.
Over the past few years, several miRs have been implicated
in various human cancers. Both losses and gains of miR func-
tion have been shown to contribute to cancer development
through a range of mechanisms (23, 24).
More often in various human tumors has been observed
an overexpression of miRs, and several of these miRs func-
tion as oncogenes. When downregulated, miRNAs are consid-
ered tumor suppressor because they usually prevent tumor
development by negatively inhibiting molecules involved in
apoptosis resistance.
Different studies show that lung adenocarcinoma has a
miR expression signature that greatly adapts to the use of
clinical data in predicting an individual's survival. Low ex-
pression of let-7a and high expression of miR-155 are linked
to unfavorable clinical outcome in lung cancer (17). The miR-
34 cluster (miR-34a, miR-34b, miR-34c) is repressed in can-
cers and miR-34c is involved in p53 tumor suppression in
many cancers, including lung cancer (25, 26). Bandi et al.
(27) identified miR-15a and miR-16 as frequently deleted inCancer Res; 70(9) May 1, 2010
Researc
on March 2cancerres.aacrjournals.org Downloaded from NSCLC, implying an increase of cell cycle. Furthermore, Nas-
ser et al. (28) showed that miR-1 was downregulated in lung
cancer and was related to increased migration and motility
of lung cancer cells.
Using real-time RT-PCR, Yu et al. (29) analyzed miR ex-
pression in 112 different NSCLC patients. They found that
two miRs acted as antitumoral genes (miR-221 and let-7a)
and three miRs were risky for NSCLC (miR-137, miR-372,
and miR-182). Liu et al. (30) found that miR-34c, miR-145,
and miR-142-5p were suppressed in transgenic lung cancers
as well as human normal versus malignant lung tissues.
MiR-212 expression levels in human cancer have not been
extensively investigated thus far. Recently, miR-212 downre-
gulation has been found to be involved in lung cancer re-
sponse to chemotherapy, in particular to docetaxel (31).
The molecular targets responsible to this resistance have
not been identified thus far, but it would be interesting to
speculate that PED may participate in this process.
Our data show that in sample specimens from lung cancer,
miR-212 expression is low compared with normal samples.
Interestingly, miR-212 expression inversely correlates with
PED expression and with response to TRAIL treatment.
Therefore, miR-212 expression could predict therapeutic re-
sponse to TRAIL in lung cancer.
The mechanisms of miR-212 downregulation in human
cancer are not clear at the moment. miR-212 is located on
human chromosome 17, in a region that is frequently lostFigure 5. Immunohistochemistry and in situ hybridization of lung carcinoma and normal tissue samples. MiR-212 (blue; A-a) and PED (red; B-b) expressions
were inversely related in lung cancer and the adjacent normal lung tissues (C-c shows colocalization expression of PED and miR-212). Top, PED (B) and
miR-212 (A) expressions were confined mostly to cancer cells. However, note that cancer cells express PED and do not express miR-212 and vice versa (C).
Bottom, a nest of cancer cells expressing only miR-212 (a). Note that PED expression (b) is confined to the benign stromal cells that are found in the
desmoplastic tissue surrounding the cancer cells nest. Bar, 25 μm. Themagnification is the same for all images. D-d, H&E.One hundred ten lung carcinoma and
normal samples were analyzed. As described in the text, the majority of cancer cells were positive for PED and negative for miR-212. In the cases of lung
carcinoma where both miR-212 and PED expressions were noted, cancer cells expressing PED were distinct from those expressing miR-212.Cancer Research
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mechanism to explain its low expression.
The silencing of miR in cancer can be caused not only by
deletions and mutations but also by epigenetic changes.
Altered patterns of epigenetic modifications, in particular
the methylation of CpG islands in the promoter regions
of some miRs, have been described (33). The miR-212 pro-
moter region is possibly rich in CpG islands. Experiments
are under way in our lab to clarify whether methylation
may be a mechanism involved in the regulation of miR-
212 expression levels.
In summary, miRs are potential antineoplasitc agents. Per-
haps combination therapy with different miRs will be needed
to confer desired antitumorigenic effects. It will be critical towww.aacrjournals.org
Researc
on March 2cancerres.aacrjournals.org Downloaded from discern which miRs are overexpressed in lung cancer and
which need to be inactivated to inhibit lung carcinogenesis.
Conceivably, these miRs or their derivates would become
agents to treat or chemoprevent lung cancer.Disclosure of Potential Conflicts of Interest
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c-FLIPL enhances anti-apoptotic Akt functions
by modulation of Gsk3b activity
C Quintavalle1, M Incoronato2, L Puca1, M Acunzo1, C Zanca1, G Romano2, M Garofalo1,3, M Iaboni1, CM Croce3 and G Condorelli*,1,4,5
Akt is a serine–threonine kinase that has an important role in transducing survival signals. Akt also regulates a number of
proteins involved in the apoptotic process. To find new Akt interactors, we performed a two-hybrid screening in yeast using
full-length Akt cDNA as bait and a human cDNA heart library as prey. Among 200 clones obtained, two of them were identified as
coding for the c-FLIPL protein. c-FLIPL is an endogenous inhibitor of death receptor-induced apoptosis through the caspase-8
pathway. Using co-immunoprecipitation experiments of either transfected or endogenous proteins, we confirmed the interaction
between Akt and c-FLIPL. Furthermore, we observed that c-FLIPL overexpression interferes with Gsk3-b phosphorylation levels.
Moreover, through its effects on Gsk3b, c-FLIPL overexpression in cancer cells induced resistance to tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL). This effect was mediated by the regulation of p27Kip1 and caspase-3 expression.
These results indicate the existence of a new mechanism of resistance to TRAIL in cancer cells, and unexpected functions of
c-FLIPL.
Cell Death and Differentiation (2010) 17, 1908–1916; doi:10.1038/cdd.2010.65; published online 28 May 2010
Apoptosis, or programmed cell death, is an evolutionarily
conserved mechanism of elimination of unwanted cells. This
endogenous death machinery is triggered via two principal
signaling pathways.1 The extrinsic pathway is activated by the
engagement of death receptors on the cell surface. The
binding of ligands, such as Fas, tumor necrosis factor (TNF),
or TNF-related apoptosis-inducing ligand (TRAIL) to cognate
death receptors (DRs) induces the formation of the death-
induced signaling complex (DISC). This DISC complex in turn
recruits caspase-8 and promotes the cascade of procaspase
activation.2 The intrinsic pathway is triggered by various
intracellular and extracellular stresses, signals of which
converge mainly to the mitochondria.2,3 The balance between
pro- and anti-apoptotic members of apoptosis is crucial for the
regulation of survival and cell death. Aberrant resistance to
apoptosis may lead to the development of cancer.
Cellular FLICE-inhibitory protein (c-FLIP) is a death effector
domain (DED)-containing family member that inhibits one of
the most proximal steps of DR-mediated apoptosis. Two
isoforms of c-FLIP are commonly detected in human cells: a
long form (c-FLIPL) and a short form (c-FLIPS). c-FLIPL, a
55-kDa protein, contains two DEDs and a caspase-like
domain, whereas c-FLIPS, a 26-kDa protein consists only of
two DEDs.4 Both isoforms are recruited to the DISC, prevent
procaspase-8 activation and block DR-mediated apoptosis,
although through different mechanisms.5,6 c-FLIPL is over-
expressed in a number of different tumors and its over-
expression is related to TRAIL resistance.7,8 Beside cell
death, c-FLIPL might also regulate other DR-mediated signals
that may be important for tumor-promoting functions, such as
proliferation, migration, inflammation or metastasis.9–11 The
activation of the transcription factor NF-kB, the PKB/Akt
pathway and mitogen-activated protein kinases (MAPKs),
such as c-Jun N-terminal kinase (JNK), extracellular signal-
regulated kinase (ERK) and p38, has been demonstrated to
be a consequence of DR triggering.9 Akt is a serine–threonine
kinase that regulates the expression and the function of a
number of proteins involved in the apoptotic process.12 Akt
interaction or phosphorylation of different signaling molecules
may regulate their function by different mechanisms, including
increased protein stability, cellular localization or binding to a
different cellular partner. Akt interacts with a number of
proteins involved in apoptotic signaling cascades, including
BAD,13 caspase-9,14 the Forkhead transcription factor
FOXO315 and Bcl-w.16 The interaction of Akt with one of
these proteins prevents apoptosis through several different
mechanisms.13 One major Akt substrate is the serine–
theronine kinase Gsk3.17 Originally studied for its role in
glycogen metabolism and insulin action, Gsk3, present in the
cells in two isoforms, Gsk3a and Gsk3b, has subsequently
been shown to have central functions in many cellular
processes, including transcription, cell cycle division, cell fate
determination and stem cell maintenance, as well as in
apoptosis.17,18 Gsk3 is constitutively active in resting cells,
and is functionally inactivated after phosphorylation in
response to different stimuli.
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In this study, we set out to find and investigate new possible
partners of Akt that may participate in the regulation of the
apoptosis pathway. In this study, we provide evidence that Akt
directly interacts with c-FLIPL. Furthermore, we demonstrate
that c-FLIPL modulates the activation of Gsk3b. We also
provide evidence that this interaction is important for the
regulation of TRAIL sensitivity, through the regulation of p27
and caspase-3 levels.
Results
Akt interacts with c-FLIPL. To find new Akt interactors, we
performed a yeast two-hybrid screening. We used the
full-length human Akt cDNA sequence as bait and a human
cDNA heart library as prey. Among the 200 clones obtained,
two were identified to code for the anti-apoptotic protein,
c-FLIPL. To prove the interaction between Akt and c-FLIPL,
we performed immunoprecipitation experiments on
endogenous proteins and on protein extracts from cells
transfected with Akt and c-FLIPL cDNAs. We were able to
confirm the Akt–c-FLIPL interaction in extracts from
transfected cells (Figure 1a), and in endogenous proteins
from different cell lines (Figure 1b). To verify whether Akt
activity has a role in Akt–c-FLIPL interaction, HeLa cells were
transfected with either wild-type Akt cDNA or with two
different Akt mutants: kinase-dead Akt (Akt D) and
constitutively active Akt (Akt Dþ ). Protein extracts were
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Figure 1 Akt interacts with c-FLIPL. (a) HeLa cells were co-transfected with HA–Akt WT, Akt Dþ or Akt D cDNAs and c-FLIPL for 48 h, as indicated. Protein extracts were
immunoprecipitated (IP) with anti-Flag antibody and blotted with an anti-HA antibody. As negative control, proteins were incubated with beads without antibody. Total lysates
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transfected with c-FLIPL or c-FLIPs cDNA. Total lysates were immunoprecipitated with an anti-Flag antibody and then blotted with an anti-Akt antibody
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immunoprecipitated using a monoclonal anti-Flag antibody
and subsequently blotted using an anti-HA antibody. As
shown in Figure 1a, c-FLIPL interacted at comparable levels
with both the activated kinase and the kinase-dead Akt.
c-FLIPL is characterized by two death effector domains
(DEDs), which are important for interaction with members of
the apoptosis cascade. We examined whether these DED
domains were important for the interaction with Akt. For this
purpose, we generated three different mutants: cFLIPL I-DED,
missing the first DED; cFLIPL II-DED, missing the second
DED; and cFLIP DDED, missing both DEDs. The three
mutants were transfected together with HA–Akt cDNA into
HeLa cells. Extracts were immunoprecipitated using anti-Flag
antibody and blotted with an anti-HA antibody. As shown in
Figure 1c, all the c-FLIPL deletion mutants interacted with Akt,
indicating that neither DED domain is necessary for the
interaction with Akt.
We next investigated whether the carboxy terminal of
c-FLIPL was the region of interaction with Akt. For this
purpose, we generated different carboxy-terminal c-FLIPL
mutants named: c-FLIPL F1 (a.a. 1–253), c-FLIPL F3 (a.a.
1–339), c-FLIPL F5 (a.a. 1–434), c-FLIPL R0 (a.a. 1–149) and
c-FLIPL R1 (a.a. 1–182). Each mutant was transfected
together with HA–Akt cDNA in HEK-293 cells. Extracts were
immunoprecipitated after 48 h with anti-Flag antibody and
blotted with anti-HA antibody. Akt interacted with F3 and F5
mutants but not with F1, R0 or R1 mutants (Figure 1d). The
interaction of Akt with the short c-FLIP isoform (FLIPs) was
barely detectable (Figure 1e). This suggests that the Akt–c-
FLIP-interacting region is located between a.a. 253 and a.a.
339, within the caspase-like domain.
Role of c-FLIPL on growth factor-mediated Akt
signaling. Beside cell death, c-FLIPL also regulates other
DR-mediated signals. Thus, we set out to verify whether Akt–
c-FLIPL interaction might modulate Akt activation. For this
purpose, we first transfected increasing amounts of c-FLIPL
cDNA and assessed the levels of the activated Akt using
specific phospho-Akt antibodies. The overexpression of
c-FLIPL did not induce significant differences in insulin-
induced Akt phosphorylation (Figure 2a), even though
it modified the phosphorylation of Gsk3b. As shown in
Figure 2b, c-FLIP expression induced a reduction in
endogenous Gsk3b basal phosphorylation level, in a dose-
dependent manner. A similar inhibition of Gsk3b phos-
phorylation, both basal and upon insulin stimulation, was
observed on co-transfecting the HA–Gsk3b together with c-
FLIP (Figure 2c). Such inhibition was not observed in the
presence of c-FLIPs (Figure 2f).
This inhibition was not observed in HeLa cells transfected
with c-FLIPL mutants that do not interact with Akt, suggesting
that Akt–c-FLIP interaction is necessary for this effect (Figure
2d and e).
Role of c-FLIP modulation of Gsk3b pathway on TRAIL-
induced cell death. Although it has been clearly shown that
c-FLIPL overexpression may cause resistance to TRAIL, the
effects of Gsk3b on cell death are more controversial.19
However, recently it was described that Gsk3b is involved in
the resistance to TRAIL-induced apoptosis. Therefore, we
investigated whether c-FLIPL-induced apoptosis resistance
upon extrinsic pathway activation was at least in part
mediated by its effects on Gsk3b activation.
For this purpose, HeLa cells were transfected with Flag
c-FLIPL cDNAs alone or in the presence of lithium chloride, an
inhibitor of Gsk3 activity.20 The cells were subsequently
incubated with TRAIL, and cell death was assessed using a
cell viability assay or with propidium iodide staining followed
by FACS analysis. As shown in Figure 3a and b, c-FLIPL
overexpression decreased the sensitivity of HeLa to TRAIL-
induced apoptosis. However, treatment with LiCl completely
counteracted the protective effect of c-FLIP on cell death
(Figure 3a and b). To exclude unspecific effects of LiCl on cell
death, the role of the Gsk3b pathway in the anti-apoptotic
effect of c-FLIP was further evaluated using a specific Gsk3b
kinase-inactive cDNA (Gsk3b-KI) and measuring caspase-8
activation. As shown in Figure 3c and d, c-FLIPL over-
expression reduced TRAIL-induced caspase-8 activation,
and this effect was counteracted by both LiCl and Gsk3b-KI
cDNA. LiCl andGsk3b-KI or GSk3bWTcDNA did not produce
any effects on endogenous c-FLIPL levels (Supplementary
Figure 1a).
Effects of c-FLIPL on p27
Kip1 expression. Recently,
Gsk3b inhibition has been suggested to regulate the cell
cycle through regulation of p27Kip1 levels.21 In addition,
we have recently shown that miRNAs regulate p27Kip1
expression and TRAIL sensitivity.22 Therefore, we
addressed the question of whether the effect of c-FLIPL on
TRAIL resistance was mediated through Gsk3b activity and
thus on p27 expression levels.
As shown in Figure 4a, we observed that the levels of
p27Kip1 were drastically reduced in HEK-293 cells stably
overexpressing c-FLIPL. A similar result was observed also in
HeLa cells stably (HeLa Tween FLIP) or transiently over-
expressing c-FLIPL (Flag FLIP; Figure 4b). However, over-
expression of c-FLIPL deletion mutants of the Akt interaction
site did not induce reduction in p27Kip1 levels (Figure 4c).
Moreover, this effect was not observed in the presence of
c-FLIPs (Figure 4f).
The downregulation of Gsk3b, by a specific siRNA or
inactivation with LiCl, induced an increase in p27Kip1 levels in
HeLa Tween FLIPL compared to cells transfected with a
scrambled siRNA (Figure 4d). Taken together these results
indicate that the effect of c-FLIP on p27Kip1 is mediated by
Gsk3b activity. We next investigated whether c-FLIPL–Gsk3
regulate p27Kip1 at mRNA levels. To assess this point, HeLa
cells were transfected with 5mg of Flag c-FLIPL cDNA or a
control vector for 48 h, and p27Kip1 cDNA levels were
evaluated by real-time PCR. Interestingly, we observed a
significant reduction of p27Kip1 mRNA levels in HeLa cells
transfected with c-FLIPL but not with its mutant (Figure 4e),
suggesting that the c-FLIPL–Gsk3 pathway regulates p27
Kip1
expression levels through a transcriptional mechanism.
The effect of p27Kip1 on TRAIL-mediated apoptotic
signaling. We recently provided evidence that p27Kip1 is
involved in TRAIL resistance in non-small cell lung cancer
(NSCLC).22 We demonstrated that in TRAIL-resistant CALU-1
cells, miR-222 and miR-221 are overexpressed and target
Gsk3–cFLIP pathway and TRAIL resistance
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p27Kip1, inducing its downregulation. However, TRAIL-
sensitive H460 cells exhibited reduced levels of miR-222
and miR-221 and increased p27Kip1 expression. We
therefore investigated whether p27Kip1 modulated sensitivity
to TRAIL-mediated cell death through the regulation of the
apoptotic machinery molecules. To this aim, HeLa Tween
FLIP cells, which express p27Kip1 at very low levels, were
transfected with HA–p27 cDNA, and caspase-3 levels were
investigated by western blot analysis. We observed a
significant increase in caspase-3 levels (Figure 5a).
Furthermore, silencing of p27Kip1 using a specific siRNA in
H460 cells, which express p27Kip1 at high levels, resulted in
reduction in caspase-3 level (Figure 5b).
To further confirm the role of the FLIP–Gsk3 pathway on
TRAIL apoptotic machinery, we evaluated caspase-3 levels in
HeLa Tween c-FLIP-overexpressing cells, Gsk3 pathway of
which was inhibited either byGsk3 siRNA or by LiCl treatment.
Both inhibitions resulted in an increase in caspase-3 expres-
sion levels, whereas no differences were observed in FADD
levels (Figure 5c).
We investigated whether c-FLIPL modulated caspase-3
transcript levels through a transcriptional mechanism by
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Figure 2 Role of c-FLIPL on Akt–Gsk3b signaling pathway. (a) c-FLIP effects on Akt activation. HeLa cells were transfected with c-FLIPL cDNA for 24 h, serum-starved for
12 h and then treated with insulin (100 nM) for 15 min. Total cellular extracts were resolved by western blot and analyzed with the indicated antibodies. FLIP overexpression
does not affect Akt phosphorylation. (b) Western blot analysis of p-Gsk3b and Gsk3b expression in HeLa WT or transfected with different concentrations of c-FLIPL cDNA
(500 ng, 1 mg and 2 mg) for 48 h. We observed a strong reduction of Gsk3b phosphorylation. (c) HeLa cells were transfected with HA–Gsk3b cDNA, and c-FLIPL cDNA or
control vector, as indicated for 24 h. Cells were starved for 12 h and then treated with insulin (100 nM) for 15 min. Cell lysates were immunoprecipitated with anti-HA antibody
and blotted with phospho-Gsk3b antibody. (d) Western blot analysis of HeLa cells transfected with c-FLIP-WT, c-FLIP-F1, c-FLIP-R0 or c-FLIP-R1 cDNA. Total lysates were
analyzed with anti-phospho-Gsk3b, Gsk3, Flag and b-actin antibodies. c-FLIP mutants were not able to decrease phospho Gsk3b levels. (e) HeLa cells were transfected with
HA–Gsk3b and c-FLIP-R1 cDNA or with a control vector, treated with insulin (100 nM) for 15 min, immunoprecipitated with anti-HA antibodies, and blotted with p-Gsk3b
antibodies. Total lysates were analyzed with the indicated antibodies. c-FLIP mutant overexpression did not reduce Gsk3b phosphorylation. (f) HeLa cells were transfected
with HA–Gsk3b cDNA, and c-FLIPL cDNA, c-FLIPs cDNA or control vector, as indicated for 24 h. Cells were serum starved for 12 h and then treated with insulin (100 nM) for
15 min. Cell lysates were immunoprecipitated with anti-HA antibody and blotted with anti-phospho-Gsk3b antibody
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real-time PCR. Interestingly, we observed a significant
reduction in caspase-3mRNA levels in HeLa cells transfected
with c-FLIPL compared with controls, whereas this effect was
not observed in FLIP R1 mutant (Figure 5d).
Finally, we also examined the activity of caspase-3 by
the colorimetric CaspACE assay in HeLa cells transfected
with an empty vector or with c-FLIPL cDNA. The expression
of c-FLIPL induced a reduction of caspase-3 activity
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Figure 3 Role of c-FLIPL and Gsk3b signaling pathway on TRAIL-induced cell death. Cell death quantification – HeLa cells were transfected with 2 mg of c-FLIPL cDNA for
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Figure 4 c-FLIP overexpression regulates p27Kip1 levels through Gsk3b. Western blot analysis of Gsk3b, p-Gsk3b and p27Kip1 levels in different cell lines. (a) HEK-293–
Tween GFP and tween–GFP c-FLIPL; (b) HeLa cells transfected with c-FLIPL cDNA and HeLa Tween c-FLIPL. There is an inverse correlation between FLIP and p-Gsk3
levels. (c) Western blot analysis of p27Kip1 levels in HeLa cells transfected with c-FLIPL mutants F1, R0 and R1 cDNA. (d) Effects of inhibition of Gsk3b on p27
Kip1 expression.
HeLa Tween FLIP cells were transfected with Gsk3b siRNA or scrambled siRNA or treated with 20 mmol lithium chloride for 24 h. Levels of p27Kip1 and Gsk3b were analyzed
by immunoblotting. (e) Real time PCR analysis of p27Kip1 mRNA with transfection of FLIPL cDNA in HeLa cells. c-FLIP reduces p27
Kip1 levels through Gsk3b. c-FLIP deletion
mutants were not able to reduce p27Kip1 levels. (f) Total lysates of HeLa cells transfected with c-FLIPL, c-FLIPs or control vector were analyzed for p27 expression
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(Figure 5e). All these effects were reverted when c-FLIPL
endogenous levels were downregulated by a specific c-FLIPL
siRNA (Figure 5f). The effects of specific RNAi constructs for
c-FLIP on FLIP expression levels are shown in Supplemen-
tary Figure 1b.
Discussion
In this study, we provide evidence for a new role of c-FLIPL.
c-FLIPL has been identified as an inhibitor of apoptosis
triggered by the engagement of death receptors, such as Fas
or TRAIL.23,24 c-FLIPL has also been implicated in other
cellular functions, such as control of gene expression by ERK
and NF-kB.9,25
We demonstrate, to the best of our knowledge, for the first
time that Akt interacts with c-FLIPL, and that this interac-
tion functionally regulates Gsk3b activation and apoptosis.
Recently, Giampietri et al.26 described that in c-FLIP
transgenic mice, the phosphorylation of Akt and Gsk3b were
reduced compared with control animals, even though cas-
pase-3 activity was unchanged, highlighting an apoptosis-
independent role of c-FLIP on pressure overload-mediated
cardiac hypertrophy. The role of c-FLIP in heart development
has been previously described in c-FLIP ko mice that, similar
to FADD ko mice, developed severe defects of heart
development.27,28 These studies identify c-FLIP as a new
regulator of heart development and the hypertrophic re-
sponse, possibly through Gsk3 signaling.
In this study, by genetic and biochemical methodologies,
we have demonstrated that Akt is able to interact with c-FLIPL
in the region stretching from a.a. 253 to a.a. 339 of the c-FLIPL
protein. We observed that overexpression of c-FLIPL,
although does not interfere with insulin-induced Akt activation,
almost abolishes Gsk3b phosphorylation. The effects on
Gsk3b were abrogated when we overexpressed c-FLIPL
mutants that do not bind Akt. This may means that, by binding
to Akt, c-FLIPL relegates the kinase in a different cellular
compartment, and abolishes its ability to bind and phosphory-
late its substrates. It is interesting that the phosphorylation
of other Akt substrates besides Gsk3b, such as BAD, was
reduced in c-FLIPL-overexpressing cells (data not shown).
It has been reported that Gsk3b contributes both to cell
death and cell survival, depending on the cellular system and
the appropriate stimuli.19 Several studies indicated that
inhibition of Gsk3b activity in cancer cells potentates
apoptosis stimulated by death receptor.29–32 Furthermore,
knocking out Gsk3b or inhibiting Gsk3b using lithium chloride,
potentates TNF-induced apoptosis, indicating an anti-apop-
totic role for Gsk3b.30
Therefore, we asked whether c-FLIPL-mediated reduction
of Gsk3b phosphorylation, and thus increase in its kinase
activity, might be necessary for the anti-apoptotic function of
c-FLIPL. Interestingly, when we interfered with Gsk3b activity,
either using LiCl or with overexpression of a kinase-inactive
form of Gsk3, anti-apoptotic c-FLIPL effects were significantly
reduced. Thus, Gsk3b may act as an important mediator that
participates in FLIP’s anti-apoptotic function in human cancer.
We have recently demonstrated that p27 expression is
linked to TRAIL resistance in NSCLC cells overexpressing
miR-222.22 We therefore investigated the level of p27 in
different cells overexpressing c-FLIPL. Interestingly, we
observed an inverse correlation between the c-FLIPL and
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p27 expression levels, as well as Gsk3b phosphorylation. This
was also true in forced c-FLIPL-expressing cells (HEK-293
and HeLa). We then investigated whether c-FLIP could affect
p27 levels through the activation of Gsk3b. For this purpose,
we interfered with Gsk3b expression levels or activity in
c-FLIPL-overexpressing cells and evaluated p27 levels. We
observed that Gsk3b inhibition increased protein and mRNA
levels of p27. The effects of FLIPL on p27 depend on its
interaction with Akt, as c-FLIPLWT overexpression, but not its
Akt-binding-site deletion mutants, was able to reduce p27
mRNA level. Recently, Wang et al.21 described that Gsk3b
negatively regulates p27 protein in MLL leukemia cells, thus
being critical for the maintenance of MLL leukemia, and
prospecting Gsk3 as an interesting target for this form of
cancer. In the MLL cellular system, the effects were mainly at
the protein level because the inhibition of Gsk3b did not affect
mRNA levels. Therefore, although the final effect is similar, the
functional relationships of Gsk3b with p27 seem to be cell type
dependent. Gsk3b is a negative regulator of heart hypertro-
phy.33 Interestingly, Hauck34 recently described that silencing
p27 induced cardiomyocyte hypertrophyc growth in the absence
of growth-factor stimulation. It is interesting to speculate that
Gsk3b mediates negative regulation of hypertrophyc growth
through its effects on p27 expression levels.
Finally, we investigated the mechanisms of c-FLIP–Gsk3b
–p27-mediated inhibition of cell death, by the evaluation of
protein and mRNA levels of apoptosis-signaling molecules.
We showed that the absence of p27 induces a reduction
in caspase-3 levels. This effect was mediated by Gsk3b
because its inactivation induced an increase in caspase-3
level. The effect was specific on caspase-3 because other
apoptosis-signaling molecules, such as FADD, were not
affected. This effect occurred at the transcriptional level
because c-FLIPL overexpression, but not its mutants, was
able to reduce caspase-3 mRNA level, as assessed by
RT-PCR. The overexpression of c-FLIPL also induces a
significant reduction in the amount of the active caspase in
untreated cells. Thus, taken together these data depict a
model in which in c-FLIP-overexpressing cells, the activation
of Gsk3b induces a reduction in p27Kip1 and caspase-3
expression and activity levels, and thus a reduction in TRAIL-
induced cell death (Figure 6).
Recently, Gsk3b has been described as a protein complex
associated with death receptors, DDX3, and cellular inhibitor
of apoptosis protein-1 (cIAP-1).29 In that study, Gsk3b
inhibited apoptosis by interfering with DISC formation and
caspase-8 activation. Our data reveal other possible mechan-
isms through which Gsk3 might inhibit apoptosis, that is,
through regulation of p27 expression and that of downstream
caspase-3 (Figure 6).
Our data show that c-FLIP overexpression strongly reduces
Akt-mediatedGsk3b phosphorylation. Furthermore, it’s down-
regulation by a specific c-FLIP siRNA resulted in an increase
in Gsk3b phosphorylation, as well as in p27 and caspase-3
levels.
In conclusion, this study demonstrates that anti-apoptotic
functions of c-FLIPL are mediated by its effects on Gsk3b
activity, and p27 and caspase-3 levels. These findingsmay be
of importance in optimizing a strategy for the treatment of
TRAIL-resistant human cancer.
Materials and Methods
Materials. Media, sera and antibiotics for cell culture were purchased from Life
Technologies (Grand Island, NY, USA). Protein electrophoresis reagents were
obtained from Bio-Rad (Richmond, VA, USA). Western blotting and ECL reagents
were procured from GE Healthcare (Pixcataway, NJ, USA). All other chemicals were
from Sigma (St. Louis, MO, USA). The antibodies: anti-caspase-8 antibody (1C12),
anti-Akt, anti-P-Akt, anti-P-Gsk3b, anti-Gsk3b and anti-p27Kip1 were purchased
from Cell Signaling Technology (Danvers, MA, USA); anti-caspase-3 antibody was
obtained from Abcam (Cambridge, MA, USA); anti-c-FLIP (NF6) antibody was
purchased from Alexis (Lausen, Switzerland); anti-Flag M2 and anti-b-actin
antibodies were obtained from Sigma; anti-HA antibody was obtained from Covance
(Berkeley, CA, USA). SuperKiller TRAIL was purchased from Alexis.
Plasmids. The plasmids pcDNA3 Flag(hs)FLIPL and FLIPs were kindly provided
by Professor Pasquale Vito and Henning Walczack, respectively. Akt WT, Akt E40K
(constitutively active, HA–Akt Dþ ) and Akt K179M (dominant-negative HA–Akt D)
with an HA tag were a kind gift of Professor Gianluigi Condorelli. Gsk3b WT and
Gsk3b kinase inactive (KI) cDNAs were kindly provided by Professor Junichi
Sadoshima. p27 cDNA was kindly provided by Professor Alfredo Fusco. pRetroSuper
vectors expressing RNAi for c-FLIP were obtained from Professor Simone Fulda.
Cell culture. Human HeLa, HEK-293, K562 and A459 cell lines were grown in
DMEM containing 10% heat-inactivated FBS with 2 mM L-glutamine and 100 U/ml
penicillin–streptomycin. DU145 and H460 cell lines were grown in RPMI containing
10% heat-inactivated FBS with 2 mM L-glutamine and 100 U/ml penicillin–
streptomycin.
Yeast two-hybrid system. All experiments were performed in the yeast
reporter MaV203. The human heart cDNA library was obtained from Invitrogen
(Carlsbad, CA, USA). Screening of the library was performed essentially following
instructions for the ProQuest two-hybrid system (Life Technologies) and has been
previously described.35 The GAL4 DNA-binding domain/human Akt fusion was
obtained from Dr. Alfonso Bellacosa (Fox Chase Cancer Center, Philadelphia, PA,
USA). Subsequently, yeast pLEx4-Akt plasmid was transformed with the pPC86AD
cDNA library and plated onto plates lacking histidine in the presence of 3AT
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Figure 6 Role of cFLIP–Gsk3 signaling pathway in the regulation of cell death.
In FLIP-overexpressing cells, activation of Gsk3b induces a reduction in p27Kip1 and
caspase-3 expression levels and a reduction in TRAIL-induced cell death
Gsk3–cFLIP pathway and TRAIL resistance
C Quintavalle et al
1914
Cell Death and Differentiation
(aminotriazole; 10 mM). Approximately 1.2 106 individual clones were plated, and
about 200 grew on the selective medium. Resistant colonies were grown on a
master plate and then replica-plated onto selection plates to determine their ability
to induce three independent reporters (HIS3, URA3 and lacZ). A total of 80
independent clones were isolated after this first screening. The DNA was isolated
from each positive clone and sequenced to identify the inserts. Independent clones
were retransformed into yeast and tested for interaction with a fresh Akt clone.
c-FLIPL deletion mutants generation. We generated three deletion
mutants of c-FLIPL by PCR, using as template the plasmid pcDNA3-3 Flag-FLIPL.
c-FLIP I-DED mutant, encoding a.a. 81–480, which lacks the first DED, was
generated using the primers: Fw: 50-cccaagcttacccacctgctcaggaaccct-30 and Rv:
50-gctctagattatgtgtaggagaggata -30; c-FLIP-II-DED, encoding a.a. 1–93 and a.a.
178–480, which lacks the second DED, was generated using the primers: Fw: 50-
cccaagcttatgtctgctgaagtcatccat-30 and Rv: 50-tgtccctgcatagtccgaaacaaggtgagg-30
for amino acids 1–93 and Fw: 50-tcggactatgcagggacaagttacaggaat-30 and Rv: 50-
gctctagattatgtgtaggagaggata-30 for amino acids 178–480; FLIPL-DDED, encoding
a.a. 178–488, which lacks both DEDs, was generated using the primers: Fw: 50-
cccaagcttgcagggacaagttacaggaat-30 and Rv: 50-gctctagattatgtgtaggagaggata-30.
The amplified sequences were cloned in p3 -Flag-CMV previously linearized with
the restriction enzymes HinDIII and XbaI. The following deletion mutants were
generated: c-FLIPL-F1, encoding a.a. 1–253, was generated using the primers: Fw:
50- tgacgataaagaattcatgtctgc-30 and Rv: 50-gattcctaggggcttgctctt-30; c-FLIPL-F3,
encoding a.a. 1–339, was generated using the primers: Fw: 50-tgacgata
aagaattcatgtctgc-30 and Rv: 50-catcctcctgatgtgatgca-30; cFLIPL-F5, encoding a.a.
1–434, was generated using the primers: Fw: 50-tgacgataaagaattcatgtctgc-30 and
Rv: 50-ttcttgtctcagtttctggg-30; c-FLIPL-R0, encoding a.a. 1–177, was generated
using the primers: Fw: 50-tgacgataaagaattcatgtctgc-30 and Rv: 50-gccctcgagttatc
cagttgatctggggcaac-30; c-FLIPL-R1, encoding a.a. 1–182, was generated using the
primers: Fw: 50-tgacgataaagaattcatgtctgc-30 and Rv: 50-gccctcgagttactgtaacttgt
ccctgctcc-30. Temperature cycles used were as follows: 951C for 1 min; 951C for
50 s, 601C for 50 s, 681C for 7 min for 35 cycles; 681C for 2 min.
Production of retroviral particles and infection of HeLa andHEK-
293 cells. The c-FLIPL cDNA was cloned in PINCO vector.
36 The amphotropic
packaging cell line Phoenix was transfected by standard calcium phosphate/
chloroquine method, and culture supernatants containing retroviral particles were
collected at 48 h after transfection. Transduction was carried out by culturing (thrice)
5 105 cells in 1 ml of 0.45-mmol/l filtered supernatant containing viral particles.
Gene-transfer efficiency was evaluated by flow cytometry analysis based on the
expression of the GFP reporter. The levels of c-FLIP expression were evaluated by
immunoblot analysis using lysates of cells infected with the empty Tween vector
(HeLa Tween and HEK-293 Tween) for comparison.
Western blotting. Total proteins from cells was extracted with RIPA buffer
(0.15 mM NaCl, 0.05 mM Tris-HCl (pH 7.5), 1% Triton X-100, 0.1% SDS, 0.1%
sodium deoxycolate and 1% Nonidet P40). A total of 50 mg of sample extract were
resolved on 7.5–12% SDS-PAGE using a mini-gel apparatus (Bio-Rad
Laboratories, Richmond, CA, USA) and transferred to Hybond-C extra
nitrocellulose. Membranes were blocked for 1 h with 5% non-fat dry milk in TBS
containing 0.05% Tween-20, incubated for 2 h with primary antibody, washed and
incubated with secondary antibody, and visualized by chemiluminescence.
Phosphorylation experiments. HeLa cells were transiently transfected
with different cDNAs as indicated. After 24 h, the cells were incubated in serum-free
culture medium for 16 h at 371C. Insulin (final concentration, 100 nM) was then
added, and the cells were rapidly rinsed with ice-cold saline followed by
solubilization with 0.5 ml of RIPA buffer per dish for 1 h at 41C. Lysates were
centrifuged at 5000 g for 20 min, and solubilized proteins were precipitated with
the indicated antibodies, separated by SDS-PAGE, and revealed by western blot
with antibodies recognizing the phosphorylated proteins.
Immunoprecipitation. Cells were cultured at a final concentration of 90% in
p100 plates. The cells were collected with RIPA Buffer on a shaker for 30 min.
A total of 1 mg of total extract was immunoprecipitated using the indicated
antibodies (5mg/ml anti-Flag, 2mg/ml anti-HA, 3 mg/ml anti-Akt and 3 mg/ml anti-
Gsk3b) for 16 h on shaker. Then, A/G beads (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) were added for 2 h. The beads were washed for three times with
washing buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% Triton X-100, 10%
glycerol), and then 20ml of sample buffer was added; the samples were boiled at
1001C for 5 min and then the supernatants resolved by SDS-PAGE.
Caspase assay. The assay was performed using the Colorimetric CaspACE
Assay System (Promega, Madison, WI, USA) as reported in the instruction manual.
Briefly, HeLa cells were transfected with lipofectamine 2000; 48 h after transfection,
cells were collected in caspase assay buffer and protein was quantified by Bradford
Assay. A total of 50mg of protein were used.
Cell death and cell proliferation quantification. Cells were plated in
96-well plates in triplicate and incubated at 371C in a 5%CO2 incubator. To induce
apoptosis, Superkiller TRAIL (Alexis) was used for 24 h at 500 ng/ml. Cell viability
was evaluated with the CellTiter 96 AQueous One Solution Cell Proliferation Assay
(Promega), according to the manufacturer’s protocol. Metabolically active cells were
detected by adding 20ml of MTT to each well. After 30 min of incubation, the plates
were analyzed in a Multilabel Counter (Bio-Rad, Richmond, VA, USA). Apoptosis
was also assessed using annexin V–FITC Apoptosis Detection Kit followed by flow
cytometric analysis. Cells were seeded at a density of 1.8 106 cells per 100-mm
dish, grown overnight in 10% FBS/RPMI, washed with PBS, and then treated for
24 h with 200 ng TRAIL. After incubation, cells were washed with cold PBS and
removed from the plates using very mild trypsinization conditions (0.01 % trypsin/
EDTA). The resuspended cells were washed with cold PBS and stained with FITC-
conjugated annexin V antibody and propidium iodide (PI), according to the
instructions provided by the manufacturer (Roche Applied Science, Indianapolis, IN,
USA). Cells (50 000 per sample) were then subjected to flow cytometry analysis.
Flow cytometry analysis and PI staining were performed as described previously.16
To quantify caspase activation, cells were transfected with the indicated cDNA or
treated with lithium chloride (20 mM) and then incubated with superkiller TRAIL for
the indicated times. Lysates were examined by western blotting with anti-caspase-8
antibodies.
siRNA transfection. HeLa cells were cultured to 80% confluence, kept in
antibiotic-free, serum-containing medium, and transiently transfected using
Lipofectamine 2000 with 150 nmol anti-Gsk3-b siRNA (Invitrogen), a pool of two
target-specific 20–25 nt siRNAs, or with siCONTROL oligonucleotides, as indicated.
Cells were incubated with siRNAs for the indicated times.
The siRNAs were transfected with 6 ml transfection reagent, as described in the
manufacturer’s protocol. Anti p27Kip1 siRNA was purchased from Santa Cruz
Biotechnology. siCONTROL Non-Targeting siRNA Pool #2 (D-001206–14–05) was
from obtained from Dhamarcon (Lafayette, CO, USA) and comprised four
siCONTROL Non-Targeting siRNAs. Each individual siRNA within this pool was
characterized by genome-wide microarray analysis and found to have minimal
off-target signatures.
c-FLIPL knockdown. Stable knockdown of c-FLIPL in HeLa cells was
obtained with siRNAs (complementary sense and antisense oligonucleotides):
FLIP-909 (50-GGAGCAGGGACAAGTTACA-30) and FLIP-1003 (50-GTAAAGAAC
AAAGACTTAA-30) or scrambled oligonucleotide were cloned in the pRSC retroviral
vector as described previously.37 Cells were selected with 10mg/ml puromycin.
RNA isolation and real-time PCR analysis. The RNA was extracted
using TRIzol solution (Invitrogen) followed by DNAse treatment (DNA free, Ambion,
Austin, TX, USA). The quality and quantity of RNA was determined by measuring
the absorbance of the total RNA at 260 and 280 nm, and by 1% agarose
electrophoresis under reducing conditions and visualized with ethidium bromide. For
mRNA profiling, reverse transcription (RT) was performed by using Superscript II First
Stand Synthesis Kit (Invitrogen). Real-time PCR to assay mRNA level was performed
in an iQ Real Time PCR Detection System (Bio-Rad, Hercules, CA, USA) with iQ
SYBR Green Supermix (Bio-Rad). All primers were synthesized commercially
(PRIMM, Milan, Italy). Polymerase chain reactions were performed in triplicate and
fold changes were calculated with the following formula: 2(sample 1DC t sample 2DC t),
where DCt is the difference between the amplification fluorescent thresholds of the
mRNA of interest and the mRNA of b-actin used as an internal reference. All reactions
were performed according to manufacturer’s protocol.
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miR-221/222 overexpession in human glioblastoma increases invasiveness
by targeting the protein phosphate PTPl
C Quintavalle1, M Garofalo2, C Zanca1, G Romano3, M Iaboni1, M del Basso De Caro4,
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State University, Columbus, OH, USA; 3Fondazione IRCCS SDN, Naples, Italy; 4Dipartimento di Scienze Biomorfologiche e Funzionali,
Sezione di Anatomia Patologica e Fitopatologia; 5Instituto Oftalmico/Hospital Universitario Gregorio Maran˜on, Madrid, Spain;
6IEOS, CNR, Naples, Italy and 7Facolta` di Scienze Biotecnologiche, ‘Federico II’ University of Naples, Naples, Italy
Glioblastoma is the most frequent brain tumor in adults
and is the most lethal form of human cancer. Despite the
improvements in treatments, survival of patients remains
poor. In order to identify microRNAs (miRs) involved in
glioma tumorigenesis, we evaluated, by a miRarray,
differential expression of miRs in the tumorigenic glioma
LN-18, LN-229 and U87MG cells compared with the non-
tumorigenic T98G cells. Among different miRs we focused
our attention on miR-221 and -222. We demonstrated the
presence of a binding site for these two miRs in the 30
untranslated region of the protein tyrosine phosphatase l
(PTPl). Previous studies indicated that PTPl suppresses
cell migration and is downregulated in glioblastoma.
Signiﬁcantly, we found that miR-221 and -222 over-
expression induced a downregulation of PTPl as analyzed
by both western blot and real-time PCR. Furthermore,
miR-222 and -221 induced an increase in cell migration
and growth in soft agar in glioma cells. Interestingly,
the re-expression of PTPl gene was able to revert the
miR-222 and -221 effects on cell migration. Furthermore,
we found an inverse correlation between miR-221 and -222
and PTPl in human glioma cancer samples. In conclusion,
our results suggest that miR-221 and -222 regulate glioma
tumorigenesis at least in part through the control of PTPl
protein expression.
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Introduction
Gliomas are the most common primary tumors in the
brain and are divided into four clinical grades on the
basis of their histology and prognosis (Tran and
Rosenthal, 2010). Among them, glioblastoma (GB,
grade IV) are highly invasive, very aggressive and are
one of the most incurable forms of cancer in humans
(Purow and Schiff, 2009). In spite of recent improve-
ments of surgical and radiotherapeutic techniques, the
prognosis for glioblastoma patients is still very poor
with a mean survival time after diagnosis raging from 9
to 12 months. The treatment strategies for this disease
have not changed appreciably for many years, and most
are based on a limited understanding of the biology of
the disease. In fact, although a number of genetic and
molecular lesions have been correlated to glioblastoma
progression, the deep understanding of the molecular
markers is fundamental to develop targets for glioblas-
toma treatment. Small non-coding RNAs named
microRNAs (miRs) are a class of endogenous non-
coding, highly conserved RNAs of B22 nucleotides in
length that are encoded in plant and animal genomes.
miRs are involved in the pathogenesis of most cancers
(Calin and Croce, 2006). They negatively regulate
mRNA expression by repressing translation or directly
cleaving the targeted mRNA. In the last few years, our
understanding of the role of miRNA has expanded from
the initially identiﬁed functions in the development of
round worms to a highly expressed and ubiquitous
regulators implicated in a wide array of critical
processes, including proliferation, cell death, differentia-
tion, metabolism and, importantly, tumorigenesis
(Croce, 2009). miRs proﬁling achieved by various
methods has allowed the identiﬁcation of signatures
associated with diagnosis, staging, progression, prog-
nosis and response to treatment of human tumors.
Therefore, miRNA ‘ﬁngerprinting’ represents a new
addition to the diagnostic and prognostic tools to be
used in medical oncology. In this study we evaluated by
a miR array differential expression of miRs in tumori-
genic glioma LN18, LN229 and U87MG cells compared
with the non-tumorigenic T98G cells. Among different
miRs we focused our attention on miRs -221 and -222.
Our results show that miRs -221 and -222 target the
protein tyrosine phosphatase m (PTPm). PTPm regulates
cell invasiveness and adhesion (Burgoyne et al., 2009a),
and has been found downregulated in human GB
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for the ﬁrst time PTPm as a miR-222 and -221 target and
explores the role of those miRs, through this target, in
GB tumorigenesis and invasiveness.
Results
miRs expression in glioma cell lines
T98G, U87MG, LN-18 and LN-229 glioma cells have
been described as having a different tumorigenic
behavior (Cerchia et al., 2009). In fact, while T98G are
not able to grow in nude mice and to form colonies,
U87MG, LN-18 and LN-229 cells are able to form
tumors when injected in nude mice and to form colonies
in soft agar, even in the absence of serum. We conﬁrmed
these data using soft agar and xenograft growth in nude
mice (Supplementary Figure 1). In order to investigate
the involvement of miR in glioma tumorigenesis, we
analyzed miR expression proﬁle in the tumorigenic
glioma LN-18 and LN-229 and U87MG cells versus
non-tumorigenic T98G cells. The analysis was per-
formed with a microarray chip containing 1150 miR
probes, including 326 human and 249 mouse miRs,
spotted in duplicates (Liu et al., 2004). Pairwise
signiﬁcance analysis (PAM) of the microarray indicated
that ﬁve miR genes were signiﬁcantly overexpressed in
tumorigenic cells with a42.5-fold change (Table 1). We
focus our attention on miR-221 and miR-222, as we and
others have already demonstrated that those miRs are
frequently overexpressed in a number of human tumors
(Pallante et al., 2006; Pineau et al., 2010; Sredni et al.,
2010). In order to conﬁrm the array results, we analyzed
the levels of miR-222 and -221 with real-time PCR (RT–
PCR). Accordingly with microarray data, we found an
upregulation of these two miRs in tumorigenic cells
(U87MG, LN-18 and LN-229) compared with non-
tumorigenic one (T98G) (Figure 1a). We conﬁrmed
those data in a larger number of glioma cell lines, with a
different tumorigenic phenotype (Supplementary Figure
3A). As shown in Supplementary Figure 3B also the
non-tumorigenic cell lines LN-308, A172 and LN-428
express low levels of miR-221 and -222 if compared with
the tumorigenic lines LN-319, LN-18 and LN-229. As
expected, the predicted miR-221 and -222 targets,
p27kip1, and PTEN were expressed at decreased levels
in the non-tumorigenic U87MG cells (Figure 1b) as
compared with T98G cells. Similar results were obtained
in the other non-tumorigenic cells (data not shown).
Table 1 Upregulated miRs in tumorigenic glioma cells
MiR Intensities
of U87MG
Intensities
of T98G
Fold
change
hsa-miR-221 11150.1 1763.5 6.323
hsa-miR-125b 4697.4 1020.4 4.603
hsa-miR-21 6236.3 1662.4 3.751
hsa-miR-222 16685.8 6014 2.774
hsa-miR-34a 319.1 26.7 11.951
All differentially expressed miRs have Qo0.01 (false positive rate).
t-test Po0.05.
These miRs were identiﬁed by PAM as predictor of glioma cells with
the lowest misclassiﬁcation error.
Figure 1 Expression of miR-222 and -221 and their targets in T98G and U87MG glioma cells. (a) Real-time PCR of miR-221 and
-222 in glioma cells. Representative of at least three independent experiments. (b) Western blot analysis of the known miR-221 and -222
targets, PTEN and p27kip1. As a consequence of decreased PTEN protein levels, p-AKT levels were increased, although total AKT
levels were comparable. b-Actin was used as the loading control. (c) Soft agar growth of T98G cells transiently transfected with
miR-221, -222 or a scrambled sequence and of U87MG cells transfected with anti-miR-221, anti-miR-222 or a scrambled sequence.
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In order to verify the involvement of these miRs in
glioma tumorigenesis we transfected the T98G cells with
pre-miR-221 and pre-miR-222 or with a scrambled
sequence, and U87MG cells with and anti-miR-221 and
-222 or with anti-miR negative control. As shown in
Figure 1c by soft agar assay, miR-221 and -222
overexpression resulted in a phenotypic change of T98G
cells that become able to form colonies. Similar results
were obtained in LN-18, LN-229 cells transfected with
miR -222 or -221 (data not shown). Furthermore, the
tumorigenic U87MG overexpressing anti-miR-221 and
-222 exhibited a much weaker capacity to form colonies in
soft agar. Similar results were obtained when T98G stably
overexpressing miRs with a tween vector were plated in
soft agar. Cells expressing the control tween vector did not
produce colonies in soft agar (Supplementary Figure 3D),
meanwhile T98G-tween-miR-221 formed a large number
of colonies indicating a greater tumorigenic behavior of
cells overexpressing miR-221/222.
Identiﬁcation of PTPm as a new target of miR-221
and -222
To ﬁnd new miR-221 and -222 targets, we used
bionformatics analysis. Comparing the results obtained
from the different searches, we found that the protein
phosphatase PTPm was predicted as a target of miR-222
by the miRanda algorithm (www.microrna.org/microrna/
home.do). RNAhybrid also predicted a possible binding
region of miR-221 and -222 in the 30 untranslated region
(UTR) of PTPm (Figure 2a). The most widely used
approach for experimentally validating miRNA targets is
to clone the predicted miRNA-binding sequence down-
stream of a luciferase reporter construct, and to co-
transfect it with the miRNA of interest for luciferase
assays. To this end, we cloned the 30UTR sequence of
human PTPm into the luciferase-expressing vector pGL3-
control downstream of the luciferase stop codon; Meg01
cells were transiently transfected with this construct in the
presence of pre-miR-221 and pre-miR222 or in the
presence of a scrambled oligonucleotide acting as a
negative control. As reported in Figure 2c, miR-221 and
miR-222 signiﬁcantly reduced luciferase activity com-
pared with the scrambled oligonucleotide. This indicates
that miR-221 and -222 bind to the 30UTR of ptpm and
impair its mRNA translation. We observed a similar
effect in the presence of both miRs added at the same
time, indicating that the target site of the miRs in the
30UTR of PTPm is the same. In order to further conﬁrm
that the region was speciﬁc for the binding with miR-222
and -221, we generated a deletion mutant (Figure 2b)
lacking the binding site, ATGTAGC. The mutant was
cloned into the 30UTR of the luciferase gene and co-
transfected with pre-miR-221 and -222 in Meg01 cells. As
shown in Figure 2d, miR-221 and -222 added singularly
or at the same time, did not signiﬁcantly reduce luciferase
activity in the presence of the 30UTR PTPmmut sequence.
This result indicates that miR-221 and -222 target PTPm
mRNA at the ATGTAGC sequence.
Expression of PTPm and miR-222 and -221 in glioma
To assess whether the expression of PTPm was inversely
correlated with miR-221 and -222 in glioma cells, we
analyzed the levels of the protein phosphatase in the
different glioma cells. We found reduced PTPm protein
(Figure 3a) and mRNA levels (Figure 3b) in U87MG,
LN-18 and LN-229 cells overexpressing miR-221 and
-222 compared with T98G.
Figure 2 Identiﬁcation of target sites in the 30-UTR of PTPm. Complementary sites for miR-222 and -221 on wild-type (a) or mutated
(b) PTPm 30UTR. The capital letters identify perfect base matches according to miRanda software (www.microrna.org/microrna/
home.do). The bold letters identify the deleted regions. For luciferase activity, Meg01 cells were transiently co-transfected with the
luciferase reporter containing wild-type PTPm-30UTR (c) or PTPm-30UTR mutant (d) in the presence of pre-miR-222, miR-221, pre-
miR-221 and miR-222 together or scrambled oligonucleotide. Luciferase activity was evaluated 24 h after transfection as described in
Materials and methods. Representative of at least three independent experiments.
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To conﬁrm these data, we extended our analysis to
different tumorigenic and non-tumorigenic cell lines. As
shown in Supplementary Figure 3B, LN-308 and LN-
428 cells that express high levels of PTPm protein express
low level of miR-221 if compared with LN-319, LN-18
and LN-229 which overexpress miR-221 and have low
levels of PTPm. The only exception was represented by
A172. These cells have been already reported to be non-
tumorigenic (Ridder et al., 1987; Liang et al., 2002;
Cerchia et al., 2009). Our data show that in A172 cells
PTPm expression is low even in the presence of low miR-
221 levels. However, A172 cells have been reported to be
strongly invasive even if they are not tumorigenic
(Ridder et al., 1987). It is then possible that in this cell
line other mechanisms are involved in the regulation of
PTPm expression and tumorigenic phenotype.
In order to establish a causative link with miRs-222 and
-221 and PTPm, we stably infected T98G cells with a Tween
lentiviral construct expressing miR-221 and -222, and then
analyzed PTPm protein and mRNA levels. miR expression
in infected cells was evaluated by RT–PCR (Figure 3c).
We observed decreased PTPm protein (Figure 3c) and
mRNA expression levels (Figure 3d) in miR-222 and -221
stably expressing cells. The same effect was observed in
T98G cells transiently transfected with a synthetic pre-
miR-222 and miR-221. We also observed a decrease of
known miR-221/222 targets, the proteins PTEN and
p27Kip1 (Figure 3e and f). The efﬁciency of miR expres-
sion upon transfection was monitored by RT–PCR
(Figure 3e). Consistently with these data, U87-MG cells
transfected with the anti-miR-222 and -221 showed an
increase of PTPm protein (Figure 4a) and RNA levels
(Figure 4b). The efﬁciency of miR downregulation upon
anti-miR transfection was monitored by RT–PCR
(Figure 4c). Similar results were obtained by transfecting
anti-miR-222 in LN-229 and LN-18 (data not shown).
Figure 3 PTPm and miR-222/221 expression levels are inversely correlated in glioma. PTPm protein (a) and RNA (b) expression levels
in T98G, U87MG LN18 and LN229 cells. Cell lysates were immunoblotted with anti-PTPm antibody. To conﬁrm equal loading, the
membrane was immunoblotted with anti–b-Actin antibody. Effect of miR transfection on PTPm expression: miR-222 and -221
constitutive (c) or transient (e) expression in glioma cells induced a decrease of PTPm protein (c, e) and RNA (d, f) expression levels.
Relative expressions of mRNA and miR-221 were calculated using the comparative threshold cycle methods. Columns, mean of four
different experiments; bars, s.d.. Fold values are expressed relative to the reference points indicated by * symbol.
Figure 4 Effects of anti miR-222 and -221 on PTPm expression levels in glioma. PTPm protein (a) and RNA (b) expression levels
in U87MG cells transfected with anti miR-222, -221 or control scrambled (scr). The anti-miRs were able to increase PTPm
expression levels. (c) Anti-miR transfection reduced miR levels as analyzed by real-time PCR. Columns, mean of four different
experiments; bars, s.d.
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miR-221 and -222 regulates cell motility in glioma cells
We hypothesized that miR-221 and -222 promote cell
migration by regulating PTPm expression. To this end,
we analyzed cell motility through a transwell assay in
U87MG, LN-229, LN-18 and T98G parental cells, and
T98G transduced with control vector (T98G-tween), or
lenti-miR221 and -222 vector (T98G miR-221 and T98G
miR-222). As shown in Figure 5a, U87MG, LN-18 and
LN-229 cells have a higher migration rate than T98G
cells. The upregulation of miR-221 and -222 in T98G
cells induced an increase of cell motility. The same result
was obtained in T98G cells transiently transfected with
miR-221 and -222. Conversely, expression of anti-miR-
222 was able to reduce cell migration of U87MG
(Figure 5b). We also tested the effects of miRs or anti-
miR expression on cell adhesion, obtaining the same
results (data not shown). In agreement with the existing
data (Burgoyne et al., 2009a), we demonstrate that
transfection of T98G cells with two different PTP short
hairpin RNA interference (shRNAi) (#1, #2) induced a
strong reduction of PTP expression levels (Supplemen-
tary Figure 2B) and at the same time an increase of cell
motility (Figure 5c). The same effect was not observed in
T98G transfected with p27kip1 and PTEN siRNAs
(Supplementary Figure 4B). In addition, we also show
that the overexpression of PTPm complementary DNA
in U87MG cells (Supplementary Figure 2A) induced a
decrease of cell motility (Figure 5c). This result suggests
that PTPm protein is able to control cell motility in
glioma cells. miRs may target different proteins. In
order to demonstrate that migration/adhesion effects
observed were carried out by PTPm, we transfected
T98G tween, tween-221 and tween-222 with ectopic
PTPm complementary DNA lacking the miRNA-bind-
ing site in its 30UTR, before assaying migration and
adhesion. Levels of transfected PTPm were analyzed by
Figure 5 Effects of miR-222 and-221 on cell migration and adhesion. T98G glioma cells showed lower migration compared with
U87MG, LN18 and LN229 cells (a), whereas T98G cells stably (a) or transiently (b) transduced with miR-222 and -221 exhibited
increased migration levels. Transfection of PTPm complementary DNA in miR-222 and -221 overexpressing cells was able to rescue the
effect of both miRs on invasion (c), whereas T98G transfected with two different PTPshRNAi (#1, #2) exhibited higher migration
compared with control scrambled small hairpin RNA (scr) (c). Each assay was performed three times in independent experiments
(n¼ 3). Error bars indicate standard deviation. *Po0.05
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western blot (Supplementary Figure 2A). Interestingly,
transfection of PTPm in miR-221- and -222-overexpres-
sing U87MG cells, was able to overcome the effects of
both miRs (Figure 5c). These rescue experiments proved
the causative connection between miR-222, PTPm and
glioma cell motility.
Effect of PTPm expression on other miR-221/222 targets
As it has been recently described that miRs targeting
multiple proteins may differently affect cellular behavior
(Poliseno et al., 2010), we investigated whether inhibit-
ing the expression of one target may affect the
expression of the others. Therefore, to exclude that the
effects of PTPm knockdown were mediated in a large
part by changes in PTEN and p27Kip1 protein expression,
we speciﬁcally silenced PTPm and then evaluated
expression levels of PTEN and p27Kip1. As shown in
supplementary Figure 2B, the knock down of PTPm did
not produce changes in expression of either PTEN or
p27Kip1. Moreover, silencing of PTEN or p27Kip1 in T98G
did not produce any changes in PTPm protein expression
(Supplementary Figure 4A) or in tumorigenicity, as the
number of colonies grown in soft agar were comparable
to that observed in cells transfected with a control
siRNA (Supplementary Figure 4C).
miR-222 and PTPm mRNA levels in glioma
To evaluate whether PTPm downregulation in GB was
related to increased miR-222 and -221 levels also in vivo,
we analyzed PTPm protein and miR-222 and -221
expression levels in tumor tissue specimens collected
from 18 glioblastoma grade IV patients. miR-221 and
-222 increased expression was not observed in all patient
analyzed. We divided samples in two groups: high-
expressing miR-221 and -222, low-expressing PTPm (A)
(12/18, 67% ) and low-expressing miR-221 and -222 and
high-expressing PTPm (B) (6/18, 33%). In both group we
observed an inverse correlation between miR-221 and
-222 with PTPm (Figure 6).
To corroborate the inverse relation between miR-221/
222 and PTPm in vivo, in situ hybridization analysis was
performed using 50-digoxigenin-labeled locked nucleic
acid probes on 66 glioma cancers (Table 2), followed
by immunohistochemical detection of co-expression of
PTPm protein. As shown in Figure 7A, miR-222 was
abundantly expressed in high-grade glioma and rarely
found in normal cells. No co-expression was found with
PTPm. Same result was obtained for miR-221 (data not
shown). Importantly, it was evident that miR-221/222
was abundantly expressed in grade III and IV aggressive
cases glioblastoma as shown by comparing grade IV
GB with oligodendroglioma, a slowly growing glioma
(Figure 7). Conversely, PTPm was highly expressed in
oligodendroglioma and normal brain compared with
grade IV glioblastoma.
Discussion
GB are among the most deadly types of cancer (Tran
and Rosenthal, 2010). Advances in standard treatments
for this tumor, such as surgery, radiotherapy and
chemotherapy, have not signiﬁcantly increased patient
survival (Huse and Holland, 2010). The lethality of GB
can be attributed to the capacity of the cells to migrate
and develop foci throughout the brain (Demuth and
Berens, 2004). It is thought that the invasive behavior of
glioblastoma cells is one of the most important causes of
poor clinical outcome, enabling tumor cells to actively
egress from the main mass and invade the surrounding
normal brain where they are out of reach of surgical
resection, radiation and chemotherapy (Giese et al., 2003).
The mechanisms of the spreading phenotype are not
well understood so far. It was recently demonstrated
that the receptor PTPm negatively regulates GB cell
migration (Burgoyne et al., 2009a). PTPm is the
prototype of the type IIb subfamily of receptor PTPs
(RPTP). This phosphatase is able to sense an extra-
cellular signal via its extracellular segment and to
Figure 6 Correlation of endogenous miR-222 and PTPm mRNA expression levels in human glioma. Total RNA extracted from tissue
specimens collected from 18 GB individuals was used to analyze miR-222/221 and PTPm mRNA expression by RT–PCR. We divided
samples in two groups: high-expressing miR-221 and -222 and low-expressing PTPm (a) (12/18, 67%) and low-expressing miR-221 and
-222 and high-expressing PTPm (b) (6/18, 33%). In each group we observed an inverse correlation between miR-221 and -222 with
PTPm was observed.
Table 2 PTPm and miR-222 staining on glioma tumors
Grade I and II
astrocytomas
(N¼ 26)
Grade III and IV
glioblastomas
(N¼ 40)
Total gliomas
(N¼ 66)
miR-222þ /PTPm 7 (27%) 13 (32%) 20 (31%)
miR-222/PTPmþ 3 (11%) 2 (6%) 5 (7%)
Abbreviations: PTPm, protein tyrosine phosphatase m.
Results of miR-222 in situ hybridization and PTPm immunohisto-
chemistry on 66 gliomas (26 Grade I and II, 40 Grade III and IV).
N, indicates the number of sample analyzed.
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transduce this signal intracellularly via its phosphatase
activity (Brady-Kalnay et al., 1995). In a xenograft
mouse model of intracranially injected U87MG cells,
PTPm small hairpin RNA was able to induce cell
migration and dispersal (Burgoyne et al., 2009a). PTPm
may be considered as a ‘migration suppressor’ with
regard to the diffuse inﬁltrative growth pattern observed
in human gliomas. It was previously shown that PTPm
protein is downregulated in glioblastoma and that its
levels correlated to tumor stage (Burgoyne et al., 2009b).
In particular, a striking loss of PTPm protein was
observed in highly dispersive GB compared with less
dispersive low-grade astrocytomas and normal brain
(Burgoyne et al., 2009a). It was recently demonstrated
that one mechanism of PTPm downregulation in GB is
proteolytic breakdown (Burgoyne et al., 2009b).
In this work, we identiﬁed a new molecular mechan-
ism of PTPm downregulation in human glioma, by
identifying two related miRs that target this phospha-
tase. In order to identify new signatures of GB
invasiveness, we investigated the microRNA expression
proﬁle of tumorigenic glioma cells compared with
non-tumorigenic cells. We identiﬁed ﬁve miR genes
signiﬁcantly overexpressed in tumorigenic cells with a
>2.5-fold change. Among the different miRs we
focused our attention on two highly related miRs,
miR-221 and -222. MiR-222 and -221 expression levels
in human cancer have been extensively investigated
(Garofalo et al., 2008, 2009) and have been frequently
found overexpressed in a number of human tumors
(Pallante et al., 2006; Garofalo et al., 2008, 2009, 2010;
Conti et al., 2009; Pineau et al., 2010). In previous works
we demonstrated that miR-221 and miR-222 regulate
death receptor signaling and TRAIL apoptosis sensitiv-
ity in non-small cell lung cancer and in hepatocarcinoma
by modulating p27kip1, PTEN and TIMP3 expression
(Garofalo et al., 2008, 2009). In GB tissues and cell
lines miR-222 and -221 were found overexpressed
Figure 7 Correlation of the in situ co-detection miR-221 and PTP expression in benign and malignant brain tissue. (A) A total of 66
low- and high- grade glioma on a TMA were analyzed for miR-222 expression by in situ hybridization and then for PTPm, respectively,
by immunohistochemistry. Panel A shows miR-222 signal (ﬂuorescent blue) and panel B shows the PTPm signal (ﬂuorescent red) in a
grade IV glioblastoma. Panel C shows the mixed signal in which ﬂuorescent yellow is indicative of miR-222 and protein co-expression;
note the lack of miR-222 and PTPm co-expression. Panel D shows the RGB image of the in situ hybridization/immunohistochemical
reaction shown in panels b–d. (B) In the normal brain one sees the miR-222 signal (ﬂuorescent blue) in panel e and the PTPm image as
ﬂuorescent red (panel f). As described in the text, the majority of normal brain was negative for miR-222 (panel e) and positive for
PTPm (panel f). Panel g shows the mixed signal in which ﬂuorescent yellow is indicative of miR and protein co-expression. Panel h
shows the RGB image of the in situ hybridization/immunohistochemical reaction shown in panels e–g. (C) Finally, on four
oligodendrogliomas, only 1/4 was miR-222þ and 4/4 were PTPm positive. Panel a shows miR-222 signal (ﬂuorescent blue) and panel b
is the PTPm signal (ﬂuorescent red). Panel c shows the mixed signal in which ﬂuorescent yellow is indicative of miR and protein co-
expression; note the lack of miR-222 and PTPm co-expression. Panel d shows the RGB image of the in situ hybridization/
immunohistochemical reaction shown in panels b–d.
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(Ciafre` et al., 2005; Conti et al., 2009) and correlated
to the stage of the disease. However, the molecular
targets of those miRs potentially involved in GB’s
invasive behavior had not been clariﬁed. In this
manuscript we provide evidence for the ﬁrst time that
miR-222 and -221 bind to the 30UTR region of PTPm
and are able to downregulate PTPm at RNA and protein
levels. By luciferase assay, we also identiﬁed the 30UTR
region of the PTP gene that represents the miR-binding
site.
As PTPm has been described to be able to suppress
glioma cell migration (Burgoyne et al., 2009a), we
hypothesized that miR-221 and -222 promote cell
migration by downregulating PTPm expression. In fact,
the analysis of cell motility in T98G cells transduced
with miR-221 or -222 demonstrated that upregulation of
those miRs induced an increase of cell motility. The
same result was obtained in T98G cells transiently
transfected with either miR-221 or -222. Conversely the
expression of anti-miR -222 was able to reduce cell
migration. Comparable results were obtained when we
analyzed cell adhesion phenotype of glioma cells. As
miRNAs can affect many different proteins, we vali-
dated the migration/adhesion effects by co-transfection
of miR-222 and ectopic PTPm lacking the miRNA
binding site in its 30UTR. These rescue experiments
proved the causative connection between miR-222/221
PTPm and migration/invasion.
Moreover, our data show that in specimens of glioma,
miR-222 and -221 expression inversely correlates with
that of PTPm. Therefore, miR-222 and -221 expression
levels could predict the aggressive behavior of glioma.
Over the past few years, several miRs have been
implicated in various human cancers. Both losses and
gains of miR function have been shown to contribute to
cancer development through a range of mechanisms
(Croce, 2009). Several miRs have been implicated in
glioma formation, including miR-21, -7, -124a, -137,
-221, -222, -34a, -125b, 146b and -181 family (Huse and
Holland, 2010). Interestingly, in our model we found
almost the same set of de-regulated miRs, indicating
that they may be a molecular signature of glioblastoma
cells.
Some of those miRs have been speciﬁcally described
to be involved in the invasive glioma phenotype.
In particular, inhibition of miR-21 reduces motility
and invasiveness of glioma cells through the regula-
tion of RECK, a membrane-anchored matrix metallo-
proteinase inhibitor important for extracellular matrix
(ECM) remodeling (Gabriely et al., 2008). Similarly, Xia
et al., 2009 described that miR-146b signiﬁcantly
reduced the migration and invasion of glioma cells by
targeting one matrix metalloproteinase family member,
matrix metalloproteinase16. miR-7, through targeting of
EGFR and AKT activity, has also been implicated in
GBM invasiveness (Kefas et al., 2008). Our data provide
evidence for the role of miR- 222 and -221 in glioma cell
migration/invasion through PTP regulation.
In conclusion, this study has identiﬁed a new
mechanism of oncogenic action by miRs-222/-221 over-
expression, leading to dissemination and invasion of GB
cells, causing a very aggressive behavior. Our results
suggest that miR-221 and -222 regulate glioma tumor-
igenesis at least in part through the control of PTPm
protein expression.
Materials and methods
Cell culture and transfection
U87MG, T98G, LN-308, LN-319, A172 and LN-428 cells were
grown in Dulbecco’s modiﬁed Eagle’s medium. LN-18 and
LN-229 were grown in Advanced Dulbecco’s modiﬁed Eagle’s
medium (Gibco, Invitrogen, Milan, Italy), Meg01 cells (hu-
man, chronic myelogenous leukemia cells) were grown in
RPMI 1640þ 2mM glutamineþ 10% fetal bovine serum.
Media were supplemented with 10% heat-inactivated fetal
bovine serum, 2mM L-glutamine and 100U/ml penicillin/
streptomycin. For miRs transient transfection, cells at 50%
conﬂuency were transfected using Oligofectamine (Invitrogen)
with 100 nM (ﬁnal) of pre-miR-221 and 222, scrambled or Anti
miR-222 and Anti miR-221 (Applied Biosystems, Milan,
Italy). For PTPm transient transfection, cells were transfected
using Lipofectamine and Plus Reagent with 5mg of PTPm
complementary DNA (Origene, Rockville, MD, USA) for 24 h.
To knock-down PTPm gene, speciﬁc small hairpin RNA were
obtained by Open Biosystems (Huntsville, AL, USA) and were
transfected using lipofectamine 2000. After 24 h the cells were
treated for 24 h with 500 ng/ml of puromicine for selection of
transfected cells. Two clones stably expressing small hairpin
RNAi-PTPm were obtained. To knock-down p27kip1 and
PTEN, cells were transfected with p27kip1- and PTEN-speciﬁc
siRNAs from SantaCruz Biotechnology (Heidelberg, Ger-
many) using lipofectamine 2000. TWEEN empty vector,
TWEEN miR-221 or TWEEN miR-222 vectors, were obtained
from Dr Ruggero De Maria (Rome).
Virus production
We produced vector stocks by calcium phosphate transient
transfection, co-transfecting three plasmids in 293T human
embryonic kidney cells, as these cells are good DNA recipients.
The three plasmid are: the packaging plasmid, pCMVDR8.74
designed to provide the HIV proteins needed to produce the
virus particle; the envelope-coding 57 plasmid, pMD.G, for
pseudotyping the virion with VSV-G and TWEEN miR-221 or
miR-222 vector, the transgene coding plasmids. The calcium
phosphate-DNA precipitate was allowed to stay on the cells
for 14–16 h, after which the medium was replaced, collected 48 h
later, centrifuged at 1000 r.p.m. for 5min at room temperature
and ﬁltered through 0.22mm pore nitrocellulose ﬁlters. On the
day of infection, the medium was removed and replaced with
viral supernatant to which 4mg/ml of polybrene had been
added. Cells were then centrifuged in their plate for 45min in
a Beckman GS-6KR centrifuge (Beckman, Milan, Italy), at
1800 r.p.m. and 32 1C. After centrifugation, cells were kept for
either 1 h 15min or ON in a 5% CO2 incubator at 32 or 37 1C,
respectively. After exposure, cells were washed twice with cold
phosphate-buffered saline and fresh medium added. At either
12 or 48 h after the infection, cells were washed with
phosphate-buffered saline, harvested with trypsin/EDTA and
analyzed by FACS for GFP expression. The GFP positive
were sorted by a FACSscan.
Soft agar assay
In all, 103 cells were plated in 60mm dishes in a solution
containing Dulbecco’s modiﬁed Eagle’s medium 2 (Sigma,
miR-221/222 overexpession in human glioblastoma
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St Louis, MO, USA), TPB Buffer (Difco, BD, Franklin Lakes,
NJ, USA), and 1.25% of Noble Agar (Difco). Brieﬂy, cells
were harvested and counted then a layer of 7ml with the
solution containing Noble Agar were left to polymerize on the
bottom of the dishes. Then cells were resuspended in 2ml of
same solution and plated. Cells were left grown for 2 weeks in
the incubator.
Injection of glioma cells in nude mice
Nude mice were provided by Charles River. A total of105 cells
of T98G, LN-18, LN-229 and U87MG were subcutaneously
injected in one ﬂank of the mice. Five mice for each cell type
were injected. Mice were followed for 4 weeks and the tumors
were measured and photographed.
Protein isolation and western blotting
Cells were washed twice in ice-cold phosphate-buffered saline,
and lysed in JS buffer (50mM HEPES pH 7.5 containing
150mM NaCl, 1% glycerol, 1% Triton  100, 1.5mM MgCl2,
5mM EGTA, 1mM Na3VO4, and 1 protease inhibitor
cocktail). Protein concentration was determined by the
Bradford assay (BioRad, Milan, Italy) using bovine serum
albumin as the standard, and equal amounts of proteins were
analyzed by SDS-polyacrylamide gel electrophoresis (12.5%
acrylamide). Gels were electroblotted onto nitrocellulose
membranes (Millipore, Bedford, MA, USA). For immunoblot
experiments, membranes were blocked for 1 h with 5% non-fat
dry milk in tris buffered saline containing 0.1% Tween-20, and
incubated at 4 1C over night with primary antibody. Detection
was performed by peroxidase-conjugated secondary antibodies
using the enhanced chemiluminescence system (Amersham-
Pharmacia Biosciences, GE Healthcare, Milan, Italy). Primary
antibodies used were: anti-PTPm (SantaCruz), anti-bActin
(Sigma), P-Ser-AKT (Promega, Milan, Italy) and anti-p27,
-AKT, -PTEN (Cell Signaling, Danvers, MA, USA).
miRNA microarray experiments
In all, 5mg of total RNA from each sample was reverse
transcribed using biotin-end-labeled random-octamer oligo-
nucleotide primer. Hybridization of biotin-labeled complemen-
tary DNA was performed on a new Ohio State University
custom miRNA microarray chip (OSU_CCC version 3.0, NCBI
accession GPL5106), which contains 1150 miRNA probes,
including 326 human and 249 mouse miRNA genes, spotted in
duplicates. The hybridized chips were washed and processed to
detect biotin-containing transcripts by streptavidin-Alexa647
conjugate and scanned on an Axon 4000B microarray scanner
(Axon Instruments, Sunnyvale, CA, USA).
Raw data were normalized and analyzed with GENE-
SPRING 7.2 software (zcomSilicon Genetics, Redwood City,
CA, USA). Expression data were median-centered by using
both the GENESPRING normalization option and the global
median normalization of the BIOCONDUCTOR package
(http://www.bioconductor.org) with similar results. Statistical
comparisons were done by using the GENESPRING analysis
of variance tool, predictive analysis of microarray (PAM) and
the signiﬁcance analysis of microarray (SAM) software (http://
www-stat.stanford.edu/Btibs/SAM/index.html).
Glioma cancer samples
A total of 18 parafﬁned high-grade glioma samples were
collected at the Federico II University of Naples, Italy and
tumor bank Unit of the Spanish National Cancer Research
(CNIO) Madrid, Spain. RNA was isolated with RecoverALL
Total Nucleic Acid Isolation kit from Ambion (Ambion Inc.,
Austin TX, USA). The samples were stored at 80 1C.
RNA extraction and RT–PCR
Total RNAs (miRNA and mRNA) were extracted using Trizol
(Invitrogen) according to the manufacturer’s protocol. Reverse
transcription of total miRNA was performed starting from
equal amounts of total RNA/sample (1 mg) using miScript
reverse Transcription Kit (Qiagen, Milan, Italy), for mRNA
was used SuperScript III Reverse Transcriptase (Invitrogen).
For cultured cells, quantitative analysis of PTPm, b-Actin (as
an internal reference), miR-221/222 and RNU5A (as an
internal reference) were performed by RT–PCR using speciﬁc
primers (Qiagen), miScript SYBR Green PCR Kit (Qiagen)
and iQ SYBR Green Supermix (BioRad), respectively. The
reaction for detection of mRNAs was performed as follow:
95 1C for 150, 40 cycles of 94 1C for 1500, 60 1C for 3000 and 72 1C
for 3000. The reaction for detection of miRNAs was performed
as follow: 95 1C for 150, 40 cycles of 94 1C for 1500, 55 1C for 3000
and 70 1C for 3000. All reactions were run in triplicate. The
threshold cycle is deﬁned as the fractional cycle number at
which the ﬂuorescence passes the ﬁxed threshold. For relative
quantization the 2(DCT) method was used as previously
described (Livak and Schmittgen, 2001). Experiments were
carried out in triplicate for each data point, and data analysis
was performed by using software (BioRad).
Luciferase assay
The 30 UTR of the human PTPm gene was PCR ampliﬁed using
the following primers: PTPm Fw: 50-TCTAGACGAGGTGGC
CCTGGAATACTTGAATTCT-30 and PTPm Rw 50-TCTAG
AGCATTTTGTGAATGAGTCCTCCCCCAA-30, and cloned
downstream of the Renilla luciferase stop codon in pGL3
control vector (Promega). This construct was used to generate,
by inverse PCR, the UTRmut-PTPm plasmid (primers: PTPm
-mut: Fw 50-GCATAATATATGCTTGCTTTCCAGGACTA
ACAGATAAATGTG-30; Rw 5-0 CACATTTATCTGTTAGT
CCTGGAAAGCAAGCATATATTATGC-30. MeG01 cells were
co-transfected with 1 mg of UTR- PTPm plasmid and with
UTRmut- PTPm plasmid and 1mg of a Renilla luciferase
expression construct pRL-TK (Promega) with Lipofectamine
2000 (Invitrogen). Cells were harvested 24 h post-transfection
and assayed with Dual Luciferase Assay (Promega) according
to the manufacturer’s instructions. We used MEG01 cell lines
as they express low levels of miR-221 and -222 and also
because they are easily transfectable (Incoronato et al., 2010).
Three independent experiments were performed in triplicate.
MiRNA locked nucleic acid in situ hybridization
of formalin-ﬁxed, parafﬁn-embedded tissue section
In situ hybridization was carried out on deparafﬁnized human
glioma tissues sections using previously published protocol
(Nuovo et al., 2009), which includes a digestion in pepsin
(1.3mg/ml) for 30min. The sequences of the probes containing
the six dispersed locked nucleic acid locked nucleic acid-modiﬁed
bases with digoxigenin conjugated to the 50 end were: miR-221-(50)
GAAACCCAGCAGACAATGTAGCT; miR-222(50) ACCC
AGTAGCCAGATGTAGCT. The probe cocktail and tissue
miRNA were co-denatured at 60 1C for 5min, followed by
hybridization at 37 1C overnight and a low-stringency wash in
0.2 SSC and 2% bovine serum albumin at 4 1C for 10min.
The probe-target complex was seen due to the action of alkaline
phosphatase on the chromogen nitroblue tetrazolium and bromo-
chloroindolyl phosphate (NBT/BCIP). Negative controls included
the use of a probe, which should yield a negative result in such
tissues. No counterstain was used, to facilitate co-labelling for
miR-221/222 overexpession in human glioblastoma
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PTPm protein. After in situ hybridization for the miRNAs, as
previously described (Nuovo et al., 2009; Incoronato et al.,
2010), the slides were immunostained to identify PTPm protein
expression. The anti-PTPm antibody (Santacruz) was incu-
bated at 1:200 for 30min. For the immunodetection, we used
the Ultrasensitive Universal Fast Red system from Ventana
Medical Systems. We used low-grade glioma tissues know to
express PTPm (Burgoyne et al., 2009a) as positive control of
PTP protein expression. The percentage of tumor cells expres-
sing PTPm and miR-221&222 was then analyzed with emphasis
on co-localization of the respective targets.
Migration assay
Transwells Permeable Supports, 6.5mm diameter inserts, 8.0mM
pore size, polycarbonate membrane (Corning Incorporate,
Corning, NY, USA) were used to perform migration assay.
T98G and U87MG cells were grown as indicated above, then
harvested by TrypLE Express (Invitrogen, Carlsbad, CA, USA),
and 105 cells were washed three times and then resuspended in
1% fetal bovine serum containing Dulbecco’s modiﬁed Eagle’s
medium medium and seeded in the upper chamber. The lower
chamber of the transwell was ﬁlled with 600ml of culture medium
containing 10% fetal bovine serum, 5mg/ml ﬁbronectin, as an
adhesive substrate. Cells were incubated at 37 1C for 24 h. The
transwells were then removed from the 24-well plates and stained
with 0.1% Crystal Violet in 25% methanol. Non-migrated cells
were scraped off the top of the transwell with a cotton swab.
Percentage of migrated cells was evaluated by eluting crystal
violet with 1% SDS and reading the absorbance at l 570 nm.
Statistical analysis
Continuous variables are expressed as mean values±s.d.
One-tailed Student’s t-test was used to compare values of
test and control samples. Po0.05 was considered signiﬁcant.
Fold increase of the bands was calculated using ImageJ
program available on web.
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ORIGINAL ARTICLE
Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in
glioma cells
C Quintavalle1,2,7, E Donnarumma3,7, M Iaboni1,2, G Roscigno1,2, M Garofalo4, G Romano3, D Fiore1, P De Marinis5, CM Croce4
and G Condorelli1,2,6
Glioblastoma is the most frequent brain tumor in adults and is the most lethal form of human cancer. Despite the improvements in
treatments, survival of patients remains poor. To define novel pathways that regulate susceptibility to tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) in glioma, we have performed genome-wide expression profiling of microRNAs (miRs). We show
that in TRAIL-resistant glioma cells, levels of different miRs are increased, and in particular, miR-30b/c and -21. We demonstrate that
these miRs impair TRAIL-dependent apoptosis by inhibiting the expression of key functional proteins. T98G-sensitive cells treated
with miR-21 or -30b/c become resistant to TRAIL. Furthermore, we demonstrate that miR-30b/c and miR-21 target respectively the
30 untranslated region of caspase-3 and TAp63 mRNAs, and that those proteins mediate some of the effects of miR-30 and -21 on
TRAIL resistance, even in human glioblastoma primary cells and in lung cancer cells. In conclusion, we show that high expression
levels of miR-21 and -30b/c are needed to maintain the TRAIL-resistant phenotype, thus making these miRs as promising
therapeutic targets for TRAIL resistance in glioma.
Oncogene advance online publication, 10 September 2012; doi:10.1038/onc.2012.410
Keywords: glioblastoma; TRAIL; therapy; microRNA; treatment; apoptosis
INTRODUCTION
Glioblastomas are the most common primary tumors of the brain
and are divided into four clinical grades on the basis of their
histology and prognosis.1 These tumors are highly invasive, very
aggressive and are one of the most incurable forms of cancer in
humans.2 The treatment strategies for this disease have not
changed appreciably for many years, and failure of treatment
occurs in the majority of patients owing to the strong resistant
phenotype. Therefore, the development of new therapeutic
strategies is necessary for this type of cancer.
A novel interesting therapeutic approach is the reactivation of
apoptosis using member of TNF (tumor necrosis factor)-family, of
which the tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) holds the greatest interest. Apoptosis is a particularly
desirable treatment outcome, as it eradicates cancer cells without
causing a major inflammatory response, which could provide
unwanted survival signals. However, many cancers develop
functional defects in the drug-induced apoptosis pathway, which
may lead to constitutive or acquired resistance. To this end,
alternative pathways, such as the one activated by death
receptors including Fas/Apo-1, or DR4 (TRAIL-R1) and DR5
(TRAIL-R2), are being explored for cancer treatment. TRAIL is a
relatively new member of the TNF family, known to induce
apoptosis in a variety of cancers.3 Treatment with TRAIL induces
programmed cell death in a wide range of transformed cells, both
in vivo and in vitro, without producing significant effects in normal
cells.3,4 Therefore, recombinant TRAIL or monoclonal antibodies
against its receptors (TRAIL-R1 and TRAIL-R2) are in phase II/III
clinical trials for different kinds of tumors, either as a single agent
or in combination with chemotherapy.5,6
However, a significant proportion of human cancer cells are
resistant to TRAIL-induced apoptosis, and the mechanisms of
sensitization seem to differ among cell types. Different studies
relate resistance to TRAIL-induced cell death to downstream
factors. It has been shown that downregulation of two anti-
apoptotic proteins such as PED (Phosphoprotein enriched in
diabetes) or cellular-FLICE such as inhibitory protein (c-FLIP)
can sensitize cells to TRAIL-induced apoptosis.7–9 However the
mechanism of TRAIL resistance is still largely unknown.
miRs are a class of endogenous non-coding RNA of 19–24
nucleotides in length that has an important role in the negative
regulation of gene expression blocking translation or directly
cleaving the targeted mRNA.10 miRs are involved in the
pathogenesis of most cancers.10 In the last few years, our
understanding of the role of miRNA has expanded from the
initially identified functions in the development of round worms
to a highly expressed and ubiquitous regulators implicated in a
wide array of critical processes, including proliferation, cell death
and differentiation, metabolism and, importantly, tumorigenesis.11
We have recently showed an important role of microRNAs in TRAIL
sensitivity in non-small cell lung cancer (NSCLC).12–14
In this study, to identify novel mechanisms implicated in TRAIL
resistance in human glioma, we performed a genome-wide
expression profiling of miRs in different cell lines. We found
that miR-30b/c and -21 are markedly upregulated in TRAIL-
resistant, and downregulated in TRAIL-sensitive glioma cells.
1Department of Cellular and Molecular Biology and Pathology, ‘Federico II’ University of Naples, Naples, Italy; 2IEOS, CNR, Naples, Italy; 3Fondazione IRCCS SDN, Naples, Italy;
4Department of Molecular Virology, Immunology and Medical Genetics, Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus,
OH, USA; 5Neurosurgery Unit, Ospedale A. Cardarelli, Napoli, Italy and 6Facolta` di Scienze Biotecnologiche, ‘Federico II’ University of Naples, Naples, Italy. Correspondence:
Professor G Condorelli, Department of Cellular and Molecular Biology and Pathology, ‘Federico II’ University of Naples, Via Pansini, 5, Ed 19 A, II floor, Naples 80131, Italy.
E-mail: gecondor@unina.it
7These authors contributed equally to this work.
Received 28 February 2012; revised 13 June 2012; accepted 23 July 2012
Oncogene (2012), 1–8
& 2012 Macmillan Publishers Limited All rights reserved 0950-9232/12
www.nature.com/onc
Our experiments indicate that miR-30b/c and -21 modulate TRAIL
sensitivity in glioma cells mainly by modulating caspase-3 and
TAp63 expression and TRAIL-induced caspase machinery.
RESULTS
Selection of TRAIL-sensitive vs TRAIL-resistant glioma cell lines
We analyzed TRAIL sensitivity of different human glioma cell lines.
Cells were exposed to TRAIL at two different concentrations for
24 h and cell death was assessed using the MTT assay (Figure 1a)
or propidium iodide staining (Figure 1b). As shown in Figure 1, we
can distinguish two sets of cells: TB10, LN229, U251 and U87MG
cells exhibited total or partial TRAIL resistance, whereas T98G and
LN18 cells underwent TRAIL-induced cell death.
miRs expression screening in TRAIL-resistant vs TRAIL-sensitive
glioma cell lines
To investigate the involvement of miRs in TRAIL resistance in
glioblastoma cell lines, we analyzed the miRs expression profile in
the most TRAIL-resistant glioma cells (TB10 and LN229) vs the
TRAIL-sensitive cells (T98G and LN18). The analysis was performed
with a microarray chip containing 1150 miR probes, including 326
human and 249 mouse miRs, spotted in duplicates. Data obtained
indicated that seven miRs (miR-21, -30b, -30c, -181a, -181d, -146
and -125b) were significantly overexpressed in resistant glioma
cells with at least 41.9-fold change (Table 1). Quantitative real-
time-polymerase chain reaction (qRT–PCR) validated the micro-
array analysis (data not shown).
Role of miRs in TRAIL resistance in glioma
To test the role of these overexpressed miRs in TRAIL sensitivity in
glioma, we transfected T98G TRAIL-sensitive cells with miR-21,
-30b, -30c, -181a, -146 and -125b. TRAIL sensitivity was evaluated
by MTT assay, propidium iodide staining and colony assay. We
obtained significant results only for miR-30b/c and miR-21 that
were then extensively investigated. In fact, data obtained with
MTT assay and FACS analysis showed that the overexpression of
miR-30b/c and -21 was able to revert TRAIL sensitivity in T98G
(Figures 2a and b). Similar results were obtained in LN18 cells
(Figures 2c and d). This effect was not restricted to glioma, as
miR-30 and miR-21 were able to exert an anti-apoptotic action
also in non small cell lung cancer (NSCLC) (Supplementary
Figure 3B). We further evaluated TRAIL sensitivity by colony assay.
T98G and LN18 cells were transfected with miR-scrambled, miR-
30b/c and miR-21 for 48 h and then were treated with 50 or
100 ng/ml of superKiller TRAIL for 24 h. Cells were grown for 6 days
and then coloured with crystal violet-methanol solution
(Supplementary Figures 1A and B). The results indicated that
both miRs induced an increase of TRAIL resistance.
To further explore the role of miR-21 and -30b/c on TRAIL
sensitivity, we transfected U251 (Figure 3a) or LN229 (Figure 3b)
TRAIL-resistant cells with anti-miR-21, -30b, 30c, or with a
scrambled sequence. As shown in Figures 3a and b, transfection
of the anti-miR sequences was able to sensitize U251 and LN229
cells to TRAIL. Anti-miR-21 and -30c were also able to sensitize
to TRAIL the CALU-1-resistant non-small cell lung cancer (NSCLC)
TRAIL-resistant cell lines (Supplementary Figure 3C), indicating
that this effect was not restricted to glioma.
Identification of cellular targets of miR-30b/c and miR-21
in glioma cells
To identify cellular targets of miR-30b/c and -21, we used as first
attempt a bioinformatic search, using programs available on the
web including Pictar, TargetScan, miRanda and Microcosm target.
miR-21 targets different tumor suppressor genes and proteins
potentially involved in TRAIL resistance in glioblastoma
cells, such as PTEN (phosphatase and tensin homologue),
PDCD4 (programmed cell death 4), TPM1 (Tropomyosin 1) and
p53.15–17 Computer-assisted analysis identified the presence of
evolutionary-conserved binding sites for miR-21 in TAp63 gene.
We focused our attention on this p53 family member, as it
regulates the expression of TRAIL receptors and molecules
involved in TRAIL signaling.18 We also searched for miR-30
targets and among them we focused on caspase-3.
TRAIL-resistant and TRAIL-sensitive glioma or NSCLC cells
exhibited different levels of miR-21 and -30c assessed by either
qRT–PCR (Figure 4a and Supplementary Figure 3A) or by northern
blot analysis (Supplementary Figure 4). Interestingly, we observed
a reduction of protein (Figure 4b and Supplementary Figure 3D)
and mRNA (Figure 4c) levels of TAp63 and caspase-3 upon,
respectively, miR-21 or miR-30c and miR-30b (data not shown)
transfection in TRAIL-sensitive cell lines. We didn’t observe aCe
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Figure 1. TRAIL sensitivity of glioblastoma cells. Glioblastoma cell
lines (104 cell) were treated with superKiller TRAIL. After 24 h of
treatment, the effect on cell death was assessed with MTT assay
(a) or by propidium iodide staining and FACS analysis (b).
Table 1. microRNA identified in TRAIL-resistant glioma (LN229 and
TB10) compared with TRAIL-sensitive (T98G, LN18) cells
miR P-value Fold difference
hsa-miR-125b1-A 6.09e! 05 3.033
hsa-miR-30b-A 9.14e! 05 2.041
hsa-miR-30c-A 0.0001199 2.337
hsa-miR-146b-A 0.0001556 5.972
hsa-miR-181a-5p-A 0.0004698 2.66
hsa-miR-181d-A 0.0004817 3.035
hsa-miR-21-A 0.0032482 1.949
miRNA expression profiles in TRAIL-sensitive vs TRAIL-resistant cells.
miRNA screening was performed in triplicate for TRAIL-sensitive and
TRAIL-resistant cell lines by a microarray as described in Materials and
methods. A two-tailed, two-sample t-test was used (Po0.05). Seven
miRNAs were found to be significantly deregulated in TRAIL-resistant cells
compared with the TRAIL sensitive.
MicroRNA, glioblastoma and TRAIL resistance
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decrease in the levels of other caspases upon miR-30c transfection
(Figure 4b). On the contrary, TAp63 and caspase-3 protein levels
increased upon anti-miR-21 and anti-miR-30c transfection
(Figure 3c and Supplementary Figure 3D) in TRAIL-resistant cell
lines. To verify a direct link between the miR-21/TAp63 and miR-
30b/c and caspase-3, we performed luciferase assay by co-
transfecting pGL3-30 untranslated region (UTR) vectors along with
miR-21 or miR-30c. The results obtained indicated a direct
interaction of miR-21 with TAp63 and miR-30c with caspase-3
(Figure 4d). As indicated in Figure 4d, miR-30b and -30c have the
same seed sequence that recognizes caspase-3, differing only at
the latest four nucleotides of the 50. Therefore, miR-30b down-
regulates caspase-3 at the same extent than miR-30c (data not
shown). Deletions in seed complementary sites rescued the
repression of miR-21 and miR-30c on their identified targets
(Figure 4d).
Validation of miR-21 and miR-30b/c mechanisms of action
To demonstrate that miR-21 and miR-30b/c, by downregulating
TAp63 and caspase-3, are responsible for the TRAIL resistance
observed in T98G and LN18 cells, we transfected T98G with
caspase-3 or TAp63 complementary DNAs lacking the miRNA-
binding site in their 30UTR or with a control vector and miR-30c
(Figure 5a) or miR-21 (Figure 5b). Interestingly, transfection of
TAp63 and caspase-3 was able to overcome the effects of miR-21
and miR-30c, decreasing cell viability and increasing apoptosis
(Figures 5a and b). The data were confirmed by colony assay in
T98G cells (Supplementary Figures 2A and B). Similar results were
obtained when we analyzed miR-30b (data not shown). These
rescue experiments proved the causative link between miR-21/
TAp63 and caspase-3/miR-30b/c and TRAIL sensitivity.
Effect of miR-21 and miR-30c expression on TRAIL sensitivity in
primary human glioma cell lines
MiR-21 and miR-30c expression levels were measured by qRT–PCR
in nine different human primary cell lines (Figure 6a), eight
derived from glioblastoma tumors (patient no. 1 to no. 8) and one
from tissue surrounding the tumor (patient no. 9), and compared
with TRAIL sensitivity. As shown in Figure 6b, TRAIL sensitivity
correlated with miR-21 and miR-30c expression levels in all cases
analyzed, with the exception of control sample that did not
respond to TRAIL. Moreover, anti-miRs expression in TRAIL-
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resistant primary cultured cells (patient no. 1 and no. 2) was able
to determine an increase of TRAIL sensitivity (Figure 6c) and
concomitantly an increase of the levels of TAp63 and caspase-3
(Figure 6d).
DISCUSSION
Sensitization of cancer cells to apoptosis could be a valuable
strategy to define new treatment options for cancer, in particular
when using agents that aim to directly activate apoptotic
pathways. A promising agent is the death receptor ligand TRAIL,19
as it induces apoptosis in most cancer cells, but not in normal
cells.20,21 Moreover, TRAIL exhibits potent tumoricidal activity
in vivo in several xenograft models, including malignant
glioma.22,23 Indeed, agonistic anti-TRAIL receptor monoclonal
antibodies (mAbs), including mapatumumab (HGS-ETR1, anti-
human DR4 mAb),24 lexatumumab (HGS-ETR2, anti-human DR5
mAb)25 and MD5-1 (anti-mouse DR5 mAb) are currently under
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intensive investigation. The former two mAbs have been tested in
phase 1 clinical trials in patients with systemic malignancy,
exhibiting excellent safety profiles. Anti-mouse DR5 mAb MD5-1
could also be administered safely without inducing hepatotoxicity
either alone or in combination with histone deacetylase inhibitors
in mice.26 The induction of apoptosis by TRAIL is essentially
dependent on the expression of specific TRAIL receptors and on
the activation of caspases,20 thus the regulation of the expression
levels of those molecules is of fundamental importance.
MicroRNAs are emerging as key regulators of multiple pathways
involved in cancer development and progression,27–29 and may
become the next targeted therapy in glioma. The present study
shows that microRNA expression may modulate TRAIL-induced
apoptosis in glioma cells, by the regulation of caspase-3 and
TAp63 levels. We analyzed the miRs profile of TRAIL-resistant
compared with TRAIL-sensitive glioma cells. We then focused our
attention on miR-30b/c and miR-21, as only these miRs among
those identified by the array, demonstrated the ability to revert
the TRAIL-sensitive phenotype. We also provided evidences that
this regulation is not restricted to glioma, but it is present also in a
different type of cancer such as NSCLC.
MiR-21 has been found overexpressed in high-grade glioma
patients30 and studies have identified different miR-21 key targets
for glioma biology, such as RECK, TIMP3, Spry2 and Pdcd4 genes,
which are suppressors of malignancy and inhibitors of matrix
metalloproteinase.16,31–33 Moreover, levels of expression of miR-21
have been associated to patients survival.34
Other studies indicate that knockdown of miR-21 in cultured
glioblastoma cells triggers activation of caspases and leads to
increased apoptotic cell death.35 Corsten et al.36 hypothesized that
suppression of miR-21 might sensitize gliomas for cytotoxic tumor
therapy. With the use of locked nucleic acid (LNA)-anti-miR-21
oligonucleotides and neural precursor cells (NPC) expressing a
secretable variant of TRAIL (S-TRAIL), they showed that the
combined suppression of miR-21 and NPC-S-TRAIL leads to a
synergistic increase in caspase activity and a decreased cell
viability in human glioma cells in vitro and in vivo in xenograft
experiments. Interestingly, Papagiannakopoulos et al.15 described
that miR-21 targets multiple important components of the p53
tumor-suppressive pathways. They showed that downregulation
of miR-21 in glioblastoma cells leads to repression of growth,
increased apoptosis and cell cycle arrest, through the regulation of
target proteins such as HNRPK and TAp63. Our study describes for
the first time the direct link between miR-21, TAp63 and TRAIL
sensitivity. We demonstrated that miR-21 targets the 30UTR
sequence of TAp63, and that transfection of miR-21 is able to
downregulate TAp63 at both mRNA and protein levels. More
importantly, we demonstrated that miR-21, through TAp63, is able
to modulate TRAIL sensitivity, as the co-transfection of miR-21 and
TAp63 cDNA renders the cells again responsive to TRAIL. TAp63 is
a transcription factor that regulates the expression levels of
different apoptosis-regulating genes, such as TRAIL receptors,
bcl2l11 and Apaf1.18 Thus, it is possible that those apoptosis-
regulating molecules are regulated by miR-21 through TAp63.
Several studies link miR-30 to apoptosis and human cancer.
Li et al.37 demonstrated that miR-30 family members inhibited
mitochondrial fission through the suppression of the expression
of p53 and its downstream target Drp1, whereas, Joglekar et al.38
demonstrated that miR-30 may have a role in epithelial-to-
mesenchymal transition. Our recent data demonstrate that miR-
30 targets the anti-apoptotic protein BIM, participating to
gefitinib resistance in lung cancer.39 MiR-30 has been also
associated with stem cell properties. Yu et al.40 described that
miR-30 is reduced in breast tumor stem cells (BT-ICs), and
demonstrated that enforced expression of miR-30 in BT-ICs
inhibits their self-renewal capacity by reducing Ubc9,
and induces apoptosis through silencing ITGB3. In our hands,
miR-30 overexpression inhibits TRAIL-induced apoptosis in
glioma cells by targeting caspase-3. In fact, modulating the
expression of either miR-30 or caspase-3, we observed a
modification of TRAIL sensitivity of glioma cells. The opposing
results on the role of miR-30 on cell death may be ascribed either
to different cell system (breast vs glioma), or to different type of
cancer cell (stem vs differentiated cells). In favour of this
hypothesis, many reports describe opposing role of miRs in a
different cell contest.28 Recently, miR-30d has been described to
target caspase-3 in breast cancer cells, and thus to regulate
apoptosis.41 The seed sequence recognizing the 30UTR of
caspase-3 is highly homologous within the members of the
miR-30 family (miR-30b/c/d) suggesting a more generalized role
of miR-30 family members in the regulation of cell death and
cancer progression.
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In many experiments, we observed that there is a redundancy
within miR-21 and miR-30 in the regulation of TRAIL sensitivity.
Our data, either in primary or in established cell lines,
demonstrates that it is sufficient that one of the two miRs is
highly expressed in the cells, that apoptosis resistance will
manifest. We have also observed that miR-30 has a predominant
effect in contrasting TRAIL-induced apoptosis. This may be related
to the effect of this miR in targeting one important component of
the cell death machinery, that is, caspase-3.
In conclusion, our study analyzed microRNA expression pattern
in TRAIL-resistant and TRAIL-sensitive glioma cells, and identified
specific miRs and their targets involved in the regulation of the
apoptotic programme. This may be of relevance for future cancer
therapy improvement in glioma.
MATERIALS AND METHODS
Cell culture and transfection
U87MG, T98G, U251, TB10, CALU-1 and 293 cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM). H460 were grown in RPMI. Media were
supplemented with 10% heat-inactivated fetal bovine serum, 2mM
L-glutamine and 100U/ml penicillin/streptomycin. LN229 and LN18 were
grown in Advanced DMEM (Invitrogen, Milan Italy)þ 2mM Glutamineþ 5%
fetal bovine serum. For miRs transient transfection, cells at 50% confluency
were transfected using Oligofectamine (Invitrogen) with 100 nM of pre-miR-
30c, -30b, -125b, -146b, -181a, -21, miR-scrambled or anti-miR- (Applied
Biosystems, Milan, Italy). For caspase-3 and TAp63 transient transfection,
cells were transfected using Lipofectamine and Plus Reagent with 4 mg of
caspase-3 cDNA (Origene, Rockville, MD, USA) or TAp63 cDNA for 24 h.
TAp63 cDNA was obtained from Professor Viola Calabro` (Naples).
SuperKiller TRAIL for cell treatment was purchased from Enzo Biochem
(New York, NY, USA).
Primary cell cultures
Glioblastoma specimens were collected at neurosurgical Unit of Cardarelli
hospital (Naples). All the samples were collected according to a prior
consent of the donor before the collection, acquisition or use of human
tissue. To obtain the cells, samples were mechanically disaggregated, then
the lysates were grown in DMEM-F12 medium supplemented with 10%
fetal bovine serum 1% penicillin streptomicyn and 20 ng/ml EGF (Sigma-
Aldrich, Milan, Italy). To exclude a fibroblast contamination, cells were
stained for GFAP, a protein found in glial cells.
Protein isolation and western blotting
Cells were washed twice in ice-cold phosphate-buffered saline, and lysed
in JS buffer (50mM HEPES pH 7.5 containing 150mM NaCl, 1% Glycerol, 1%
Triton X-100, 1.5mM MgCl2, 5mM EGTA, 1mM Na3VO4 and 1# protease
inhibitor cocktail). Protein concentration was determined by the Bradford
assay (Bio-Rad, Milan, Italy) using bovine serum albumin as the standard,
and equal amounts of proteins were analyzed by SDS–PAGE (12.5%
acrylamide). Gels were electroblotted onto nitrocellulose membranes
(Millipore, Bedford, MA, USA). For immunoblot experiments, membranes
were blocked for 1 h with 5% non-fat dry milk in Tris-buffered saline
containing 0.1% Tween-20, and incubated at 4 1C over night with primary
antibody. Detection was performed by peroxidase-conjugated secondary
antibodies using the enhanced chemiluminescence system (GE Healthcare,
Milan, Italy). Primary antibodies used were: anti-bActin from Sigma-Alrich;
anti-caspase-8, 9 and 10 were from Cell Signalling Technology (Boston, MA,
USA); anti-Caspase 3 and anti-TAp63 from Santa Cruz Biotechnologies
(Santa Cruz, CA, USA).
miRNA microarray experiments
From each sample, 5 mg of total RNA (from T98G, LN18, TB10, LN229 cells)
was reverse transcribed using biotin-end-labelled random-octamer oligo-
nucleotide primer. Hybridization of biotin-labelled cDNA was performed on
an Ohio State University custom miRNA microarray chip (OSU_CCC version
3.0), which contains 1150 miRNA probes, including 326 human and 249
mouse miRNA genes, spotted in duplicates. The hybridized chips were
washed and processed to detect biotin-containing transcripts by
streptavidin-Alexa647 conjugate and scanned on an Axon 4000B micro-
array scanner (Axon Instruments, Sunnyvale, CA, USA).
Raw data were normalized and analyzed with GENESPRING 7,2 software
(zcomSilicon Genetics, Redwood City, CA, USA). Expression data were
median-centered by using both the GENESPRING normalization option
and the global median normalization of the BIOCONDUCTOR package
(www.bioconductor.org) with similar results. Statistical comparisons were
done by using the GENESPRING ANOVA tool, predictive analysis of
microarray and the significance analysis of microarray software (http://
www-stat.stanford.edu/Btibs/SAM/index.html).
RNA extraction and real-time PCR
Total RNAs (miRNA and mRNA) were extracted using Trizol (Invitrogen)
according to the manufacturer’s protocol. Reverse transcription of total
miRNA was performed starting from equal amounts of total RNA per
sample (1mg) using miScript reverse Transcription Kit (Qiagen, Milan, Italy),
for mRNASuperScript III Reverse Transcriptase (Invitrogen) was used. For
cultured cells, quantitative analysis of Caspase-3, Tap63, b-Actin (as an
internal reference), miR-30b/c, miR-21 and RNU5A (as an internal
reference) were performed by real-time PCR using specific primers
(Qiagen), miScript SYBR Green PCR Kit (Qiagen) and iQ SYBR Green
Supermix (Bio-Rad), respectively. The reaction for detection of mRNAs was
performed as follow: 95 1C for 150 , 40 cycles of 94 1C for 150 , 60 1C for 300
and 72 1C for 300 . The reaction for detection of miRNAs was performed as
follow: 95 1C for 150 , 40 cycles of 94 1C for 150 , 55 1C for 300 and 70 1C for
300 . All reactions were run in triplicate. The threshold cycle (CT) is defined
as the fractional cycle number at which the fluorescence passes the
fixed threshold. For relative quantization, the 2(!DCT) method was used
as previously described.42 Experiments were carried out in triplicate
for each data point, and data analysis was performed by using software
(Bio-Rad).
Northern blot analysis
RNA samples (30mg) were separated by electrophoresis on 15%
acrylamide, 7mol/l urea gels (Bio-Rad, Hercules, CA, USA) and transferred
onto Hybond-Nþ membrane (Amersham Biosciences, Piscataway, NJ,
USA). Hybridization was performed at 37 1C in 7% SDS/0.2 mol/l Na2PO4
(pH 7.0) for 16 h. Membranes were washed at 42 1C, twice with 2#
standard saline phosphate (0.18mol/l NaCl/10mmol/l phosphate (pH 7.4)),
1 mmol/l EDTA (saline–sodium phosphate–EDTA; SSPE) and 0.1% SDS and
twice with 0.5# SSPE/0.1% SDS. The oligonucleotides (PRIMM, Milan, Italy)
used, complementary to the sequences of the mature miRNAs, were: miR-
21-probe 50-TCAACATCAGTCTGATAAGCTA-30 ; miR-30c-probe 50-GCTGAG
AGTGTAGGATGTTTACA-30 . An oligonucleotide complementary to the
U6 RNA (50-GCAGGGGCCATGCTAATCTTCTCTGTATCG-30) was used to
normalize the expression levels. Totally, 100 pmol of each probe were
end labelled with 50mCi [g-32P]ATP using the poly-nucleotide kinase
(Roche, Basel, Switzerland). Blots were stripped by boiling in 0.1% SDS for
10min before re-hybridization.
Luciferase assay
The 30 UTR of the human Caspase-3 genes was PCR amplified using the
following primers: Caspase-3 forward: 50-TCTAGAAGGGCGCCATCGCCAAG
TAAGAAA-30 , Caspase-3 reverse: 50-TCTAGACCCGTGAAATGTCATACTGA
CAG-30 and cloned downstream of the Renilla luciferase stop codon in
pGL3 control vector (Promega, Milan, Italy). A deletion was introduced into
the miRNA-binding sites by using the QuikChange Mutagenesis Kit
(Stratagene, La Jolla, CA, USA) using the following: primers: Caspase-3
mut forward 50-GCAAAATTCTTAAGTATGTTATTTTCTGTTGAAATCAAAGGA
AAATAGTAATGTTTTATACT-30 . Caspase-3mut reverse 50-AGTATAAAACAT
TACTATTTTCCTTTGATTTCAACAGAAAATAACATACTTAAGAATTTTGC-30 .
The 30 UTR of the human TAp63 gene was PCR amplified using the
following primers: TAp63 forward: 50-TCTAGAGCAAGAGATAAGTCTTT
CATGGCTGCTG-30 , TAp63 reverse: 50-TCTAGATGGAAATCCCACTATCCCA
AG-30 , and cloned downstream of the Renilla luciferase stop codon in
pGL3 control vector (Promega). A deletion was introduced into the miRNA-
binding sites by using the QuikChange Mutagenesis Kit (Stratagene) using
the following: primers:TAp63 mut forward 50-CTGGTCAAGGGCTGTCATTG
CACTCCATTTTAATTT-30 TAp63 mut reverse 50-AAATTAAAATGGAGTGCAAT
GACAGCCCTTGACCAG-30 .
Hek-293 cells were cotransfected with 1.2mg of generated plasmid and
400mg of a Renilla luciferase expression construct pRL-TK (Promega) with
Lipofectamine 2000 (Invitrogen). Cells were harvested 24 h post transfec-
tion and assayed with Dual Luciferase Assay (Promega) according to the
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manufacturer’s instructions. Three independent experiments were per-
formed in triplicate.
Cell death quantification
Cells were plated in 96-well plates in triplicate, stimulated and incubated
at 37 1C in a 5% CO2 incubator. SuperKiller TRAIL was used at final
concentration of 50 or 100 ng/ml for 24 h. Apoptosis was analyzed via
propidium iodide incorporation in permeabilized cells by flow cytometry.
The cells (2# 105) were washed in phosphate-buffered saline and
resuspended in 200ml of a solution containing 0.1% sodium citrate, 0.1%
Triton X-100 and 50 mg/ml propidium iodide (Sigma). Following incubation
at 4 1C for 30min in the dark, nuclei were analyzed with a Becton Dickinson
FACScan flow cytometer (Becton Dickinson, Milan, Italy). Cellular debris
was excluded from analyses by raising the forward scatter threshold, and
the DNA content of the nuclei was registered on a logarithmic scale. The
percentage of elements in the hypodiploid region was calculated. Cell
viability was evaluated with the CellTiter 96 AQueous One Solution Cell
Proliferation Assay (Promega) according to the manufacturer’s protocol.
Metabolically active cells were detected by adding 20ml of MTS to each
well. After 2 h of incubation, the plates were analyzed in a Multilabel
Counter (BioTek, Milan, Italy).
Colony assay
Cells were transfected with miR-scrambled, miR-30b/c or miR-21 for 24 h,
then were harvested and 2.4# 104 cells were plated in six-well plates. After
24 h, cells were treated with 50 or 100 ng/ml of superKiller TRAIL for 24 h,
as indicated. Cells were transferred to 100mm dishes and let grown for
6 days. Finally, the cells were coloured with 0.1% crystal violet dissolved in
25% methanol for 20min at 4 1C. Dishes were washed with water and then
let dry on the bench, and then photographs were taken.
ACKNOWLEDGEMENTS
This work was partially supported by funds from Associazione Italiana Ricerca sul
Cancro, AIRC to GC (grant n.ro 10620), and MERIT (RBNE08E8CZ_002) to GC. CQ and
MI are supported by the ‘Federazione Italiana Ricerca sul Cancro’ (FIRC) Post-Doctoral
Research Fellowship. GR is supported by a MERIT project Fellowship.
REFERENCES
1 Tran B, Rosenthal MA. Survival comparison between glioblastoma multiforme and
other incurable cancers. J Clin Neurosci 2010; 17: 417–421.
2 Purow B, Schiff D. Advances in the genetics of glioblastoma: are we reaching
critical mass? Nat Rev Neurol 2009; 5: 419–426.
3 Schaefer U, Voloshanenko O, Willen D, Walczak H. TRAIL: a multifunctional cyto-
kine. Front Biosci 2007; 12: 3813–3824.
4 Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: Decisions
between life and death. Int J Biochem Cell Biol 2007; 39: 1462–1475.
5 Younes A, Vose JM, Zelenetz AD, Smith MR, Burris HA, Ansell SM et al. A Phase
1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin’s
lymphoma. Br J Cancer 2010; 103: 1783–1787.
6 Trarbach T, Moehler M, Heinemann V, Kohne CH, Przyborek M, Schulz C et al.
Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that
targets and activates the tumour necrosis factor apoptosis-inducing ligand
receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer
2010; 102: 506–512.
7 Garofalo M, Romano G, Quintavalle C, Romano MF, Chiurazzi F, Zanca C et al.
Selective inhibition of PED protein expression sensitizes B-cell chronic lympho-
cytic leukaemia cells to TRAIL-induced apoptosis. Int J Cancer 2007; 120:
1215–1222.
8 Zanca C, Garofalo M, Quintavalle C, Romano G, Acunzo M, Ragno P et al. PED is
overexpressed and mediates TRAIL resistance in human non-small cell lung
cancer. J Cell Mol Med 2008; 12: 2416–2426.
9 Quintavalle C, Incoronato M, Puca L, Acunzo M, Zanca C, Romano G et al. c-FLIPL
enhances anti-apoptotic Akt functions by modulation of Gsk3b activity. Cell Death
Differ 2010; 17: 1908–1916.
10 Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;
6: 857–866.
11 Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat
Rev Genet 2009; 10: 704–714.
12 Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A et al. miR-221 &
222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and
TIMP3 downregulation. Cancer Cell 2009; 16: 498–509.
13 Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C et al.
MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.
Oncogene 2008; 27: 3845–3855.
14 Incoronato M, Garofalo M, Urso L, Romano G, Quintavalle C, Zanca C et al. miR-212
increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in
non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res
2010; 70: 3638–3646.
15 Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 targets a network of key
tumor-suppressive pathways in glioblastoma cells. Cancer Res 2008; 68:
8164–8172.
16 Gaur AB, Holbeck SL, Colburn NH, Israel MA. Downregulation of Pdcd4 by mir-21
facilitates glioblastoma proliferation in vivo. Neuro-Oncology 2011; 13: 580–590.
17 Zhu S, Si M-L, Wu H, Mo Y-Y. MicroRNA-21 Targets the Tumor Suppressor Gene
Tropomyosin 1 (TPM1). J Biol Chem 2007; 282: 14328–14336.
18 Gressner O, Schilling T, Lorenz K, Schulze Schleithoff E, Koch A, Schulze-Bergka-
men H et al. TAp63[alpha] induces apoptosis by activating signaling via death
receptors and mitochondria. EMBO J 2005; 24: 2458–2471.
19 Nagane M, Huang HJS, Cavenee WK. The potential of TRAIL for cancer che-
motherapy. Apoptosis 2001; 6: 191–197.
20 Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL.
Oncogene 2010; 29: 4752–4765.
21 Walczak H, Bouchon A, Stahl H, Krammer PH. Tumor necrosis factor-related
apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-
xL-overexpressing chemotherapy-resistant tumor cells. Cancer Res 2000; 60:
3051–3057.
22 Balyasnikova IV, Ferguson SD, Han Y, Liu F, Lesniak MS. Therapeutic effect of
neural stem cells expressing TRAIL and bortezomib in mice with glioma xeno-
grafts. Cancer Lett 2011; 310: 148–159.
23 Unterkircher T, Cristofanon S, Vellanki SHK, Nonnenmacher L, Karpel-Massler G,
Wirtz CR et al. Bortezomib primes glioblastoma, including glioblastoma stem cells,
for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin Cancer Res
2011; 17: 4019–4030.
24 Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H et al.
Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies
to death receptor 4. J Immunol 2001; 166: 4891–4898.
25 Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R et al. Phase 1 and phar-
macokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer
Res 2007; 13: 6187–6194.
26 Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T et al. Tumoricidal activity of a
novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat
Med 2001; 7: 954–960.
27 Garofalo M, Condorelli G, Croce CM. MicroRNAs in diseases and drug response.
Curr Opin Pharmacol 2008; 8: 661–667.
28 Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G. miR221/222 in
cancer: their role in tumor progression and response to therapy. Curr Mol Med
2012; 12: 27–33.
29 Garofalo M, Condorelli GL, Croce CM, Condorelli G. MicroRNAs as regulators of
death receptors signaling. Cell Death Differ 2010; 17: 200–208.
30 Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stu¨hler K, Meyer HE et al.
Identification and functional characterization of microRNAs involved in the
malignant progression of gliomas. Brain Pathol 2009; 20: 539–550.
31 Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS et al. MicroRNA
21 promotes glioma invasion by targeting matrix metalloproteinase regulators.
Mol Cell Biol 2008; 28: 5369–5380.
32 Kwak HJ, Kim YJ, Chun KR, Woo YM, Park SJ, Jeong JA et al. Downregulation of
Spry2 by miR-21 triggers malignancy in human gliomas. Oncogene 2011; 30:
2433–2442.
33 Moore LM, Zhang W. Targeting miR-21 in glioma: a small RNA with big potential.
Expert Opin Therap Targets 2010; 14: 1247–1257.
34 Lakomy R, Sana J, Hankeova S, Fadrus P, Kren L, Lzicarova E et al. MiR-195, miR-
196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyl-
transferase methylation status are associated with clinical outcome in glio-
blastoma patients. Cancer Sci 2011; 102: 2186–2190.
35 Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in
human glioblastoma cells. Cancer Res 2005; 65: 6029–6033.
36 Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K. Micro-
RNA-21 knockdown disrupts glioma growth in vivo and displays synergistic
cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer
Res 2007; 67: 8994–9000.
37 Li J, Donath S, Li Y, Qin D, Prabhakar BS, Li P. miR-30 regulates mitochondrial
fission through targeting p53 and the dynamin-related protein-1 pathway. PloS
Genet 2010; 6: e1000795.
38 Joglekar MV, Patil D, Joglekar VM, Rao GV, Reddy ND, Mitnala S et al. The miR-30
family microRNAs confer epithelial phenotype to human pancreatic cells. Islets
2009; 1: 137–147.
MicroRNA, glioblastoma and TRAIL resistance
C Quintavalle et al
7
& 2012 Macmillan Publishers Limited Oncogene (2012), 1 – 8
39 Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon Y-J, Ngankeu A et al. EGFR and
MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis
and gefitinib resistance in lung cancers. Nat Med 2011; 18: 74–82.
40 Yu F, Deng H, Yao H, Liu Q, Su F, Song E. Mir-30 reduction maintains self-renewal
and inhibits apoptosis in breast tumor-initiating cells. Oncogene 2010; 29:
4194–4204.
41 Li N, Kaur S, Greshock J, Lassus H, Zhong X, Wang Y et al. A combined array-based
comparative genomic hybridization and functional library screening approach
identifies mir-30d as an oncomir in cancer. Cancer Res 2011; 72: 154–164.
42 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-
time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:
402–408.
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
MicroRNA, glioblastoma and TRAIL resistance
C Quintavalle et al
8
Oncogene (2012), 1 – 8 & 2012 Macmillan Publishers Limited
ORIGINAL PAPER
Electrochemical detection of miRNA-222 by use of a magnetic
bead-based bioassay
Francesca Bettazzi & Ezat Hamid-Asl &
Carla Lucia Esposito & Cristina Quintavalle &
Nello Formisano & Serena Laschi & Silvia Catuogno &
Margherita Iaboni & Giovanna Marrazza &
Marco Mascini & Laura Cerchia & Vittorio De Franciscis &
Gerolama Condorelli & Ilaria Palchetti
Received: 6 July 2012 /Revised: 18 September 2012 /Accepted: 2 October 2012 /Published online: 26 October 2012
# Springer-Verlag Berlin Heidelberg 2012
Abstract MicroRNAs (miRNAs, miRs) are naturally occur-
ring small RNAs (approximately 22 nucleotides in length) that
have critical functions in a variety of biological processes,
including tumorigenesis. They are an important target for
detection technology for future medical diagnostics. In this
paper we report an electrochemical method for miRNA detec-
tion based on paramagnetic beads and enzyme amplification.
In particular, miR 222was chosen asmodel sequence, because
of its involvement in brain, lung, and liver cancers. The
proposed bioassay is based on biotinylated DNA capture
probes immobilized on streptavidin-coated paramagnetic
beads. Total RNA was extracted from the cell sample,
enriched for small RNA, biotinylated, and then hybridized
with the capture probe on the beads. The beads were then
incubated with streptavidin–alkaline phosphatase and ex-
posed to the appropriate enzymatic substrate. The product of
the enzymatic reaction was electrochemically monitored. The
assay was finally tested with a compact microfluidic device
which enables multiplexed analysis of eight different samples
with a detection limit of 7 pmol L−1 and RSD015 %. RNA
samples from non-small-cell lung cancer and glioblastoma
cell lines were also analyzed.
Keywords MicroRNA .Magnetic beads . Electrochemical
assay . miRNA-222
Introduction
MicroRNAs (miRNAs, miRs) are naturally occurring small
RNAs (approximately 22 nucleotides in length) that act as
regulators of protein translation. Because many diseases are
caused by the misregulated activity of proteins, miRNAs have
also been implicated in a number of diseases including differ-
ent kinds of cancer [1], heart disease [2], and immunological
and neurological diseases [3–5]. Expression of miRNAs con-
trols a number of physiological and pathological responses [6,
7]. Consequently, miRNAs are intensely studied as candidates
for diagnostic and prognostic biomarkers. Moreover, the abil-
ity to selectively regulate protein activity through miRNAs
could enable treatment of many forms of cancer [8] and other
serious illness. Standardized methods for detection of miR-
NAs, all relying on hybridization [9], are northern blotting,
microarray, and real-time PCR (RT-PCR).
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Biosensors are emerging options for miRNA detection
[10–16]. Electrochemistry is regarded as one of the most ap-
pealing techniques in term of cost, ease of operation and auto-
mation. Recently, some examples of sensitive electrochemical
miRNA biosensing have been reported in the literature [17–26].
Pohlmann and Sprinzl [24] used a four-component hybridiza-
tion assay for sensitive and specific detection of miR 16 based
on an enzymatic electrochemical signal; the detection limit was
2 pmol L−1. The crucial feature of this method was the gener-
ation of base stacking between immobilized capture DNA,
miRNA, a complementary RNA probe, and the enzyme–DNA
conjugate. An electrochemical sensing technique for miR 21
detection is reported in Ref. [25]; functionalized gold nano-
particles were used to increase the amount of enzymatic label
on the electrode surface and thus the sensitivity of the method.
In all the references cited, however, the electrode surface
was used both as solid support for the hybridization and as
the surface for the electrochemical measurement.
Bead-based hybridization has the theoretical advantage
that it might more closely approximate hybridization in
solution [27–31]. Beads are disposable, which enables one
to consider irreversible binding chemistry on bead surfaces
for sensing with concomitant improvements in binding
specificity. Moreover, magnetic beads enable easy separa-
tion and washing steps. Indeed, beads-based miRNA detec-
tion is both feasible and attractive because of its high speed
and relatively low cost. Bead-based optical microarrays for
miRNA analysis have been reported in the literature [29].
In this paper, two electrochemical methods based on para-
magnetic beads for multiplexing miRNA detection are
reported. In the first approach disposable screen-printed elec-
trodes were used as transducers. Biotinylated DNA capture
probes were immobilized on streptavidin-coated paramagnet-
ic beads. Total RNAwas extracted from the sample, enriched
in the small fragments, biotinylated, and then hybridized with
the beads. The beads were then incubated with streptavidin
alkaline phosphatase (AP) and exposed to the enzymatic
substrate (α-naphthyl phosphate). The product of the enzy-
matic reaction (α-naphthol) was electrochemically monitored
by differential pulse voltammetry. To improve the analytical
performance, this bead-based assay was also integrated into a
microfluidic device. Microfluidic systems are well recognized
for their ability to move small volumes of fluids through
different processes and over a sensing surface.
The core of the system used in this study is an electrochem-
ical chip containing eight polymer microchannels. The presence
of microelectrodes in each channel enables direct quantification
of the hybridization reaction by conducting eight electrochem-
ical measurements in parallel. In this approach, magnetic beads
are modified and hybridized with sample containing the target
miRNA, as described above. They are introduced into the
microchannel inlet of a chip, and accumulated on nearby elec-
trode surfaces, by virtue of a magnetic holder positioned above
the microchannels. A solution of the enzymatic substrate (p-
aminophenyl phosphate) is added for in-situ signal detection.
After readout, the magnet array is flipped away, the beads are
removed by addition of regeneration buffer, and the chip is
ready for other assays. The detection step is particularly rapid,
because the extent of the hybridization reaction is followed by
real-time measurement of the AP enzyme kinetics, without the
need to wait for a longer incubation time. High sensitivity can
be achieved, because of the concentration of the product of the
enzymatic reaction, which increases rapidly because of the
small size of the microchannels.
Previously, we described a microfluidic-based electrochem-
ical assay coupled to magnetic beads for analysis of DNA
sequences of Legionella pneumophila [36]. Here, we apply
the bead-based method for electrochemical detection of miR-
NAs and demonstrate the feasibility of the assay for sensitive
and specific detection of synthetic miRNAs. In particular, we
used the developed method for detection of miRNAs from lung
and brain cancer cell lines known to express different levels of
miR 222. miR 222 is markedly upregulated in aggressive non-
small-cell lung cancer, hepatocarcinoma [6, 7, 33, 34], and
glioblastoma–astrocytoma [35] cells, as compared with less
invasive and/or normal brain, lung, and liver cells.
The experimental results obtained are discussed in the
following sections.
Materials and methods
Reagents
Streptavidin–alkaline phosphatase-conjugated (strp-AP), α-
naphthyl phosphate, diethanolamine, d-biotin, bovine serum
albumin (BSA), diethyl pyrocarbonate (DEPC), 97 % by
NMR, and polyoxyethylene-20-sorbitan monolaurate (Tween
20) were obtained from Sigma–Aldrich (Italy). Disodium
hydrogen phosphate, potassium chloride, magnesium chlo-
ride, sodium chloride, Tris HCl, and EDTA were purchased
fromMerck (Italy). p-Aminophenyl phosphate was purchased
from Diagnoswiss (Switzerland).
MilliQ-grade water was used throughout this work. DEPC
was added to water. DEPC treatment of solutions is accom-
plished by adding 1 mL DEPC per liter of water, stirring over-
night, autoclaving for 1 h to hydrolyze any remaining DEPC,
and then passing the solution through a 0.2-μm RNAse-free
filter (Sarstedt, Germany). Dynabeads Myone streptavidin C1
10 mgmL−1 were purchased from Dynal Biotech (Milan, Italy).
Synthetic oligonucleotides were purchased from Eurofins
MWG Operon (www.eurofinsdna.com). The sequences are
reported below:
& MaturemiRNA222 (Target) sequence: 5′-AGCUACAUC
UGG CUA CUG GGU CUC-biotin TEG-3′
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& Capture probe sequence: 5′-GAG ACC CAG TAG CCA
GAT GTA GCT-biotin TEG-3′
& Non complementary sequence (a 16-mer sequence of
miRNA-16): 5′-UAG CAG CAC GUA AAU A-biotin
TEG-3′
& Three base mismatch sequence of miRNA 222 (mismatch):
5′-AGC UAC AUC UUC UUA CUG GGU CU-biotin
TEG-3′
& Mature miRNA-221: 5′-AGC UAC AUU GUC UGC
UGG GUU UC-biotin TEG-3′
The RNA pre-miR sequence was obtained by transcrip-
tion with T7 polymerase of the PCR amplified sequence.
RNA concentration was measured with NanoDrop (Thermo
Scientific). The sequence:
& Pre-miRNA-222: 5′ GCU GCU GGA AGG UGU AGG
UAC CCU CAA UGG CUC AGU AGC CAG UGU
AGA UCC UGU CUU UCG UAA UCA GCA GCU
ACA UCU GGC UAC UGG GUC UCU GAU GGC
AUC UUC UAG CU 3′
The compositions of the buffers are:
& PB-T: phosphate buffer 0.5 mol L−1, pH 7.4, containing
0.05 % Tween 20
& DEA: diethanolamine 0.1 mol L−1 pH 9.6, 0.1 mol L−1
KCl, 1 mmol L−1 MgCl2, 0.05 % Tween 20
& 2×W&B (washing and binding buffer): 10 mmol L−1
Tris HCl, 1 mmol L−1 EDTA, 2.0 mol L−1 NaCl, 0.05 %
Tween 20
& 1× W&B (washing and binding buffer): 5 mmol L−1 Tris
HCl, 0.5 mmol L−1 EDTA, 1.0 mol L−1 NaCl, 0.05 %
Tween 20
& Substrate buffer: 0.10 mol L−1 2-methylaminoethanol at
pH 9 (recipe for 200 mL: 1.60 mL 2-methylaminoethanol
and 81 mg magnesium chloride in distilled water)
& Regeneration solution: Diagnoswiss proprietary solution
of dimethyl sulfoxide (Sigma–Aldrich)
Analytical method
Experimental conditions, for example beads modification, and
hybridization and labeling conditions have already been opti-
mized as described in our previous papers [36, 37]. In this
paper, application of the method to real samples, and in partic-
ular to small miRNA sequences, and integration of the proce-
dure in to a microfluidic device is presented (Fig. 1). The
method is based on biotinylated DNA capture probes (CPs)
immobilized on streptavidin-coated paramagnetic beads
(Fig. 1a). Total RNA is extracted from the cell samples
(Fig. 1b), enriched for small species and biotinylated, and then
hybridized with the modified beads. The beads were then
incubated with streptavidin alkaline phosphatase (AP) and
exposed to α-naphthyl-phosphate (Fig. 1c). The product of
the enzymatic reaction was electrochemically monitored by
use of a disposable screen-printed electrochemical cell
(SPEC) (Fig. 1d). Moreover, a compact microfluidic device
(Gravi-Cell), which enables multiplexed analysis of eight
different samples, was tested (Fig. 1e). To perform the
measurement with the Gravi-Cell, beads are passed through
the microchannels of a suitable miniaturized chip and a
magnet array is placed on the channels to block the
functionalized beads along the embedded microelectrodes
contained in each microchannel (Fig. 1f). The enzyme
substrate is then added for in-situ signal detection. Upon
readout, the magnet array is flipped away, the beads are
removed by addition of regeneration buffer, and the so-
regenerated chip is ready for further analysis [36].
Fitting of calibration curves was performed by use of
Origin Software version 8.1.
Disposable screen-printed electrodes
The screen-printed electrochemical cell (SPEC) consists of a
carbon working electrode, a carbon counter electrode, and a
silver pseudoreference electrode. Materials and procedures
used to screen-print the transducers and to couple the cell with
a magnet (to collect the beads for the measurement) are
described elsewhere [38, 39]. Electrochemical measurements
were performed using a μAutolab type II potentistat/galvano-
stat with the GPES 4.9 software package (Ecochemie, The
Netherlands). All potentials were referred to the Ag/AgCl
screen-printed pseudo-reference electrode. All electrochemi-
cal experiments were carried out at room temperature (25 °C).
To perform electrochemical measurement using magnetic
beads, SPECs were kept horizontal and a magnet holding
block was placed on the bottom part of the electrode, to better
localize the beads on to the working surface. A known volume
of a solution containing the enzymatic substrate was then
placed on the SPEC surface to close the electrochemical cell.
Biomodification of paramagnetic and streptavidin-coated
beads
Functionalization with the biotinylated capture probe was
carried out on aliquots of 0.1 mL, containing 10 mgmL−1
beads. The beads were washed three times with 250 μL 2×
W&B buffer solution and re-suspended in 200 μL of the same
buffer. DEPC water (200 μL) containing 5 μmol L−1 capture
probe was added to the suspension of the beads. After incu-
bation for 15 min with continuous mixing, the beads were
washed three times with 1× W&B. Finally, modified beads
were incubated for 30 min with 100 μL of a 1 mmol L−1
solution of biotin in 1×W&B, to block remaining streptavidin
active sites on the probe-functionalized surface and thus pre-
vent the undesired binding of other biotinylated oligonucleo-
tides. The probe-modified and biotin-blocked beads were then
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washed three times with 1× W&B and re-suspended in
500 μL 1× W&B. Every aliquot, stored at 4 °C, can be used
for several experiments.
Hybridization procedure
Biotinylated targets (oligonucleotides and samples) were
diluted to the desired concentration in PB-T. Both the blank
and non-complementary strands were used as negative con-
trols. For every assay 20 μL probe-modified beads was used.
After magnetic separation of the beads, using a magnetic
particle concentrator (MagneSphere Magnetic Separation
Stand, Promega), the buffer was removed carefully and the
beads were then incubated with 50 μL of the target solution
for 30 min. When real samples were analyzed, a thermal
denaturation procedure (5 min in boiling water and 1 min in
ice bath) was used before hybridization. After hybridization,
the beads were washed three times with 250 μL DEA, to
remove non-specifically adsorbed sequences.
After the hybridization and washing steps, beads were
then incubated with 50 μL of a solution containing 0.75 U
mL−1 streptavidin–alkaline conjugate and 10 mgmL−1 BSA
in DEA buffer. After 20 min beads were washed three times
with 250 μL DEA buffer. After washing, beads were re-
suspended in 50 μL DEA buffer.
Electrochemical measurement of miRNA using a SPEC
The electrochemical measurements were performed by plac-
ing the magnetic particles concentrator under the SPEC. The
Fig. 1 Schematic diagram of the assay. (a) Biotinylated DNA capture
probes are immobilized on streptavidin-coated magnetic beads. (b)
Cell samples are lyzed in a denaturing lysis solution. The total RNA
is extracted from the lysate is purified and enriched in miRNAs. The
enriched fraction is then terminal-conjugated with biotin using enzyme
terminal transferase. (c) Probe-modified and biotin-blocked beads are
incubated with the biotinylated miRNA targets (diluted to the desired
concentration in PB-T). Both the blank and non-complementary
strands are used as negative controls. (d) The biotinylated hybrids are
labeled with a streptavidin–alkaline phosphatase conjugate. The par-
ticles are then magnetically entrapped on to a screen-printed electrode.
The substrate is added and the enzymatic product is measured by DPV.
(e) The assay has also been integrated into a microfluidic device that
enables multiplexed analysis. Reprinted with permission from Ref.
[36]. (f) Schematic diagram of beads blocked within the microchannel,
on the electrode surface, by the magnet
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bead suspension (10 μL) was deposited on the working
electrode surface; the electrochemical cell was then cov-
ered with 60 μL of 1 mgmL−1 α-naphthyl phosphate in
DEA buffer. After 5 min of incubation, the electrochem-
ical signal of the enzymatically produced α-naphthol was
measured by DPV.
Electrochemical measurements of mature miRNA
using the microfluidic-based device
The Gravi-Cell (DiagnoSwiss, Monthey, Switzerland) micro-
fluidic device was used. The Gravi-Cell is a USB powered,
microfluidic-based immunoassay device for running bead pro-
cedures with standard immunology reagents. The instrument
works with Gravi-Chip, a chip containing eight microchannels
of ~300 nL volume with integrated gold microelectrodes. The
main advantages of this device are that, because the fluidics are
driven solely by natural forces, there are no serviceable pumps,
tubes, or valves.
A highly detailed description of the system and its soft-
ware control can be found elsewhere [36]. The procedure
ends with the electrochemical detection step, in which the
kinetics of the enzyme-label reaction are followed by real-
time chronoamperometry, by measuring the current alter-
nately on each channel and then reporting it vs. time [36].
The time evolution of the measured current follows Michae-
lis–Menten kinetics, so that the concentration of the target
analyte is given by the current slope at the origin in the
individual microchannels. The analytical signal is reported
as the linear slope of the current (current per unit time)
relative to analyte concentration. Once terminated, the pro-
gram automatically applies a chip-regeneration procedure
that must be followed by the user. The measured electrical
current is directly linked to the concentration of the product
of the enzyme reaction, and thus to the concentration of the
enzyme and hence of the complex within the microchannels.
Just after electrochemical measurements, the beads are re-
leased by removing the magnet array. Another advantage is
that each Gravi-Chip can be regenerated for multiple uses.
This can be achieved by washing the microchannels and
reservoirs several times with the appropriate buffers. In this
manner, the chip can be used for up to 100 analyses. For
working with Gravi-Chip, some pretreatments are necessary.
The microchannels should be wet three times by alternately
filling the bottom and the upper reservoirs with ethanol and
waiting each time for 30 s. The microchannels are then
washed with washing buffer, by filling the upper and the
bottom reservoirs and aspirating the solution with a pipette.
The bottom reservoirs are then filled with 15 μL washing
buffer before starting the experiment. This procedure ena-
bles wetting of the microchannels to ensure appropriate
filling with aqueous solutions, and prevents air bubble for-
mation that could partially block the fluid flows. To perform
the measurements the magnetic holder of the Gravi-Cell
should be on; thus a 15-μL aliquot of modified beads is
added simultaneously to each of the eight upper reservoirs
of the chip, to accumulate the magnetic particles within the
microchannels in the vicinity of the electrode surface. The
beads flow down the microchannels for 4 min. The electro-
chemical detection step was finally carried out. To this end,
15 μL substrate buffer was introduced into the upper reser-
voirs andmaintained for 30 s. Subsequently, 15μL 12.0mmol
L−1 p-aminophenyl phosphate (pAPP) solution (in this ap-
proach the electrochemical substrate for detection by use of
AP) prepared in the substrate buffer was dispensed in the
upper reservoirs and removed after 20 s. This step was repeat-
ed once again, and electrochemical detection of the enzymatic
reaction product starts. Finally, the regeneration procedure for
reusing the Gravi chip is performed. For this step, 10 μL
regeneration solution is dispensed into the top reservoirs.
Sample preparation for analysis with the electrochemical
method
Cell culture
Human non-small-cell lung cancer Calu 1 cell line, and glioblas-
toma U87MG and T98G cell lines were grown in Dulbecco’s
modified Eagle medium (DMEM). Human non-small-cell lung
cancer H460 cell line was grown in Roswell Park Memorial
Institute medium (RPMI). Both media were supplemented with
10 % heat-inactivated fetal bovine serum (FBS) with 2 mmol
L−1L-glutamine and 100 U mL−1 penicillin–streptomycin.
RNA extraction
Total RNA was extracted with Trizol Reagent in accordance
with the manufacturer’s instructions (Invitrogen), while RNA
enriched in small molecules was obtained with the mirVana
miRNA isolation kit in accordance with the manufacturer’s
instructions (Applied Biosystems). RNA concentration was
measured with NanoDrop (Thermo Scientific).
RNA ligation: procedure and control
Total RNA or RNA enriched in small molecules (200 pmol)
was terminal conjugated with biotin with 400 U μL−1 of the
enzyme terminal transferase (Roche) in accordance with the
manufacture’s procedure.
RT-PCR procedure for mature miRNA analysis
Total RNAs (miRNA and mRNA) were extracted using Trizol
(Invitrogen) in accordance with the manufacturer’s procedure.
Reverse transcription of total miRNAwas performed starting
from equal amounts of total RNA/sample (1 μg) using the
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miScript reverse transcription kit (Qiagen). For cultured cells,
quantitative analysis of miR 222 and RNA-U6B (as an inter-
nal control of the measurement [40]) were performed by real-
time PCRwith specific primers (Qiagen) with miScript SYBR
green qPCR kit (Qiagen). The reaction for detection of miR-
NAs was performed as follow: 95 °C for 15 min, 40 cycles of
94 °C for 15 s, 55 °C for 30 s, and 70 °C for 30 s. All reactions
were run in triplicate. The threshold cycle (CT) is defined as
the fractional cycle number at which the fluorescence passes
the fixed threshold. For relative quantification the 2(−ΔCT)
method was used as described elsewhere [40]. Experiments
were performed in triplicate for each data point, and data
analysis was performed by use of software (Bio-Rad).
Results and discussion
Calibration curves of mature miRNA
To test the sensitivity and analytical performance of the
assay and to check reliability of the chosen capture probe, a
calibration experiment was designed using a synthetic bioti-
nylated miRNA target. The results are reported in Fig. 2. The
DPV response increased with the target concentration up to
50 nmol L−1. Detection limits, calculated considering the
slope of the linear portion of the calibration curve in the range
0–1 nmol L−1 (y03×10−6x+2×10−7, r200.995), and fitting to
the respective linear equation the mean of the blank solution
response plus three times its standard deviation, were found to
be 12 pmol L−1. The reproducibility of the analysis, calculated
as average RSD, was 9.6 % and the sensitivity was 3 μA
nmol−1L. This detection limit is better than those of other
electrochemical methods for miRNA detection [26].
The selectivity of the assay was monitored by use of two
miRNA sequences (miR 16 and miR 221). As for miR 222,
miR 16 is also associated with many tumors (i.e. it is deregu-
lated in B-cell chronic lymphocytic leukemia). However, its
sequence markedly differs from that of miR 222. It can, there-
fore, be regarded as a fully non-complementary sequence. In
contrast, miR 221 is structurally closely related to miR 222, and
both are frequently overexpressed in human malignancies.
To further test the selectivity, a synthetic sequence (called
“mismatch”) was designed with three central bases mis-
matched compared with miR 222. Thus, beads modified with
miR 222 complementary CPs were incubated with different
concentrations of miR 222, miR 16, mismatch, and miR 221.
Results are reported in Fig. 3. The signal observed with the
complementary sequence (miRNA-222) is always higher than
that obtained with the other sequences, for all the concentra-
tions tested. It should, moreover, be pointed out that the
current signal for miR 16 (the fully non-complementary se-
quence) is of the same order of magnitude as that for the blank.
Assuming the complementary hybridization efficiency is
100 %, the hybridization efficiency was approximately 30 %
for miR 221 as compared with that of miR 222 (100%), for all
the concentrations tested.
The signals for the mismatch sequence were 24 %, 21 %,
and 24 % of that for miR 222 (100 %) at 0.5, 1, and 2.5 nmol
L−1, respectively. Similar values of efficiency of discrimination
between closely related and mismatch miRNA sequences have
previously been reported for other electrochemical assays [23,
24]. Thus, these results demonstrated that the bioassay was able
to discriminate complementary miR-222. Nevertheless, im-
provement of mismatch discrimination and thus of selectivity
can possibly be achieved by introducing modified nucleotides
(for example LNA) in the capture probe sequence [41].
Selectivity was also monitored versus pre-miR 222. Pre-miR
222 is the 110-oligonucleotide stem–loop precursor of mature
miR 222, and thus contains the sequence of mature miR 222.
We investigated the selectivity of the assay for mature miRNA
Fig. 2 Calibration curve for
mature miR 222. Error bars are
standard deviations from three
replicates. Disposable screen-
printed electrochemical cells
were used as transducers. Inset:
The calibration curve at the low
concentration end
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by analyzing signal changes observed when beads were ex-
posed to solution containing the pre-miRNA, the mature
miRNA, and an equimolar mixture of both, as reported in
Fig. 4. The DPV current signal of the pre-miRNA (0.20±
0.10 μA) is only slightly different from that of the blank (0.18
±0.02 μA); this could be related to non-specific adsorption.
However the signal of mature miRNA (0.99±0.11 μA) is
significantly higher than that of pre-miRNA, and when mix-
tures of miRNA-222 and pre-miRNAwere analyzed the current
signal (1.0±0.1 μA) was comparable with the electrochemical
signal in the presence of miRNA-222 only.
Having confirmed the analytical performance for the
miRNA target, the method was tested by using RNA samples
extracted from cell lines. Levels of miRNA-222 have been
shown to be increased in brain (glioblastoma), lung, and liver
cancers [31–35]. For this reason the cell lines Calu 1, H460,
U87MG, and T98G were studied. Calu1 and H460 cells are
well-characterized non-small-cell lung cancer (NSCLC) cell
lines and are regarded as an in-vitro model of lung cancer. In
the literature [31–35], it is reported that miRNA-222 is overex-
pressed in Calu1, as compared with H460. Therefore, we used
Calu1 cells to determine their levels of miRNA-222, and com-
pared these levels with that for H460 cells. Similarly we tested
the level of miRNA-222 in human U87MG glioblastoma–
astrocytoma cells, which are known to express higher levels
of miRNA-222 than human T98G glioblastoma cells [31–35].
Several independent samples of Calu1, H460, U87 MG,
and T98G cells were evaluated for miRNA-222 levels by use
of the electrochemical bioassay. The same samples were also
analyzed by qRT-PCR. As reported in the “Materials and
methods” section, total RNA was extracted from the cell
sample, enriched for small RNA, ligated with biotin at the 3′
terminus (to introduce the enzymatic label), and then hybrid-
ized with the capture probe on the beads. The results of the
electrochemical bioassay are shown in Fig. 5. For glioblasto-
ma cells, the signal obtained for U87MG is higher than the
signal obtained for T98G. Similarly, for NSCLC cells, Calu1
gave a signal higher than that obtained for the H460 cell line.
In particular, a current increase of approximately twofold was
observed for Calu1 and U87MG cells compared with H460
Fig. 3 Analysis of non-complementary (miR 16), miR 221, mismatch,
and complementary (miR 222) sequences by use of miR 222 CP-
modified beads. Error bars are standard deviations from three repli-
cates. Disposable screen-printed electrochemical cells were used as
transducer
Fig. 4 Analysis of samples containing pre-miR 222, mature miR 222,
and a equimolar mixture of 0.5 nmolL−1 pre-miR and 0.5 nmolL−1
mature miR 222, using miR 222 CP-modified beads. Error bars are
standard deviations from three replicates. Disposable screen-printed
electrochemical cells were used as transducer
Fig. 5 Analysis of cell samples. The total RNA is extracted from
U87MG and T98G glioblastoma cells and from Calu1 and H460
NSCLC cells. After extraction RNA was purified, enriched in small
fragments and biotinylated in vitro. Before analysis, each sample was
diluted 1:3 in PB-T containing CP-modified beads. Disposable screen-
printed electrochemical cells were used as transducer. Error bars are
standard deviations from three independent samples. The same sam-
ples were also analyzed by RT-PCR, which revealed that miR-222 is
up-regulated in U87MG versus T98G cells and in Calu1 vs. H460 cells
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and T98G cells, respectively. The normalized current value
reported in Fig. 5 is the ratio of the current signal for the
sample to the current signal for the blank (in this way fluctua-
tions of signal values because of enzymatic activity are con-
trolled). The qRT-PCR results are also reported in Fig. 5. As
can be seen, the relative threshold cycle (CT) values were
reported. The CT is the cycle number at which the fluores-
cence associated with a particular amplicon crosses a thresh-
old line [40]. To study the amount of an amplified target, the
CT absolute value is not meaningful. CT values are only used
in comparative methods when normalized to an endogenous
reference (ΔCT) and relative to a calibrator sample [40]. By
comparing the ΔCT for Calu1 with that for H460, it was
confirmed that levels of the miRNA amplicons of Calu1
samples were higher than those for H460. qRT-PCR data also
confirmed overexpression of miR-222 in U87MG samples
compared with T98G.
Because of the limited dynamic range of the assay (0.01–
1 nmol L−1), multiple analyses of unknown RNA extracted
from the cell samples at different dilutions were performed.
The voltammetric profiles of the different dilutions of
miRNA extracted from glioblastoma cells are reported in
Fig. 6. The signals for both the glioblastoma cell lines
decreased as the dilution factor was increased, with higher
signals being obtained for a dilution of 1:3 (Fig. 6a). De-
crease in current signal was observed for both cell lines, but
it was more important for U87MG than for T98G. This is
possibly because the T98G miRNA current signal is low
and, on increasing the dilution factor, this current signal is
leveled by the blank signal. The dilution factor 1:3 was also
used to analyze Calu1 and H460 samples (Fig. 6B).
Analysis with the microfluidic device
The assay scheme was also integrated into a microfluidic
device. The commercially available device used (Fig. 1e),
combines a special chip containing eight polymer micro-
channels with a PC-controlled instrument. The presence of
microelectrodes in each channel enables eight parallel elec-
trochemical measurements. To perform the measurements,
beads are passed through the microchannels of the chip and
a magnet array is placed on the channels to block the
functionalized beads along the embedded microelectrodes
contained in each microchannel. The substrate is then added
for chronoamperometric measurement of the enzyme kinet-
ics. The eight channels were sequentially measured, each
2 s, at a potential of +250 mV vs. Ag/AgCl, for a total
Fig. 6 Voltammetric scans obtained from analysis of samples
extracted from the cell lines. (a) U87MG and T98G glioblastoma cell
lines at different dilutions. Before analysis each sample was diluted
with PB-T. (a) dilution 1:3; (b) dilution 1:5; (c) dilution 1:10. Other
conditions as reported in Fig. 5. (b) Calu1 and H460 cell lines at
dilution 1:3. Other conditions as reported in Fig. 5
1032 F. Bettazzi et al.
acquisition time of 90 s; in this way many measurement
cycles are recorded, and a plot of current as a function of
time is obtained for each channel. The slope of the linear
portion of the plot is a direct measure of the p-aminophenol
concentration and, hence, of the enzyme concentration.
The calibration curve, with the synthetic target, are reported
in Fig. 7. The electrochemical response rapidly increased with
increasing sample concentration up to 2.5 nmol L−1 then de-
creased slowly; the trend observed could not be explained in
terms of saturation of all available bead-immobilized capture
probes. Future experiments will be devoted to better analysis of
this behavior and extending the range of concentration analyzed
at higher concentrations. The detection limit, calculated by
considering the slope of the linear portion of the calibration
curve in the range 0–1 nmol L−1 (y00.4831x, r200.998) and
fitting, with the respective linear equations, the mean of the
blank solution response plus three times its standard deviation,
was found to be 7 pmol L−1, coupled with reproducibility of the
analysis of 15 %, calculated as average RSD %, and sensitivity
of 0.4831 nAs−1nmol−1L. This detection limit is even better
than that obtained with the first approach based on screen-
printed electrodes and DPV measurements.
RNA samples from the cell lines of glioblastoma and
lung cancer were also tested (Fig. 8). In Fig. 8a are reported
the current profiles vs. time for samples from the different
cell lines. For the glioblastoma cells, the slope values
obtained for U87MG are higher than the values obtained
for T98G. Similarly, for NSCLC cells, the slope for Calu1
was steeper than that obtained for the H460 cell line. The
slopes are reported in Fig. 8b. The expression levels mea-
sured with the microfluidic-based electrochemical assay
confirmed that miR-222 is more highly expressed in Calu1
and U87MG cells than in H460 and T98G cells. It should,
however, be noted that all the samples analyzed are inde-
pendent samples and thus can express different levels of
miRNA. Thus, the absolute value of analytical signal can
vary among samples of the same cell line. Nevertheless, the
behavior among U87G and T98 cells and among Calu1 and
H460 is consistent.
Conclusions
Small non-coding RNA species, known as microRNAs, have
critical functions in a variety of biological processes, includ-
ing development, cell growth, differentiation, apoptosis, and
tumorigenesis. Recent studies have revealed the value of
miRNA expression patterns for diagnostic, prognostic, and
therapeutic uses, thus heightening interest in miRNAs’ poten-
tial as biomarkers of tumor development, progression, and
chemosensitivity. Some unique features of miRNAs, for ex-
ample their small total number and short length, have created
Fig. 7 Electrochemical detection using the Gravi-Cell microfluidic
device—calibration curve for mature miR 222. Error bars are standard
deviations from three experiments. Inset: the calibration curve at the
low concentration end
Fig. 8 Electrochemical analysis of the miRNAs extracted from cell
samples using the Gravi-Cell microfluidic platform. After extraction,
RNAwas purified, enriched in small fragments, and biotinylated in vitro.
Before analysis each sample was diluted 1:3 with PB-T. Error bars are
standard deviations from three replicates on the same samples. (a) Chro-
noamperometric detection of enzyme kinetics in a chip for the different
samples. Each symbol represents a single current acquisition value. Data
were then processed using a fitting tool; for each channel a plot of current
as a function of time was obtained. The slope of the linear portion of the
plot, which is a direct measure of the p-aminophenol concentration, was
used as analytical data. The chronoamperometric detection was performed
at +250 mV vs. Ag/AgCl. (b) the corresponding analytical signal
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technical obstacles to direct application in a variety of proce-
dures, leading to a need to develop novel methods designed to
measure miRNAwith high specificity and sensitivity.
The method reported in this paper is based on magnetic
beads coupled to enzymatic amplification. The assay was also
integrated into a compact, commercially available, microflui-
dic device. Given desktop dimensions and USB powering, the
microfluidic device is highly portable. Its portability leads to a
very interesting approach to monitoring miRNA expression
profiles with eight samples processed simultaneously, in ac-
cordance with the concept of multiplexed point of care testing.
The detection limit of the proposed method (7 pmol L−1) was
better than that in a recently published paper [26] or for those
for other methods [17, 18, 24]. The results reported indicate
the method can be used to discriminate among different cell
lines which express different amounts of miRNA-222. More-
over, the method can be easily multiplexed—merely by using
beads modified with different CPs and using the microfluidic
device, analyses of eight different samples can be performed
simultaneously. In our opinion this method is of promise for
discriminating upregulated mature miRNA levels (i.e. in some
human malignancies) from normal levels in cell samples.
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